T cell receptors directed against melanoma preferentially expressed antigens and uses thereof - Patents.com
PRAME-specific T-cell receptors and modified T cells address the challenge of targeting PRAME-expressing tumors, enhancing immune responses and reducing tumor burden in melanoma and other cancers.
Patent Information
- Application Number
- JP2021043579
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2015-03-10
- Filing Date
- 2021-03-17
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2036-03-09
AI Technical Summary
Current treatments for hyperproliferative diseases such as melanoma and other cancers lack specificity and efficacy in targeting the PRAME antigen, which is highly expressed in various tumor types, limiting the effectiveness of immune responses.
Development of PRAME-specific T-cell receptors (TCRs) and genetically modified T cells that express these receptors, combined with inducible caspase-9 polypeptides, to induce targeted immune responses against PRAME-expressing cells.
The PRAME-specific TCRs enhance the specificity and efficacy of immune responses against melanoma and other cancers, leading to reduced tumor burden and improved treatment outcomes.
Smart Images

Figure 0007579726000054 
Figure 0007579726000055 
Figure 0007579726000056
Abstract
Description
[Technical field]
[0001] (Related Applications) The application, filed on March 10, 2015, entitled "T Cell Receptors Directed Against the Preferentially Expressed Antigen of Melanoma and Its Uses Thereof Priority is claimed from U.S. Provisional Patent Application No. 62 / 130,884, which is incorporated by reference. and is incorporated by reference in its entirety.
[0002] (Field) This technology is based, in part, on the detection of the preferentially expressed antigens in melanoma. Compositions for inducing an immune response against Proteus tigen of Melanoma (PRAME) and The present invention relates to a method for treating hyperproliferative disorders by inducing an immune response against the PRAME antigen. The immune response is directed against PRAME by T cells. Induced by specifically targeting PRAME-expressing cells using the cellular receptor It is possible. [Background technology]
[0003] (background) Activation of T cells is essential for the defense against pathogenic microorganisms (e.g., viruses, bacteria, and parasites), foreign proteins, and proteins that cause inflammation. In protective immunity against proteins and harmful chemicals in the environment, as well as in cancer and other This is also an important step in the development of immunity against hyperproliferative diseases. Second, a receptor that recognizes antigens displayed on the cell surface (i.e., the T cell receptor) During a normal immune response, these antigens are presented to T cells in the context of MHC antigen presentation. By binding to the cell receptor, intracellular changes are induced, leading to T cell activation.
[0004] Adoptive T cell therapy is a treatment for hyperproliferative diseases (tumors) by providing antigen-specific immune responses. One method is to use extracellular antibodies that bind to antigens. The present invention requires the use of genetically modified T cells that express antigen-specific proteins having do. Summary of the Invention [Means for solving the problem]
[0005] (Summary) The PRAME gene is involved in most tumors (melanoma, non-small cell lung cancer, renal cell carcinoma (RCC) cancer, breast cancer, cervical cancer, colon cancer, sarcoma, and neuroblastoma), as well as some types of tumors. PRAME is expressed at high levels in a variety of leukemias. PRAME-specific T cell clones have been identified. These T cell clones were able to express these different tumor types (Ewing sarcoma, synovial sarcoma, The PRAME-specific TCR recognizes IL-1, IL-1, and IL-2 cell lines. The TCR gene transfer approach used in the treatment of hyperproliferative diseases (e.g., sarcoma, acute lymphoblastic leukemia, leukemia, acute myeloid leukemia, uveal melanoma, and neuroblastoma) This may result in novel treatment modalities for patients.
[0006] T cell receptors, nucleic acids encoding T cell receptors, and nucleic acids that recognize the PRAME antigen Compositions and methods are provided herein that include cells expressing a T cell receptor that recognizes the T cell receptor. The cells may also express an inducible caspase-9 polypeptide.
[0007] Certain embodiments are further described in the following description, examples, claims and drawings. It will be published. [Brief description of the drawings]
[0008] The drawings are illustrative of certain embodiments of the present technology, but are not limiting. For clarity and ease of illustration, the drawings are not drawn to scale and in some cases may be Various aspects may be shown exaggerated or enlarged to facilitate understanding of particular embodiments. .
[0009] [Figure 1] FIG. 1A provides a schematic of the components of adoptive T cell therapy; FIG. 1B provides a bar graph of antigen expression in various tissues.
[0010] [Figure 2A] FIG. 2A provides a schematic illustrating an example of the method used to generate a T cell clone library; FIG. 2B provides a bar graph of cytokine production. [Figure 2B] FIG. 2A provides a schematic illustrating an example of the method used to generate a T cell clone library; FIG. 2B provides a bar graph of cytokine production.
[0011] [Diagram 3] Figure 3 provides the results of FACs analysis showing the isolation of activated CD8+ T cells following HLA-mismatched stem cell therapy. The patient recipient was HLA-A2+ and the donor was HLA-A2-.
[0012] [Figure 4] Figures 4A-4C provide bar graphs measuring the tumor specificity of three different T cell clones: Figure 4A provides a bar graph for clone 12; Figure 4B provides a bar graph for clone 35; Figure 4C provides a bar graph for clone 54.
[0013] [Diagram 5] Figures 5A-5C provide graphs of IFNγ showing that the T cell clones are PRAME specific. Figure 5A provides a graph of the first dim: water / ACN / TFA HPLC fraction; Figure 5B provides a graph of the second dim: water / IPA / TFA HPLC fraction; Figure 5C provides a graph of the third dim: water / ACN / formic acid HPLC fraction.
[0014] [Figure 6] Figures 6A-6C provide the results of an experiment comparing the avidity of allo-restricted and non-allo-restricted PRAME-specific T cells. Figure 6A provides the FACs results; Figure 6B provides a line graph; Figure 6C provides a bar graph.
[0015] [Figure 7] Figures 7A and 7B are bar graphs showing the high specificity of PRAME-specific allo-HLA-restricted T cells. Figure 7A provides a bar graph representing melanoma cell lines; Figure 7B provides a bar graph representing primary AML samples.
[0016] [Figure 8] FIG. 8 is a bar graph showing the restricted reactivity of PRAME-specific T cell clones to mature dendritic cells (DCs) derived from healthy CD34+ cells.
[0017] [Figure 9] FIG. 9 is a scatter plot showing that cell recognition by PRAME-specific T cell clones correlates with PRAME expression levels on targeted cells.
[0018] [Figure 10]Figures 10A-10C are bar graphs showing that silencing of PRAME expression by shRNA correlated with reduced reactivity of PRAME-specific T cell clones. Figure 10A provides a bar graph representing renal cell carcinoma RCC 1257; Figure 10B provides a bar graph representing mature dendritic cells derived from CD34+ cells (CD34 mDC); Figure 10C provides a bar graph representing proximal tubule epithelial cells (PTEC).
[0019] [Figure 11] FIG. 11 is a bar graph showing high tumor reactivity of PRAME-TCR transduced T cells.
[0020] [Figure 12] FIG. 12 is a bar graph showing the reactivity of T cells transduced with the PRAME TCR construct, with or without the caspase-9 encoding polypeptide, against target cells with or without AP1903 treatment.
[0021] [Figure 13-1] Figure 13 provides a bar graph showing the reactivity of PRAME-specific T cell clones to Ewing sarcoma cells with or without 48 hours of treatment with IFN-γ / IFN-α. HLA expression of Ewing sarcoma cell lines with or without IFN-γ / IFN-α is shown on the right side of the figure. Figure 13 is provided in the figure on page 6 herein. [Figure 13-2] Figure 13 provides a bar graph showing the reactivity of PRAME-specific T cell clones to Ewing sarcoma cells with or without 48 hours of treatment with IFN-γ / IFN-α. HLA expression of Ewing sarcoma cell lines with or without IFN-γ / IFN-α is shown on the right side of the figure. Figure 13 is provided in the figure on page 6 herein. [Figure 13-3]Figure 13 provides a bar graph showing the reactivity of PRAME-specific T cell clones to Ewing sarcoma cells with or without 48 hours of treatment with IFN-γ / IFN-α. HLA expression of Ewing sarcoma cell lines with or without IFN-γ / IFN-α is shown on the right side of the figure. Figure 13 is provided in the figure on page 6 herein. [Figure 13-4] Figure 13 provides a bar graph showing the reactivity of PRAME-specific T cell clones to Ewing sarcoma cells with or without 48 hours of treatment with IFN-γ / IFN-α. HLA expression of Ewing sarcoma cell lines with or without IFN-γ / IFN-α is shown on the right side of the figure. Figure 13 is provided in the figure on page 6 herein. [Figure 13-5] Figure 13 provides a bar graph showing the reactivity of PRAME-specific T cell clones to Ewing sarcoma cells with or without 48 hours of treatment with IFN-γ / IFN-α. HLA expression of Ewing sarcoma cell lines with or without IFN-γ / IFN-α is shown on the right side of the figure. Figure 13 is provided in the figure on page 6 herein. [Figure 13-6] Figure 13 provides a bar graph showing the reactivity of PRAME-specific T cell clones to Ewing sarcoma cells with or without 48 hours of treatment with IFN-γ / IFN-α. HLA expression of Ewing sarcoma cell lines with or without IFN-γ / IFN-α is shown on the right side of the figure. Figure 13 is provided in the figure on page 6 herein.
[0022] [Figure 14-1] Figure 14 provides a bar graph showing the reactivity of PRAME-specific T cell clones against neuroblastoma cells with or without 48 hours of treatment with IFN-γ / IFN-α. HLA expression of neuroblastoma cell lines with or without IFN-γ / IFN-α is shown on the right side of the figure. Figure 14 is provided in the figure on page 4 of this specification. [Figure 14-2]Figure 14 provides a bar graph showing the reactivity of PRAME-specific T cell clones against neuroblastoma cells with or without 48 hours of treatment with IFN-γ / IFN-α. HLA expression of neuroblastoma cell lines with or without IFN-γ / IFN-α is shown on the right side of the figure. Figure 14 is provided in the figure on page 4 of this specification. [Figure 14-3] Figure 14 provides a bar graph showing the reactivity of PRAME-specific T cell clones against neuroblastoma cells with or without 48 hours of treatment with IFN-γ / IFN-α. HLA expression of neuroblastoma cell lines with or without IFN-γ / IFN-α is shown on the right side of the figure. Figure 14 is provided in the figure on page 4 of this specification. [Figure 14-4] Figure 14 provides a bar graph showing the reactivity of PRAME-specific T cell clones against neuroblastoma cells with or without 48 hours of treatment with IFN-γ / IFN-α. HLA expression of neuroblastoma cell lines with or without IFN-γ / IFN-α is shown on the right side of the figure. Figure 14 is provided in the figure on page 4 of this specification.
[0023] [Figure 15] Figures 15A and 15B are bar graphs showing the reactivity of T cells transduced with PRAME TCR and PRAME TCR+icasp9 constructs against melanoma cells. 15A) without AP1903 treatment, 15B) with AP1903 treatment.
[0024] [Figure 16] Figures 16A-16D are bar graphs showing the recognition of Ewing sarcoma cells by PRAME-specific T cell clones. Ewing sarcoma cell lines were treated with or without IFN-γ / IFN-α for 48 hours. Figure 16A provides a bar graph of EW3 cell line; Figure 16B provides a bar graph of EW3 cell line HLA expression with or without IFN-γ / IFN-α; Figure 16C provides a bar graph of EW7 cell line; Figure 16D provides a bar graph of EW3 cell line with or without IFN-γ / IFN-α.
[0025] [Figure 17A] FIG. 17A provides the amino acid sequence of PRAME clone 54SLL (TRAV8-4*04) in the PRAME / icasp9 construct; FIG. 17B provides the amino acid sequence of PRAME clone 54SLL (TRBV9*01) in the PRAME / icasp9 construct. [Figure 17B] FIG. 17A provides the amino acid sequence of PRAME clone 54SLL (TRAV8-4*04) in the PRAME / icasp9 construct; FIG. 17B provides the amino acid sequence of PRAME clone 54SLL (TRBV9*01) in the PRAME / icasp9 construct.
[0026] [Figure 18A] Figure 18A provides the amino acid sequence of PRAME clone 46SLL (TRAV35*02). Figure 18B provides the amino acid sequence of PRAME clone 46SLL (TRBV28*01). [Figure 18B] Figure 18A provides the amino acid sequence of PRAME clone 46SLL (TRAV35*02). Figure 18B provides the amino acid sequence of PRAME clone 46SLL (TRBV28*01).
[0027] [Figure 19A] FIG. 19A provides the amino acid sequence of PRAME clone DSK3 QLL (TRAV12-2*01), and FIG. 19B provides the amino acid sequence of PRAME clone DSK3 Qll (TRBV9*01). [Figure 19B] FIG. 19A provides the amino acid sequence of PRAME clone DSK3 QLL (TRAV12-2*01), and FIG. 19B provides the amino acid sequence of PRAME clone DSK3 Qll (TRBV9*01).
[0028] [Figure 20A]Figure 20A provides a bar graph of PRAME expression in samples of primary AML cells. Figure 20B provides a bar graph of PRAME-specific T cell reactivity to samples of primary AML cells. [Figure 20B] Figure 20A provides a bar graph of PRAME expression in samples of primary AML cells. Figure 20B provides a bar graph of PRAME-specific T cell reactivity to samples of primary AML cells.
[0029] [Figure 21-1] FIG. 21A provides a timeline of assays of tumor response in mice following treatment with PRAME TCR-expressing cells in an NSG immunodeficient mouse xenograft model; FIG. 21B provides photographs of mice treated with non-transduced (NT) and PRAME TCR-expressing cells (Cell A) on days 7-35; FIG. 21C provides photographs of mice treated with non-transduced (NT) and PRAME TCR-expressing cells on days 41-74; FIG. 21D provides a fluorescence color scale; FIG. 21E provides a line graph of the mean radiance of tumors in mice treated with non-transduced cells; FIG. 21F provides a line graph of the mean radiance of tumors in mice treated with control (NT) cells and mice treated with PRAME TCR-expressing cells; FIG. 21G provides a line graph of the mean radiance of tumors in mice treated with PRAME TCR-expressing cells. [Figure 21-2]FIG. 21A provides a timeline of assays of tumor response in mice following treatment with PRAME TCR-expressing cells in an NSG immunodeficient mouse xenograft model; FIG. 21B provides photographs of mice treated with non-transduced (NT) and PRAME TCR-expressing cells (Cell A) on days 7-35; FIG. 21C provides photographs of mice treated with non-transduced (NT) and PRAME TCR-expressing cells on days 41-74; FIG. 21D provides a fluorescence color scale; FIG. 21E provides a line graph of the mean radiance of tumors in mice treated with non-transduced cells; FIG. 21F provides a line graph of the mean radiance of tumors in mice treated with control (NT) cells and mice treated with PRAME TCR-expressing cells; FIG. 21G provides a line graph of the mean radiance of tumors in mice treated with PRAME TCR-expressing cells.
[0030] [Figure 22] FIG. 22A provides a FACs analysis of spleens from mice treated with PRAME-TCR expressing T cells following administration of rimizuside; FIG. 22B provides a graph summarizing the FACs analysis of FIG. 22A.
[0031] [Figure 23] Figure 23A provides flow cytometry results of spleen and bone marrow cells harvested from mice treated with either NT- or Cell A on day 51 after T cell injection (day 74 after tumor implantation) and counted and analyzed for CD8+ expression; Figure 23B provides flow cytometry analysis of cells counted and analyzed for CD4+ expression; Figure 23C provides flow cytometry analysis of cells counted and analyzed for Vβ1 expression on CD8+ T cells; Figure 23D provides flow cytometry analysis of cells counted and analyzed for Vβ1 expression on CD4+ T cells.
[0032] [Figure 24]FIG. 24 provides the flow cytometry results of splenocytes and bone marrow cells isolated from Cell A-treated animals analyzed above and cultured overnight with or without 10 nM limizuside.
[0033] [Diagram 25] Figure 25 provides a plasmid map of SFG.iC9-2A-SLL.TCR. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] (Detailed Description) Recombinant T cell receptors specific for particular antigens are used to provide specificity to T cells. They have been used to treat certain types of cancer and to provide antigen-specific immune responses in patients. The method involves the use of a gene that expresses an antigen-specific protein having an extracellular domain that binds to the antigen. This requires the use of engineered T cells.
[0035] Adoptive T cell transfer using genetically modified T cells expressing a xenogeneic T cell receptor (TCR) Cell therapy involves the administration of high-avidity, target-cell-specific T cells as part of a patient's T cell repertoire. Adoptive T cell therapy can provide a CR by providing an antigen-specific immune response. T cells have been used to treat hyperproliferative diseases, including tumors. To generate T cells with a specificity (e.g., specificity for tumor cells). The method of adoptive T cell therapy is provided as a schematic in FIG. As discussed herein, T cells isolated from an allo-HLA repertoire are capable of targeting a target. It may provide higher avidity, which is desirable for efficiently eradicating tumors. Allo-HLA-restricted T cells are compared to self-restricted T cells in Table 1 below: [Table 1A]
[0036] Thus, in some embodiments, a nucleic acid molecule comprising a CDR3-encoding polynucleotide is The present invention provides a method for the preparation of a melanoma-preferentially expressed antibody, comprising: Specific to the preferentially expressed antigen in melanoma (PRAME) The CDR3-encoding polynucleotide encodes a T cell receptor that specifically binds to the T cell receptor; The nucleic acid sequence encodes a first polypeptide comprising the CDR3 region of a TCRα polypeptide. said CDR3-encoding polynucleotide comprising a first polynucleotide encoding a TCR β polypeptide; a second polynucleotide encoding a second polypeptide comprising the CDR3 region of the polypeptide; and the CDR3 region of the TCR alpha polypeptide and the TCR beta polypeptide. In some embodiments, the nucleic acid molecule In some embodiments, the first or A nucleotide sequence encoding a second polypeptide or the first and second polypeptides. In some embodiments, the first or second codon sequence is codon optimized. In some embodiments, the first and second polypeptides or the amino acid sequence of the first or second polypeptide is selected from the group consisting of a polypeptide sequence for expression of a recombinant TCR. Cysteine modified to increase the nucleotide sequence. This means that the code sequence encodes a polypeptide containing an additional cysteine residue. Sequence optimized refers to a sequence that is sequence optimized to enhance expression of the encoded polypeptide. Examples of codon-optimized nucleotide sequences are described herein. Although shown, other nucleotide sequences that similarly encode the CDR3 regions provided herein are also contemplated. A sequence may be used, the term codon-optimized, but the CDR3 polypeptide (TC The CDR3 regions of the Rα and TCRβ chains, or the polypeptide sequences provided herein (including derivatives thereof that are 90% or more identical to It is understood that the term "amino acid sequence" includes nucleotide sequences such as In calculating the identity of a derivative, recombinant TCR α or β polypeptide, or Cysteines used to enhance expression of the CDR3 region or other fragments of is the percentage when the sequence provided herein as SEQ ID NO: does not have a cysteine modification. are not considered as part of the portfolio calculation.
[0037] In some embodiments, the CDR3 region of the T cell receptor has the amino acid sequence Specific binding to PRAME polypeptides containing SLLQHLIGL. In one embodiment, the first polypeptide comprises the amino acid sequence of SEQ ID NO:1, and the second polypeptide comprises the amino acid sequence of SEQ ID NO:1. the polypeptide comprises the amino acid sequence of SEQ ID NO:4; or the first polypeptide The second polypeptide comprises the amino acid sequence of SEQ ID NO:26. amino acid sequence, or the sequence of SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 23, or SEQ ID NO: 26 A derivative having an amino acid sequence 90% or more identical to the sequence. In some embodiments, the first polynucleotide comprises SEQ ID NO:2 or or a derivative thereof, The nucleotide sequence of SEQ ID NO:5 or SEQ ID NO:6, or a derivative thereof. or the first polynucleotide is the nucleotide sequence of SEQ ID NO:24 or SEQ ID NO:25. 90% or more identical to the nucleotide sequence of SEQ ID NO:24 or SEQ ID NO:25. and derivatives thereof having more than 90% identical consecutive nucleotides, The nucleotide sequence of SEQ ID NO:27 or SEQ ID NO:28, or SEQ ID NO:27 or a sequence of consecutive nucleotides that is 90% or more identical to the nucleotide sequence of SEQ ID NO:28. This includes derivatives thereof having the structure
[0038] In some embodiments, the CDR3 region of the T cell receptor has the amino acid sequence Specific binding to PRAME polypeptides including QLLALLPSL. In one embodiment, the first polypeptide comprises the amino acid sequence of SEQ ID NO:45, and the second polypeptide comprises the amino acid sequence of SEQ ID NO:45. The polypeptide of claim 2 has the amino acid sequence of SEQ ID NO: 48, SEQ ID NO: 45 or SEQ ID NO: 48 The amino acid sequence of the present invention includes an amino acid sequence having 90% or more than 90% identity to the sequence of the present invention. In some embodiments, the first polynucleotide is SEQ ID NO: 46 or SEQ ID NO: 47, or the nucleotide sequence of SEQ ID NO: 46 or SEQ ID NO: 47 and derivatives thereof having 90% or more than 90% consecutive nucleotide identity to said sequence, The polynucleotide of SEQ ID NO: 49 or SEQ ID NO: 50, or is 90% or more identical to the nucleotide sequence of SEQ ID NO:49 or SEQ ID NO:50 and derivatives thereof having consecutive nucleotides of
[0039] In some embodiments, the CDR3 region of the T cell receptor is human PRAM In some embodiments, the CDR3 region of the T cell receptor comprises Binds to PRAME in the context of MHC class I HLA presentation. In the method, the CDR3 region of the T cell receptor specifically binds to a peptide-MHC complex. wherein the MHC molecule is an MHC class I HLA molecule and the peptide binds In some embodiments, the MHC molecule is an MH In some embodiments, the PR is a C class 1 HLA A2.01 molecule. The AME epitope is SLLQHLIGL or the PRAME epitope is , QLLALLPSL.
[0040] In some embodiments, the nucleic acid is a nucleic acid sequence that encodes the CDR3-encoding polynucleotide. In some embodiments, the nucleic acid molecule further comprises a promoter operably linked thereto. The subject invention relates to a chimeric caspase-9 polypeptide comprising a multimeric ligand-binding domain and a caspase-9 polypeptide. In some embodiments, the method further comprises the step of: The present invention relates to a method for producing a chimeric caspase-9 polypeptide comprising the steps of: Modified cells transfected or transduced with the nucleic acids of the application are provided. In some embodiments, the modified cell is a T cell.
[0041] In some embodiments, a plasmid vector or virus vector comprising the nucleic acid molecule of the present application. In some embodiments, vectors are provided that are transfected with the nucleic acid molecules of the present application. Transfected or transduced modified cells are provided. In one embodiment, the cell comprises a multimeric ligand binding domain and a caspase-9 polypeptide. A nucleic acid molecule comprising a polynucleotide encoding a chimeric caspase-9 polypeptide comprising In some embodiments, the modified cell is a T cell.
[0042] In some embodiments, the modified cells of the present application, the nucleic acids of the present application, or the and a pharma- ceutical acceptable carrier. A pharmaceutical composition comprising the compound is also provided.
[0043] In some embodiments, in a subject diagnosed with a hyperproliferative disease or condition Methods for enhancing immune responses are provided, said methods comprising treating the modified cells of the present application. In some embodiments, the method further comprises administering to the subject an effective amount of the compound. The body has at least one tumor, wherein the size of said at least one tumor is In some embodiments, the subject has: From the group consisting of sarcoma, acute lymphoblastic leukemia, acute myeloid leukemia, and neuroblastoma Have been diagnosed with a selected condition or disease, such as melanoma, leukemia, lung cancer, Intestinal cancer, renal cell carcinoma, breast cancer, sarcoma, acute lymphoblastic leukemia, acute myeloid leukemia, and The patient has been diagnosed with a disease selected from the group consisting of neuroblastoma and neuroblastoma.
[0044] In some embodiments, the method comprises administering to a subject a cell-mediated isoform to a target cell population or tissue in the subject. A method for stimulating a cellular immune response is provided, the method comprising using the modified cells of the present application. In some embodiments, the method further comprises administering to the subject a The number or concentration of target cells that are resistant to the targeted therapy is decreased following administration of the modified cells. In some embodiments, the modified cells comprise a chimeric caspase-9 polypeptide. and the method further comprises, after administration of the modified cells to the subject, administering to the subject a multimeric ligand that binds to the multimeric ligand binding region. In some embodiments, administration of the multimeric ligand results in The number or concentration of modified cells containing the melCaspase-9 polypeptide is determined by the multimeric linker. The chimeric caspase-9 polypeptide in a sample obtained from the subject prior to administration of the drug. and administering the multimeric ligand to the subject in comparison to the number or concentration of engineered cells containing the polypeptide. is subsequently decreased in samples obtained from said subjects.
[0045] In some embodiments, a T cell receptor that specifically binds to PRAME in a cell. Also provided is a method for expressing a peptide comprising combining a nucleic acid molecule of the present application with a cell. under conditions whereby the nucleic acid is incorporated into the cell, The cells then express the T cell receptor from the integrated nucleic acid.
[0046] As used herein, the term "comprises" in the claims and / or specification The use of the word "a" or "an" when used with "mprising" is "one," but "one or more," "at least one," and "one or "one or more." "containing" and "comprising" "open ended" and "open-ended" are interchangeable and those skilled in the art will understand that these terms are open ended. I recognize that it is a term that ends with "n".
[0047] As used herein, the term "allogeneic" refers to an allogeneic cell that is antigenically identical to the host cell and the donor cell. Refers to different HLA or MHC loci.
[0048] Thus, cells or tissues transplanted from the same species may be antigenically different. The mice can differ at one or more genetic loci (congenic), whereas allogeneic mice can be derived from the same The background may be
[0049] As used herein, the term "autologous" refers to a combination of antigenicity between the host and donor cells. Not separate (e.g., when donor cells are obtained from the host) HLA loci or MHC Refer to the locus.
[0050] As used herein, the term "antigen" is defined as a molecule that elicits an immune response. This immune response involves the production of antibodies or the activation of specific immunocompetent cells, or both. Antigens may be organisms, subunits of proteins / antigens, killed or inactivated Exemplary organisms include Helicobacter, Campylobacter, Clostridium, Corynebacterium diphtheria eriae, Bordetella pertussis, influenza virus, Influenza virus, respiratory syncytial virus, Borrelia burgdorferi fei, plasmodium, herpes simplex virus, human immunodeficiency virus, papilloma Viruses, Vibrio cholera, Escherichia coli, measles virus, rotavirus, dysentery Examples include Salmonella typhi, Neisseria gonorrhea, and Thus, the present invention can be applied to virtually any protein or peptide. Any macromolecule, including peptides, can serve as an antigen. In addition, antigens can be recombinant DNA or gels. It can be derived from genomic DNA, pathogenic genomes, or proteins that induce an immune response. The nucleotide sequence or partial nucleotide sequence of a gene or a fragment of a gene Any DNA containing the gene will result in the synthesis of an antigen. The present compositions and methods are not limited to the use of the entire nucleic acid sequence. The present invention relates to the use of partial nucleic acid sequences of genomes and the identification of species in which these nucleic acid sequences elicit a desired immune response. This includes, but is not limited to, being arranged in various combinations.
[0051] The term "antigen-presenting cell" refers to a cell that presents at least one antigen or antigenic fragment to the cell. Can be displayed, acquired or presented on a surface (or on a cell surface) In general, the term "cell" refers to any of a variety of cells that can be bound to an antigen or antigenic composition. Strengthening of immune response (i.e., immune response from either the T cell or B cell arms of the immune system) to The cells may be any that achieve the goal of helping to transform the Immunology,supp.4th edition,WHFreeman and company, which is incorporated herein by reference. As used herein in certain embodiments, normal or class II predominant subpopulations Displaying antigens on immune cells in association with histocompatibility molecules or major histocompatibility complexes In certain embodiments, a cell (e.g., , APC cells) can be derived from another cell, e.g., a recombinant cell or a tumor cell expressing the desired antigen. Methods for preparing fusions of two or more cells include, for example, For example, Goding, JW, Monoclonal Antibodies: Pri nciples and Practice,pp.65-66,71-74(Acad emic Press, 1986);Campbell, Monoclonal Ant ibody Technology,Laboratory Techniques i n Biochemistry and Molecular Biology,Vol. .13,Burden & Von Knippenberg,Amsterdam,E lseview,pp.75-83,1984; Kohler & Milstein ,Nature,256:495-497,1975;Kohler & Milste In,Eur. J. Immunol.,6:511-519,1976,Gefter et al. , Somatic Cell Genet., 3:231-236, 1977 (these each of which is incorporated herein by reference. Immune cells that display or present antigens are CD4 + They are TH cells. Additional molecules expressed on APCs or other immune cells may help enhance the immune response Secreted or soluble molecules, such as cytokines and adjuvants, may be Bunting may also aid or enhance the immune response to an antigen. Various examples are given in the present specification. This is discussed in the book.
[0052] An "antigen recognition portion" is any polypeptide or fragment thereof that binds to an antigen, e.g. For example, it may be an antibody fragment variable domain, naturally derived or synthetic. Examples of recognition moieties include polypeptides derived from antibodies (e.g., single chain variable fragments (sc Fv), Fab, Fab', F(ab') 2 , and Fv fragments); Polypeptides derived from cell receptors (such as TCR variable domains); signal transduction Secreted factors (e.g., cytokines, growth factors) that can be artificially fused to the delivery domain (e.g., (e.g., "zytokines"), and bind to extracellular cognate proteins. Any ligand or receptor fragment (e.g., CD27, NKG2D) may be used. Combinatorial libraries can also be used to identify, but are not limited to, tumor-associated targets. The method can be used to identify peptides that bind with high affinity to a target protein.
[0053] The term "autologous" refers to cells, nucleic acids, proteins, polypeptides, etc., which are subsequently The modified cells of the present method are those derived from the same individual that are administered to the individual. For example, the cells may be autologous (such as, for example, autologous T cells).
[0054] As used herein, the term "cancer" refers to a cancer that has a unique characteristic: the loss of normal controls. Loss of this receptor leads to uncontrolled growth, lack of differentiation, local tissue invasion and metastasis. It is defined as an overgrowth of cells. Examples include melanoma, non-small cell lung cancer, and small cell lung cancer. Cancer, lung cancer, hepatocellular carcinoma, leukemia, retinoblastoma, astrocytoma, glioblastoma, gum cancer, Tongue cancer, neuroblastoma, head cancer, neck cancer, breast cancer, pancreatic cancer, prostate cancer, eye cancer, Kidney cancer, bone cancer, testicular cancer, ovarian cancer, mesothelioma, cervical cancer, digestive cancer, lymphoma, brain Cancers include, but are not limited to, colon cancer, sarcoma, or bladder cancer.
[0055] As used herein, the terms "cell," "cell line," and "cell culture" are used interchangeably. All of these terms include any and all subsequent generations of such terms. It is possible that all progeny may not be identical due to deliberate or inadvertent mutations. It is understood that there is.
[0056] As used herein, the term "cDNA" refers to a nucleic acid sequence derived from a messenger RNA (RNA) as a template. The term "genomic DNA" is intended to refer to DNA prepared using mRNA. or genomic RNA templates, unprocessed RNA templates or partially processed RNA templates. Using cDNA as opposed to DNA polymerized from a sequenced RNA template The advantage of this approach is that the cDNA contains primarily the coding sequence for the corresponding protein. In some cases, complete or partial genomic sequences may be used, e.g., non-coding sequences may be used for optimal expression. If coding regions are required, or non-coding regions such as introns are involved, the antisense strand There are cases where it is targeted in latent diseases.
[0057] As used herein, the term "expression construct" or "transgene" refers to a gene product. A nucleic acid coding sequence is defined as any type of genetic construct that contains a nucleic acid that codes for a nucleic acid molecule. Part or all of the code sequence can be transcribed, and the construct is inserted into a vector. A transcript may, but does not necessarily, be translated into a protein. In certain embodiments, expression refers to the transcription of a gene and the translation of mRNA into a gene product. In another embodiment, expression is transcription of a nucleic acid encoding a gene of interest. The term "therapeutic construct" is used to refer to an expression construct or a transgene. The expression construct or transgene may also be used to treat, for example, a hyperproliferative disease or hyperplasia. The expression constructs or vectors may be used as therapeutics to treat reproductive disorders, such as cancer. The transgene may be a therapeutic or a prophylactic construct.
[0058] As used herein, the term "expression vector" refers to a vector that contains a gene capable of being transcribed. The term "vector" refers to a vector that contains a nucleic acid sequence that codes for at least a portion of a gene product. In some cases, the RNA molecule is then translated into a protein, polypeptide, or peptide. In other cases, for example in the production of antisense molecules or ribozymes, these sequences are Expression vectors can contain a variety of regulatory sequences, which are specific to a particular host. To transcribe and possibly translate an operably linked coding sequence in a host organism. Vectors and expression vectors refer to nucleic acid sequences necessary for transcription and translation. In addition to governing regulatory sequences, nucleic acid sequences which serve other functions as well may be included, which are described below. To be discussed.
[0059] As used herein, the term "ex vivo" refers to "outside" the body. The terms "ex vivo" and "in vitro" may be used interchangeably herein.
[0060] T cell receptors (TCRs) are immune proteins that specifically bind to antigenic molecules. The TCR is composed of two distinct polypeptides present on the surface of T cells. They recognize or specifically bind to antigens bound to major histocompatibility complex molecules. Upon binding to the antigen, the T cell is activated. T cell receptor or fragment(s) thereof (e.g., TCRα polypeptide) The TCRβ polypeptide and the TCRβ polypeptide together contact the antigen and identify it as a target. The TCR is composed of an α polypeptide and a β polypeptide, The α and β polypeptides may comprise two extracellular domains or chains. The α and β polypeptides comprise a variable domain and a constant domain. The variable domain has three complementarity determining regions (CDRs); CDR3 is responsible for determining the epitope. The α polypeptide is thought to be the main CDR responsible for recognition by VJ rearrangement. The β polypeptide comprises a V and J region generated by VDJ rearrangement. The V, D, and J regions are connected to each other. The CDR3 region corresponds to the CDR4 region. TCRs are often referred to as International Immunogenetics (IMG) T) TCR nomenclature (IMGT Database, www.IMGT.org; Gi udicelli, V. et al., IMGT / LIGM-DB, IMGT (registered trademark) co mprehensive database of immunoglobulin a nd T cell receptor nucleotide sequences, Nucl. Acids Res., 34, D781-D784 (2006). PMID: 16381979;T Cell Receptor Factsboo k, LeFranc and LeFranc, Academic Press I They are named using the SBN 0-12-441352-8.
[0061] "Specifically binds" when referring to a T cell receptor or to a compound as used herein. Recombinant T cell receptor, polypeptide, polypeptide fragment, variant, or The T cell receptor may be an analog or a modified cell (e.g., PRAME T cell receptor, T cell receptor The CDR3 region of the receptor and the engineered cells expressing the PRAME TCR are referred to as When the T cell receptor or a fragment thereof recognizes the PRAME antigen, It means that the antibody can selectively bind to or bind to a specific antibody under certain conditions (e.g., immunoassays). (e.g., in the immunoassays discussed herein), the T cell receptor is P The T cell receptor binds to RAME and does not bind to other polypeptides in significant amounts. Sceptors are at least 5, 10, 2, or 3 times more potent than the control antigenic polypeptide. 0, 30, 40, 50, or 100 times higher affinity to PRAME. Binding of the PRAME TCR can also be indirectly mediated in the context of engineered T cells expressing the PRAME TCR. For example, in an assay such as the assays discussed herein, The engineered T cells can be derived from PRAME-expressing cell lines, cells, or tissues (e.g., myeloma, AM L, or ALL cells. The PRAME TCR-expressing T cells were compared with control cells that were not PRAME-expressing cell lines. At least 5, 10, 20, 30, 40 times higher than its reactivity against the strain 50-fold, 50-fold, or 100-fold higher reactivity in PRAME-expressing cell lines. ME T cell receptor, T cell receptor CDR3 region, and PRAME TCR expression The current cell line is capable of binding, for example, to PRAME expressed on the cell surface, and typically , major histocompatibility marker In the context of MHC class I HLA presentation (e.g., MHC class I HLA presentation), e.g. For example, in the context of MHC class 1 HLA A2.01 presentation, .
[0062] As used herein, the term "functionally equivalent" refers to, for example, a T cell receptor. or T cell receptor nucleic acid fragments, variants, or analogs When referring to T cell receptors or T cells that stimulate an immune response to an antigen or cell, TCR refers to a nucleic acid that encodes a cellular receptor polypeptide. In this situation, the TCR recognizes the antigen as an epitope as part of a peptide-MHC complex. "Functionally equivalent" or "functional fragments" of T cell receptor polypeptides A "fragment" is, for example, a fragment that lacks a T cell receptor domain (e.g., a constant region). It refers to a T cell receptor that can stimulate an immune response typical of T cells. T cell receptor fragments, for example, bind to antigens, either alone or in an MHC complex. capable of specifically binding to or recognizing an antigen, and upon binding or recognition, T lymphocytes For example, the TCR or the TCR alpha or beta polypeptides may be activated. Derivatives of nucleic acid molecules or nucleotide sequences encoding the CDR3 regions of peptides are known in the art. R, or a functional CDR3 region of a TCR α polypeptide or a TCR β polypeptide. and specifically binds to the antigen, e.g., alone or in an MHC complex. or a nucleic acid molecule or nucleotide sequence encoding a polypeptide that recognizes the antigen. The nucleotide sequence encoding the TCR α or TCR β polypeptide is These derivatives include, for example, TCRα or TCRβ polypeptides. A sequence that is 80%, 85%, 90%, 95% or more identical to the corresponding nucleotide sequence The CDR3 region of the T cell receptor polypeptide may have a "functionally An "equivalent" or "functional fragment thereof" may, for example, have an altered amino acid sequence. and, for example, the amino acid sequence of the α or β polypeptide, or The corresponding α and β polypeptides are 80%, 85%, 90%, and 95% or more than 95% identical, but the T cell receptor (e.g., recombinant T cell receptor) α polypeptides that, when included as part of the The term refers to a T cell receptor that may have an amino acid sequence and an amino acid sequence. In calculating the identity of the acid sequence derivatives or nucleotide sequences, the recombinant TCRα A polypeptide or a β-polypeptide, or a CDR3 region or other fragment thereof A cysteine or a cysteine residue that is used to enhance expression of the target gene. The codons are the same as those in the sequences provided herein as SEQ ID NOs: The terms "functionally equivalent" or "functional "Fragments" may refer to other nucleic acids or polypeptides (e.g., caspase-9 or cleavage fragments). When applied to a caspase-1 or -2 enzyme (such as type 2 caspase-9), the term is used in conjunction with the method reference points herein. This refers to fragments, variants, etc. that have the same or similar activity as a polypeptide. For example, a functional fragment of a tumor antigen polypeptide (such as PSMA) can be The ligand-binding region may be antigenic and may generate antibodies that recognize specific tumor antigens. Functional fragments, such as Fvls, are fragments of a ligand that are sufficient to bind to an appropriate ligand. "Functionally equivalent" includes, for example, a portion of the extracellular domain of the polypeptide. lacking IL-1, but amplifying T cell-mediated tumor killing responses when expressed in T cells Costimulatory polypeptides that can stimulate the activation of the stimulatory pathway.
[0063] The term "hyperproliferative disease" is defined as a disease resulting from the hyperproliferation of cells. Suitable hyperproliferative diseases include, but are not limited to, cancer or autoimmune diseases. Other hyperproliferative diseases include vascular occlusion, restenosis, atherosclerosis or Inflammatory bowel disease may be mentioned.
[0064] As used herein, the term "gene" refers to a functional protein, polypeptide, or As will be understood, this functional use is defined as a unit that codes for a polypeptide. The term includes genomic sequences, cDNA sequences, and proteins, polypeptides, domains, peptides, and the like. The present invention relates to a method for the preparation of a peptide, a fusion protein, and a mutant thereof, which can be expressed or adapted to express the peptide, a fusion protein, and a mutant thereof. The present invention includes smaller engineered gene segments.
[0065] The term "immunogenic composition" or "immunogen" refers to a substance that is capable of eliciting an immune response. Examples of immunogens include antigens, which play a role in the induction of autoimmune diseases, and These include self-antigens that play a role in the pathogenesis of cancer, and tumor-associated antigens expressed on cancer cells.
[0066] As used herein, the term "immunocompromised" refers to a condition in which the immune system is weakened or weakened. An immunocompromised state is defined as a subject who is suffering from a deficiency or dysfunction of the immune system. This may be due to impaired function or other factors that increase susceptibility to infection and / or disease. Such a classification provides a conceptual basis for evaluation, but immunocompromised individuals are classified as one group. or does not entirely fit into the other group. Deficiencies can be affected, for example, certain T lymphocyte deficiencies caused by HIV. Individuals with HIV have neutropenia caused by drugs used for antiviral treatment. Patients may have mild symptoms or may be immunocompromised because the integrity of the skin and mucous membranes has been breached. Immunocompromised status may be associated with indwelling central lines. al lines) or other types of impairment resulting from intravenous drug abuse. or may be caused by secondary malignancies, malnutrition, or other infectious diseases. Infected with a protozoan (e.g., tuberculosis) or sexually transmitted disease (e.g., syphilis or hepatitis) This may be due to the following.
[0067] As used herein, the term "pharmacologically acceptable" refers to a compound that is pharma- ceutically or pharmacologically acceptable to an animal. or when administered to humans, It refers to molecular entities and compositions that do not produce untoward reactions.
[0068] As used herein, a "pharmaceutically acceptable carrier" refers to any and all All solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. The use of such media and agents for pharma- ceutical active substances is within the scope of the Any conventional media or agent may be used to express the vectors presented herein. Except where the compound is incompatible with the host or cell, its use in a therapeutic composition is contemplated. Supplementary active ingredients can also be incorporated into the compositions. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. .
[0069] As used herein, the term "polynucleotide" refers to a chain of nucleotides. Further, a nucleic acid is a polymer of nucleotides. As used herein, nucleic acid and polynucleotide are interchangeable. Nucleic acids are monomeric A polynucleotide that can be hydrolyzed into "nucleotides." Monomeric nucleotides As used herein, a polynucleotide can be hydrolyzed to a nucleoside. includes all nucleic acid sequences obtained by any means available in the art. Such means include, but are not limited to, recombinant means, i.e., conventional Cloning techniques and PCR TMRecombinant libraries or cell genomes using These include, but are not limited to, cloning of nucleic acid sequences from Additionally, polynucleotides include variations of polynucleotides, including those known in the art. This includes, but is not limited to, mutations of nucleotides or nucleosides by nucleic acid manipulations. may comprise one or more polynucleotides.
[0070] As used herein, the term "polypeptide" refers to a polypeptide that generally has a defined sequence. A polypeptide is defined as a chain of amino acid residues. As used herein, a polypeptide is a The term may be interchangeable with the term protein.
[0071] As used herein, the term "promoter" refers to a molecule that initiates the specific transcription of a gene. Recognized by the cellular or introduced synthetic machinery required for It is defined as a DNA sequence.
[0072] As used herein, the terms "controlling an immune response" and "regulating an immune response" refer to Or, "controlling an immune response" refers to being able to modify an immune response. For example, In addition, the composition can enhance and / or activate the immune response. Additionally, the composition may also inhibit an immune response. For example, a dimeric analog of a chemical may act as a costimulatory ligand. This results in dimerization of the peptide, resulting in T cell activation, however, the chemical Monomeric analogs of the substance do not result in dimerization of costimulatory polypeptides and activate T cells. Does not become.
[0073] The terms "transfection" and "transduction" are interchangeable and refer to the transfer of an exogenous gene to a cell. Refers to the process by which NA sequences are introduced into a eukaryotic host cell. Transfection (or transduction) can be achieved by electroporation, microinjection, or gene guns. Delivery, retroviral infection, lipofection, superfection This can be accomplished by any one of several means, including by a multi-step process (e.g., a multi-step process for detecting the presence of a target object).
[0074] As used herein, the term "syngeneic" refers to a genetically identical or identically genotyped or identically grafted. have genotypes that are closely related or immunologically compatible to be For example, identical twins or animals of the same inbred strain. Syngeneic and isogenic may be used interchangeably.
[0075] The terms "patient" and "subject" are interchangeable and as used herein , organisms or animals; mammals (e.g., humans, non-human primates (e.g., monkeys), mice, Pigs, cows, goats, rabbits, rats, guinea pigs, hamsters, horses, monkeys, sheep, including other non-human mammals); non-mammals (e.g., non-mammalian vertebrates, e.g., Birds (e.g., chickens or ducks) or fish, as well as non-mammalian invertebrates. This includes, but is not limited to:
[0076] As used herein, the term "vaccine" refers to a form that can be administered to an animal. The term "formulation" refers to a formulation that contains the compositions presented herein, which are present in a pharmaceutical form. Cutin provides a conventional saline or buffered aqueous medium in which the composition is suspended or dissolved. In this form, the composition is intended to prevent, ameliorate, or otherwise treat a condition. Vaccines, when introduced into a subject, can be used to induce the production of antibodies, serogroups, and / or antibodies against a particular target cell. Inducing an immune response, including but not limited to the production of cytokines and / or other cellular responses. can be caused.
[0077] As used herein, the terms "under transcriptional control" or "operably linked" refer to A promoter is a nucleic acid that controls the initiation of RNA polymerase and the expression of a gene. is defined as being in the correct position and orientation with respect to
[0078] As used herein, the terms "treatment," "treat," and "treated" refer to "Treating" refers to prophylaxis and / or therapy. The term, when used in reference to a solid tumor, e.g., a cancerous solid tumor, refers to refers to prevention by prophylactic treatment to enhance a subject's resistance to solid tumors or cancer. In some examples, a subject may be treated to prevent cancer, where the Cancer is familial or genetically related. The term can also refer to, for example, infectious diseases. When used in a therapeutic setting, it is a prophylactic treatment that enhances the resistance of a subject to infection by a pathogen, i.e. In other words, the subject may be susceptible to infection with a pathogen or may be attributable to the infection. Preventive treatments to reduce the likelihood of showing symptoms of disease, as well as treatments to combat infectious diseases, e.g. , to weaken or eliminate an infectious disease or to prevent it from worsening, Refers to the treatment after a subject has been infected.
[0079] The methods provided herein include, for example, treating a disease, disorder in which elevated expression of a tumor antigen is present. or may be used to treat a condition.
[0080] As used herein, the term "vaccine" refers to a form that can be administered to an animal. The term "formulation" refers to a formulation that contains the compositions presented herein, which are present in a pharmaceutical form. Cutin provides a conventional saline or buffered aqueous medium in which the composition is suspended or dissolved. In this form, the composition is intended to prevent, ameliorate, or otherwise treat a condition. Vaccines can be used to treat a variety of conditions, including cancer, cancers, and cancers. Vaccines, when introduced into a subject, can stimulate the production of antibodies. These include, but are not limited to, induction of cell proliferation, production of cytokines and / or production of other cellular responses. This can trigger a novel immune response.
[0081] Hematological disease: As used herein, the terms "hematological disease," "hematological disorder," and / or "hematological disorder" refer to "Disorders of the Blood" refers to disorders of blood and its components (including blood cells, hemoglobin, and blood proteins) (but not limited to) production of blood proteins, clotting mechanisms, blood production, Non-limiting examples of blood disorders include conditions that affect the production of blood glucose, insulin, and blood sugar, and combinations thereof. Examples include anemia, leukemia, lymphoma, hematological neoplasms, albuminemia, nemias, and hemophilia.
[0082] Bone marrow disease: As used herein, the term "bone marrow disease" refers to a disorder that affects the production of blood cells and platelets. In some bone marrow disorders, the normal bone marrow structure is may be displaced by infection (e.g., tuberculosis) or malignant disease, which then leads to the destruction of blood cells and Non-limiting examples of bone marrow disorders include leukemia, bacterial infections, and osteoporosis. Radiation sickness or poisoning, pancytopenia, enia, anemia, and multiple myeloma.
[0083] T cells and activated T cells (CD3 + ): T cells (also called T lymphocytes) Lymphocytes belong to a group of white blood cells called lymphocytes. Lymphocytes are generally involved in cell-mediated immunity. "T" in "T cells" refers to cells that originate in the thymus or whose maturation is influenced by the thymus. T cells react to the presence of cell surface proteins known as T cell receptors. Thus, other lymphocyte types (e.g., B cells and natural killer (NK) cells) As used herein, the term "activated T cells" refers to class II primary histopathological Immune responses (e.g., by recognition of antigenic determinants presented on the MHC markers) The term refers to T cells that have been stimulated to produce a specific type of T cell proliferation (e.g., clonal expansion of activated T cells). T cells respond to antigenic determinants, cytokines and / or lymphokines, and differentiation classes. Target cell surface proteins (e.g., CD3, CD4, CD8, etc. and combinations thereof) Cells expressing the cluster of differential proteins are activated by the presence of They are often said to be "positive" for expression of that protein on the T cell surface (e.g. For example, cells positive for CD3 or CD4 expression are CD3 + or CD4 + It is called The CD3 and CD4 proteins mediate signal transduction in T cells directly and and / or a cell surface receptor or co-receptor which may be indirectly involved.
[0084] Peripheral blood: As used herein, the term "peripheral blood" refers to blood obtained from the circulating pool of blood. or cellular components of blood that are prepared and not sequestered in the lymphatic system, spleen, liver, or bone marrow (e.g., red blood cells, white blood cells, and platelets).
[0085] Umbilical cord blood: Umbilical cord blood is a type of blood that is separated from peripheral blood and blood that is sequestered within the lymphatic system, spleen, liver, or bone marrow. The term "umbilical blood" may be used interchangeably. ), "umbilical blood" or "cord blood" "Oral blood" refers to the blood that remains in the placenta and in the umbilical cord after birth. Umbilical cord blood often contains stem cells, including hematopoietic cells.
[0086] For example, "obtained or prepared" as in the case of cells means that the cells or cells The cell culture is isolated, purified or partially purified from its source. where the source can be, for example, umbilical cord blood, bone marrow or peripheral blood. These terms are used when the original source or cell culture is grown and the cells are replicated, and This also applies when the cell is derived from the original source and its progeny.
[0087] "Kill" as in when a certain percentage of cells are killed "Killing" refers to any known method for measuring apoptosis. The term refers to the death of cells by apoptosis, as measured using a It may also refer to exfoliation.
[0088] Donor T cells: As used herein, the term "donor T cells" refers to T cells that are transplanted after allogeneic stem cell transplantation. are often administered to recipients to confer antiviral and / or antitumor immunity to Donor T cells are used to inhibit bone marrow graft rejection and and to increase the success of allogeneic grafting. However, the same donor T cells can also mount an allogeneic response to host antigens. may trigger an alloaggressive response, which may then , which can lead to graft-versus-host disease (GvHD). Certain activated donor T cells can Activated T cells may induce a higher or lower GvHD response than activated T cells. may also be reactive against tumor cells of the recipient organism, resulting in a beneficial graft-versus-tumor effect. .
[0089] Function-conservative variants change the overall structure and function of a protein or enzyme. A protein or enzyme in which a given amino acid residue has been altered without affecting the function of the Amino acids are classified as molecules with similar properties, including polar or nonpolar nature, size, shape, and charge. This includes, but is not limited to, replacing the amino acid with an amino acid that is not present in the target gene. Conservative amino acid substitutions for many of the amino acids not encoded by ribozyme are well known in the art. Conservative substitutions for other non-encoded amino acids are not The determination may be based on physical properties compared to the characteristics.
[0090] Amino acids other than those indicated as conserved amino acids are not distinct in proteins or enzymes. and the protein sequence or amino acid sequence between any two proteins that are similar in function. The percentage of similarity between sequences may vary and is determined according to an alignment scheme. , e.g., at least 70%, at least 80%, at least 90%, e.g., at least As referred to herein, "sequence similarity" refers to the degree of similarity between nucleotide sequences. The degree of similarity between two sequences is determined by the degree of sequence or protein sequence relatedness. The term "sequence identity" as used herein may be based on percent sequence identity and / or conservation. "Sequence alignment" refers to the degree to which two nucleotide or amino acid sequences are invariant. An "indentation" is a sequence that is the maximum identity (and amino acid sequence) for the purposes of assessing the degree of similarity. In the case of alignment, it refers to the process of aligning two or more sequences to achieve a certain level of sequence conservation. There are numerous methods for aligning sequences and assessing similarity / identity (e.g. For example, the Cluster method based on the MEGALIGN algorithm and the BLA Such protocols as STN, BLASTP and FASTA are well known in the art. When using any of the markers, the settings used are those that give the highest sequence similarity. This is a light setting.
[0091] Mesenchymal stromal cells: As used herein, the term "mesenchymal stromal cells" or "Bone marrow-derived mesenchymal stromal cells" are capable of producing ex vivo, in vitro and in vivo They can differentiate into adipocytes, osteoblasts and chondroblasts, and can form plastic cells under standard culture conditions. These multipotent stem cells can be further defined as a subset of mononuclear bone marrow cells that adhere to culture dishes. This refers to a condition in which hematopoietic markers are negative and CD73, CD90, and CD105 are positive. be.
[0092] Embryonic stem cells: As used herein, the term "embryonic stem cells" refers to cells that are 50-150 cells This refers to pluripotent stem cells derived from the inner cell mass of the blastocyst, an early embryo. The embryo has the ability to reproduce itself indefinitely, as well as the ability to form the three primary germ layers: the ectoderm, endoderm and Pluripotent cells are characterized by their ability to differentiate into all cell types, including the pluripotent stem cell and all derivatives of the mesoderm. whereas multipotent cells (e.g., adult stem cells) can only give rise to a limited number of cell types. Pluripotent means that cells cannot differentiate into multiple cells. It is distinguished from the tent.
[0093] Induced pluripotent stem cells: As used herein, the term "induced pluripotent stem cells" or "human "Pluripotent stem cells" are cells that, like embryonic stem cells, can differentiate into many, but not all, cell types. Genetic manipulation (e.g., expression of a gene that subsequently activates pluripotency) can be used to generate cells that can current), biological manipulation (e.g., treatment with viruses or retroviruses) and / or has been "reprogrammed" or modified by chemical manipulation (e.g., small molecules, peptides, etc.) Induced pluripotent stem cells are cells that have been induced to become adult or differentiated cells. , intermediately differentiated or terminally differentiated situations (e.g., skin cells, bone cells, fibroblasts, etc.) ) and then induced to dedifferentiate, thereby forming multipotent or pluripotent cells. They are distinguished from embryonic stem cells in that they regain some or all of the ability to generate sex cells.
[0094] CD34 + Cells: As used herein, the term "CD34 + "Cells" have a number of As used herein, "CD34" refers to cells expressing the CD34 protein on the surface of the nucleus of the nucleus. 34" often acts as an intercellular adhesion molecule and is involved in T cell entry into lymph nodes. Cell surface glycoproteins that are members of the “differentiation cluster” gene family (e.g. CD34 is a sialomucin protein that is found in bone marrow and extracellular matrix. Alternatively, it may mediate the direct attachment of stem cells to stromal cells. + The cells are In the umbilical cord and bone marrow, as hematopoietic cells, a subset of mesenchymal stem cells, endothelial precursor cells, Lymphatic vessels (except for lymphatic vessels in the pleura) but not in endothelial cells of blood vessels, mast cells, and the dermis of the skin A subpopulation of dendritic cells in the interstitium and around the adnexa (negative for factor XIIIa), and certain soft tissue tumors (e.g., alveolar soft part sarcoma, pre-B acute lymphoblastic leukemia, Hematologic malignancies (Pre-B-ALL), acute myeloid leukemia (AML), AML-M7, cutis protuberans Fibrosarcoma, gastrointestinal stromal tumor, giant cell fibroblastoma, granulocytic sarcoma, Kaposi's sarcoma, liposarcoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, meningeal hemangiopericytoma These are often found in cells of tumors in tumors such as meningiomas, neurofibromas, schwannomas, and papillary thyroid carcinomas. stomach.
[0095] Tumor infiltrating lymphocytes (TILs) infiltrate tumors in a targeted manner, This refers to T cells that have various receptors that kill tumor cells. By controlling the activity of TILs through the expression of T cells, more direct control of tumor cell elimination can be achieved. It is possible.
[0096] Gene Expression Vector: As used herein, which may be used interchangeably throughout this document The terms "gene expression vector," "nucleic acid expression vector," or "expression vector" used herein are intended to mean It is capable of replicating within a host cell and is used to introduce a gene or genes into the host cell. Obtaining a nucleic acid molecule (e.g., a plasmid, a phage, an autonomously replicating sequence (ARS), an artificial chromosome , yeast artificial chromosomes (e.g., YACs). A gene may be an endogenous gene (e.g., a gene normally found in a host cell or host organism) or is a heterologous gene (e.g., a gene not normally found in the genome or host cell or organism) A gene introduced into a cell by an expression vector can be a gene on an extrachromosomal nucleic acid. can be a naturally occurring gene, or a modified or engineered gene. The vector facilitates efficient transcription of one or more genes carried on the expression vector. enhancer sequences, promoter regions and / or termini, It may also be engineered to include 5' and 3' untranslated regulatory sequences, which may sometimes function as transcriptional sequences. Gene expression vectors sometimes are designed to be expressed in specific cell types, cell locations or tissue types. The functionality of replication and / or expression (e.g., transcription and translation) in the vector is engineered. Expression vectors sometimes contain a nucleic acid sequence that is required to maintain the vector in a host or recipient cell. Contains a selection marker.
[0097] Developmentally-regulated promoter: As used herein, the term "developmentally-regulated A "promoter" is a gene that is controlled or initiated by a developmental program or pathway. RNA polymerase that transcribes genes that are expressed under certain conditions that are either activated or affected The term refers to a promoter that acts as the first binding site for a transcription factor. The promoters that are expressed affect the transcription of genes that are part of a developmental program or pathway. The promoter is provided with additional regulatory regions for binding to activators or repressors of transcription that result in transcriptional activation. They are often located in or near the promoter region. Promoters are sometimes involved in the transcription of genes whose products influence the development and differentiation of cells.
[0098] Developmentally Differentiated Cells: As used herein, the term "developmentally differentiated cells" refers to cells that are They often involve the expression of specific genes that are biologically regulated and are required to carry out specific functions. the process by which cells develop from less specialized to more specialized forms Non-limiting examples of developmentally differentiated cells include liver cells, lung cells, These include skin cells, nerve cells, and blood cells. Changes in development and differentiation are usually caused by changes in gene expression. (e.g., changes in patterns of gene expression), rearrangements of genes (e.g., silenced Remodeling or chromatin remodeling, which hides or exposes genes that are expressed or hidden, respectively. These include changes in the DNA sequence (e.g., differentiation of immune diversity) and sometimes changes in the DNA sequence (e.g., differentiation of immune diversity). Cell differentiation can be understood as the result of a gene regulatory network. A gene regulatory module is expressed upstream of an input (e.g., a developmental pathway or program). It receives a protein (which is then sent to another part of the network) and provides an output elsewhere in the network. , a node in a gene regulatory network (e.g., the The offspring products act on other genes downstream in that developmental pathway or program).
[0099] The term "hyperproliferative disease" is defined as a disease resulting from the hyperproliferation of cells. Suitable hyperproliferative diseases include, but are not limited to, cancer or autoimmune diseases. Other hyperproliferative diseases include vascular occlusion, restenosis, atherosclerosis or Inflammatory bowel disease may be mentioned.
[0100] In some embodiments, the nucleic acid is contained within a viral vector. In one embodiment, the viral vector is an adenoviral vector, a retroviral vector, or a In some embodiments, the cell is an expression vector or a lentiviral vector. In some embodiments, the cells are contacted with the viral vector in vivo. It is understood that contact with the viral vector occurs in vivo.
[0101] In certain embodiments, the cells are also contacted with an antigen. Contacting the antigen in vivo Sometimes, the cells are contacted with the antigen in vivo. In some embodiments, the cells are present in a subject and an immune response is generated against an antigen. Sometimes the immune response is a cytotoxic T lymphocyte (CTL) immune response. In one embodiment, the immune response is directed against a tumor antigen. It is activated without the addition of adjuvant.
[0102] In some embodiments, the cells are transduced with a nucleic acid ex vivo and administered intradermally. In some embodiments, the cells are administered to a subject by ex vivo administration. and administered to the subject by subcutaneous administration. Sometimes, the cells are transduced with a nucleic acid ex vivo. To be transduced.
[0103] In some embodiments, the cells are sometimes contacted with the antigen ex vivo. In certain embodiments, the cells are present in a subject and are capable of inducing an immune response, e.g., a cytotoxic A CTL immune response is mounted against the antigen. In some cases, an immune response is mounted against tumor antigens (e.g., PSMA). In one embodiment, the nucleic acid is prepared ex vivo, e.g., by intradermal or transdermal administration. Sometimes, the cells are administered to a subject by ex vivo or in vivo administration. The nucleic acid is then transduced or transfected into the host.
[0104] In some embodiments, the nucleic acid is operably linked to a polynucleotide sequence. Alternatively, the nucleic acid may comprise a promoter sequence. The present invention includes ex vivo transcribed RNA, including
[0105] "Reducing tumor size" or "inhibiting tumor growth" of solid tumors means Guidelines for evaluating the efficacy of treatment for solid cancers (Re sponse Evaluation Criteria in Solid Tumo rs) means response to treatment or stabilization of disease according to (RECIST) criteria. For example, this may be approximately 5%, 10%, 20%, 30%, 40%, 50%, or 60% of the diameter of a solid tumor. 0%, 60%, 70%, 80%, 90% or 100% reduction or tumor, circulating tumor Approximately 5%, 10%, 20%, 30%, 40%, 50%, 6% of the number of cells or tumor markers The tumor size may include a 0%, 70%, 80%, 90% or 100% reduction. For example, CT scan, MRI, e.g. CT-MRI, chest X-ray (for lung tumors) or Molecular imaging, e.g., PET scans, e.g., inhibitors of TROFEX TM / M For example, PSA labeled with iodine 123, such as IP-1072 / 1095, For example, PET scans after administration of PSMA ligands, or molecular imaging, e.g. For example, SPECT, or PSA, e.g., PSMA antibodies, e.g., 111-Iridium Capromad pendetide, a PSMA antibody labeled with PET scans using fluoroscopy (e.g., Prostascint) and other The data may be analyzed in any manner.
[0106] "Reducing, retarding or inhibiting tumor angiogenesis" refers to reducing, retarding or inhibiting tumor angiogenesis prior to treatment. Approximately 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 2 0%, 50%, 60%, 70%, 80%, 90% or 100% reduction or new blood About 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 8% of the appearance of tubular structures This means a 0%, 90% or 100% reduction in the number of tumors per tumor. Sometimes referred to as the sum or average of angiogenesis in more than one tumor. Methods for measuring tumor angiogenesis include, for example, CAT scan, MRI, For example, CT-MRI, or molecular imaging, such as SPECT or PET scans. Can, for example, the inhibitor TROFEX TM / MIP-1072 / 1095 For example, PSA labeled with iodine 123, e.g., PSA after administration of a PSMA ligand ET scan, etc., or PSA, e.g., PSMA antibodies, e.g., 111-iridium Capromab pentetide (Prostascint), a PSMA antibody labeled with Examples of such scans include PET scans using
[0107] For example, the tumor may be one that is present in the prostate or that originates from a tumor in the prostate. It may be a tumor that has spread from a tumor in the prostate or may produce PSA. If the tumor is classified as a tumor of the prostate or as part of an organ, For example, if the tumor has the same or similar chromosomal features as the tumor in the subject's prostate, When a tumor is determined to have a breakpoint, it is believed to have metastasized from a tumor in the prostate. be.
[0108] With respect to hematological malignancies, "reducing, delaying or inhibiting hematological malignancies" " refers to a significant increase in the amount or concentration of malignant cells obtained, for example, from a subject, when compared to the amount or concentration of malignant cells before treatment. When measured in samples, approximately 5%, 10%, 20%, 30%, 40%, 50%, 60% %, 70%, 80%, 90% or 100% reduction, delay or For measuring the amount or concentration of malignant cells or tumor burden. Methods include, for example, qRT-PCR and genome-wide sequencing. .
[0109] With respect to hematological tumors, "reducing, slowing or inhibiting tumor burden" means When compared to the amount or concentration of tumor cells before treatment, e.g., in a sample obtained from the subject When measured at approximately 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70% %, 80%, 90% or 100% reduction, delay or inhibition of tumor cell mass or concentration The method for measuring the amount or concentration of tumor cells includes, for example, These include RT-PCR and genome-wide sequencing.
[0110] Engineering Expression Constructs The expression construct for expressing the TCR or chimeric polypeptide of the present invention may be It comprises a peptide coding region and a promoter sequence, all operably linked. The term "operably linked" means that the promoter sequence is linked to a second a promoter sequence corresponding to the second sequence, said promoter sequence being operably linked to said second sequence; The term "tRNA" is used to refer to a transcription factor that initiates and mediates the transcription of a target DNA.
[0111] In certain instances, a polynucleotide encoding a TCR or other polypeptide is The polynucleotide encoding the second polypeptide may be contained in the same vector (e.g., a virus vector). The second polypeptide is contained in a vector (such as a vector or a plasmid vector). The peptide can be, for example, a caspase polypeptide (as discussed herein) or a marker. In these examples, the construct may be a cleavable 2A polypeptide. two peptides linked by an internal ribosome entry sequence (IRES) a nucleic acid comprising a polynucleotide encoding a polypeptide of In these examples, the first and second promoters can be designed together. The polypeptide is cleaved during translation to produce the TCR and additional polypeptides. In one example, the two polypeptides can be expressed separately from the same vector, Each nucleic acid comprising a polynucleotide encoding one of the above polypeptides is a separate polypeptide. In yet another embodiment, a promoter is operably linked to two operably linked to the polynucleotide, producing two separate RNA transcripts, and thus directs the production of two polypeptides; in one example, the promoter is bidirectional. The coding region may be in the opposite 5'-3' orientation. Such an expression construct may contain at least one, or at least two promoters.
[0112] In yet another example, two polypeptides (e.g., a TCR and a caspase polypeptide) The peptides, etc., can be expressed by the cell using two separate vectors. may be co-transfected or co-transformed with a vector, or can be introduced into the cells at different times.
[0113] The polypeptides vary in their order from amino to carboxy terminus. The order of the various domains may be adjusted, for example, as described herein, to obtain optimal expression and activity. The assay can be performed using methods such as those discussed in.
[0114] Selection marker In certain embodiments, the expression construct may include a marker in the expression construct. The present invention also includes nucleic acid constructs whose expression can be determined in vitro or in vivo by Such markers provide identifiable variants that allow easy identification of cells containing the expression construct. Inclusion of a drug selection marker is usually an advantage in cloning and Useful for selection of transformants. For example, neomycin, puromycin, hygromycin Genes that confer resistance to cyclosporine, DHFR, GPT, zeocin, and histidinol is a useful selection marker. Alternatively, the thymidine kinase gene of herpes simplex virus ( Enzymes such as tk are used to detect extracellular non-signaling domains, including immunological surface markers. Main or various proteins (e.g., CD34, CD19, low affinity nerve growth factor receptor Sceptor (LNGFR) can also be used, allowing detection by magnetic or fluorescent antibodies. The selectable markers used are genetically modified. This is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding the product. Further examples of selectable markers include reporters (e.g., GFP, EGF P, beta-gal or chloramphenicol acetyltransferase (CAT) In certain embodiments, the marker protein, e.g., CD19 etc. are used for the selection of cells for transfection, e.g., in immunomagnetic selection etc. As discussed herein, the CD19 marker can be detected by anti-CD19 antibodies, i.e. , for example, an scFv that binds CD19, a TCR or other antigen recognition moiety.
[0115] In certain embodiments, the marker polypeptide is an inducible chimeric signal transduction polypeptide. For example, the marker polypeptide may be linked to a polypeptide sequence, such as The chimeric signaling molecule may be linked to the inducible chimeric signaling molecule via a cleavable 2A-like sequence or the like. The marker polypeptide can be, for example, CD19, ΔCD19, or, for example, For example, a heterologous tag selected so as not to affect the activity of the inducible chimeric signaling molecule may be used. It may be protein.
[0116] 2A-like sequences or "peptide bond skipping" 2A sequences are, for example, These sequences are derived from many different viruses, including those derived from Asigna. Sequences of this type are sometimes known as "peptide skipping sequences". When placed within a cistron between two peptides that are intended to be cleaved, The peptide bond is skipped, and in the case of the sequence of Thosea asigna, In this case, the bond between the Gly amino acid and the Pro amino acid in the carboxy-terminal "PGP" This is because the co-stimulatory polypeptide cytoplasmic domain and the marker polypeptide are omitted. In this case, 2 to 3 polypeptides remain. When this sequence is used, the 5' The peptide encoded by the 2A sequence is It may end with additional amino acids, including any upstream residues. The peptide to be treated contains at the amino terminus a Pro residue and any downstream 2A sequence following the It may end with additional amino acids containing residues.
[0117] In some embodiments, the polypeptide is used to aid in sorting cells. For example, the CD34 minimal epitope can be included in the expression vector. In some embodiments, the TCRs provided herein can be expressed in The expression vector used to express the CD34 gene encodes a 16 amino acid minimal CD34 epitope. Certain embodiments provided in the examples herein further include polynucleotides that encode the In some embodiments, such as embodiments, the CD34 minimal epitope is is incorporated at the amino terminal position of
[0118] Ligand Binding Region The ligand binding region can be included in the chimeric polypeptides discussed herein, e.g., as an inducible The expression construct may include a ligand binding ("dimer") polypeptide. The "binding" domain binds natural or non-natural ligands (e.g., non-natural synthetic ligands). The multimerization region or linker may be any convenient domain that allows for induction using the multimerization region or linker. The ligand-binding domain can be attached to the cell membrane depending on the nature of the construct and the choice of ligand. They can be internal or external. A wide variety of ligand-binding proteins (including receptors) , including ligand binding proteins that associate with the cytoplasmic domains shown above. As used herein, the term "ligand binding domain" is used interchangeably with the term "receptor." The ligands (e.g., small organic ligands) may be known or readily available. Of particular interest are the ligand-binding proteins that can be produced. These ligand-binding domains or receptors such as FKBP and cyclophilin receptors, steroid receptors , tetracycline receptors, other receptors as set forth above, etc., as well as antibodies, particularly "Non-natural" receptors that can be derived from heavy or light chain subunits, their mutated forms, Random amino acid sequences obtained by sequencing, stochastic procedures, combinatorial synthesis, etc. In certain embodiments, the ligand binding region comprises an FKBP ligand binding sequence. domain, cyclophilin receptor ligand binding domain, steroid receptor ligand binding Domain, Cyclophilin Receptor Ligand Binding Domain, and Tetracycline Receptor The ligand binding domain is selected from the group consisting of F v F vls Sometimes, the above F v’ F vls The sequence further comprises an additional Fv' sequence. The FKBP12 region may, for example, include an amino acid substitution at position 36, e.g., valine, It may have an amino acid substitution selected from the group consisting of leucine, isoleucine and alanine. For example, see Kopytek, SJ et al., Chemistry & Biology 7:313-321 (2000) and Gestwicki, J. E. et al., Combinatorial Chem. & High Throughp ut Screening 10:667-675 (2007);Clackson, T. (2006) Chem Biol Drug Des 67:440-2; Clackson, T., in Chemical Biology: From Small Molecules to Systems Biology and D Rug Design (Schreiber, S. et al., Wiley, 2007) For example, the amino acid sequence of SEQ ID NO: 77 is There is an amino acid substitution of valine at position 6 (position 35 in the sequence herein). The amino acid sequence of SEQ ID NO:84 represents an example of a sequence (provided as amino acids) of The wild type phenylalanine in 1 represents the amino acid sequence of FKBP12 (provided as
[0119] Generally, the ligand binding domain or receptor domain is a naturally occurring domain or The truncated active portion thereof may be at least about 50 amino acids, and at least about 350 amino acids. The binding domain may be less than 100 amino acids in length, typically less than 200 amino acids. The size of the vector may be <25 kDa, allowing efficient transfection with may be monomeric, may be non-immunogenic, may form due to dimerization, may be synthetically available The antibody may have a cell-permeable, non-toxic ligand that is capable of binding to the antibody.
[0120] The receptor domains are selected depending on the design of the expression construct and the availability of appropriate ligands. For hydrophobic ligands, the binding domain may be located in the membrane or outside the cell. In the case of hydrophilic ligands, particularly protein ligands, the ligand may be on either side. In the absence of a transport system to internalize the dopamine in a form available for binding, The domain may usually be external to the cell membrane. In the case of an intracellular receptor, the construct may be , a signal peptide and a transmembrane domain are located 5' or 3' of the receptor domain sequence. or a lipid attachment signal sequence 5' to the receptor domain sequence. The receptor domain is located between the signal peptide and the transmembrane domain. In some cases, the receptor domain may be extracellular.
[0121] The portion of the expression construct encoding the receptor may be subjected to mutagenesis for a variety of reasons. Mutagenized proteins can provide higher binding affinity and are more efficient than naturally occurring receptors. This allows for differentiation of the receptor from the mutated receptor by ligand, and Alterations in the receptor may provide an opportunity to design ligand pairs, etc. Combinatorial random mutagenesis and known amino acid changes were used to where the amino acids involved in the binding site or other amino acids involved in the conformational change are The codon for the particular amino acid may be changed by known changes to the codon(s) for the particular amino acid. Randomly altering the polypeptides and expressing the resulting proteins in a suitable prokaryotic host, and then The resulting proteins are subjected to mutagenesis by screening for binding. obtain.
[0122] Antibodies and antibody subunits, such as heavy or light chains, in particular fragments, more particularly Specifically, the antibody may comprise all or part of a variable region, or a fusion of a heavy chain and a light chain that provides high affinity binding. Contemplated antibodies include those capable of eliciting an immune response. First, extracellular domains, which are not generally expressed in the periphery (i.e., outside the CNS / brain region), Examples of such products include those that are ectopically expressed human products. The endothelial nerve growth factor receptor (LNGFR) and embryonic surface proteins (i.e., oncofetal Antigens).
[0123] Furthermore, the antibody may be characterized as a physiologically acceptable hapten molecule and as to its binding affinity. The subunits can be prepared for screening. The cDNA encoding the ribozyme was isolated and subjected to deletion of the constant region, a portion of the variable region, and a mutation in the variable region. By modifying the binding domain through induction or other means, the binding domain can be made to have the appropriate affinity for the ligand. In this way, most physiologically acceptable protein domains can be obtained. Any haptenic compound may be used as a ligand or may be epitaxially linked to a ligand. Instead of antibody units, binding domains may be used to provide a known For this purpose, natural receptors for which there are available ligands for binding can be used.
[0124] Oligomerization The signal to be transduced is usually a ligand-mediated oligomerization of the chimeric protein molecule. This can occur by oligomerization, i.e., as a result of oligomerization after the ligand is bound. However, other binding events, such as allosteric activation, can be used to initiate a signal. The construction of chimeric proteins can be achieved by varying the order of the domains and the individual domains. As regards the number of repeats, there may be variation.
[0125] When the caspase-9 polypeptide is multimerized, a chimeric derived caspase-9 polypeptide is obtained. The ligand for the ligand-binding domain / receptor domain of a peptide is usually at least Both have two binding sites, each of which is linked to a ligand receptor domain. "Multimeric ligand-binding domains" may be multimeric in the sense that they can be combined with one another. The term "ligand binding region" refers to a ligand binding region that binds to a multimeric ligand. The term "ligand" includes dimeric ligands. Dimeric ligands are ligand-receptor complexes. Desirably, the ligand of interest may have two binding sites capable of binding to the domain. The amides are small synthetic organic compounds that are dimers or higher oligomers, usually up to about tetramers. The individual molecules may be of a size of at least about 150 Da and less than about 5 kDa. A variety of synthetic ligand-receptor pairs have been used. For example, in an embodiment involving the native receptor, dimeric FK506 may be Dimerized cyclosporine A can be used with the FKBP12 receptor to The dimerized estrogen can be used with the rhofilin receptor to bind to estrogen. The dimerized glucocorticoids can be used with the glucocorticoid receptor. The dimerized tetracycline can be used with the tetracycline receptor. Vitamin D can be used with the vitamin D receptor, and dimerized vitamin D can be used with the vitamin D receptor. Alternatively, higher order ligands, e.g., trimers, may be used. Non-natural receptors, such as antibody subunits, engineered antibody subunits, A heavy chain variable region and a light chain variable region separated by a flexible linker domain are used. Single chain antibodies containing tandem or modified receptors and mutated sequences thereof For embodiments including the above, any of a wide variety of compounds may be used. A significant feature of the ligand unit is that each binding site is capable of binding to a receptor with high affinity. and that their Ligand units can be chemically dimerized. Also, the ligands can be dissolved in serum at functional levels and still be used for most applications. Due to the hydrophobicity / Hydrophilicity balancing methods are also available.
[0126] In certain embodiments, the method comprises the step of: used the method of chemically induced dimerization (CID) to generate polypeptides. In addition to being inducible, this approach allows for the decomposition or monoclonalization of labile dimerizers. The effect is reversible due to administration of a competitive inhibitor of the agonist.
[0127] The CID system uses synthetic bivalent ligands fused to the ligand-binding domain. Rapidly cross-links signaling molecules. This system is used to bind cell surface proteins (Spenc er, DM et al., Science, 1993.262:p.1019-1024;Sp Encer DM et al. Curr Biol 1996,6:839-847;Bla u, CA et al., Proc Natl Acad.Sci.USA 1997,94:3 076-3081) or cytosolic proteins (Luo, Z. et al., Nature 19 96,383:181-185; MacCorkle, RA et al., Proc Natl. Acad Sci USA 1998,95:3655-3660) and activation, recruitment of transcription factors to DNA elements that regulate transcription (Ho, SN et al., Nature 1996, 382:822-826; Rivera, V.M. .et al., Nat. Med. 1996,2:1028-1032) or stimulate signal transduction. Recruitment of signaling molecules to the plasma membrane (Spencer DM et al., Proc.Natl.Acad.Sci.USA 1995,92:9805-9809 ;Holsinger, LJ et al., Proc. Natl. Acad. Sci. USA 1995,95:9810-9814).
[0128] The CID system is a novel method to detect surface receptor aggregation that efficiently activates downstream signaling cascades. In its simplest embodiment, the CID system is based on the concept of selectively activating lipids. The dimeric analog of the cell-permeable immunosuppressant FK506 was used, which It has lost its normal biological activity but is genetically modified to the FK506-binding protein, FKBP12. It has acquired the ability to crosslink molecules fused to it. By fusing the binding sequence to the cytoplasmic signaling domain of the target receptor, Signals in a merizer drug-dependent but ligand- and ectodomain-independent manner This allows for temporal control, monomeric drug analogs, and stimulation of neurotransmission. Using the 3rd generation AP, a reversible and highly specific system is provided. 20187 / AP1903 CIDs for their binding domain, FKBP12 The high affinity of FKBP12 reduces the non-specific side effects caused by endogenous FKBP12 in vivo. This allows for specific activation of the recombinant receptor without the need for drug dimerization. FKBP12 variants with amino acid substitutions and deletions (e.g., FKBP1 2 v 36) can also be used. In addition, synthetic ligands are resistant to protease degradation. is antagonistic to the receptor, thereby inhibiting the delivery of It is more effective than most protein drugs.
[0129] The ligand used can bind to more than one of the ligand binding domains. When a Mela protein contains two or more ligand-binding domains, it can bind to two or more ligands. The ligand may be capable of binding to a target protein. Exemplary ligands include dimeric FK506 (e.g., FK1012 ), but are not limited to these.
[0130] Other ligand binding regions may be modified, for example, by dimerization or wobble substitutions. The ligand binding region may be, for example, FKBP12(V36): F36 is replaced by V Recombinant human 12 kDa FK506 binding protein, complete mature coding sequence (amino acid The amino acids 1-107 provide the binding site for the synthetic dimerizer drug AP1903 (J emal, A. et al. CA Cancer J. Clinic. 58, 71-96 (200 8);Scher, H.I. and Kelly, W.K., Journal of C. Clinical Oncology 11, 1566-72 (1993). Two tandem copies of the protein were found to be involved in the formation of higher order oligomers, which were then cross-linked by AP1903. It may also be used in the construct as derived herein.
[0131] F36V'-FKBP: F36V'-FKBP is the codon wobble of F36V-FKBP It is a version that encodes the same polypeptide sequence as F36V-FKPB. However, at the nucleotide level, they share only 62% homology. Designed to reduce recombination in retroviral vectors (Schel lhammer, PF et al., J. Urol. 157, 1731-5 (1997)). F 36V'-FKBP was constructed by PCR assembly procedures. The transgene was Contains one copy of F36V'-FKBP directly linked to one copy of F36V-FKBP .
[0132] In some embodiments, the ligand is a small molecule. An appropriate ligand for the region can be selected. Often the ligand is a dimer, and sometimes Typically, the ligand is a dimeric FK506 or a dimeric FK506 analog. In certain embodiments, the ligand is AP1903 (INN: rimizuside, CAS index name 2-Piperidinecarboxylic acid, 1-[(2S)-1-oxo-2-(3,4,5-trimethyl 1,2-ethanediylbis[imino(2-oxo-2,1 -ethanediyl)oxy-3,1-phenylene [(1R)-3-(3,4-dimethoxyphenyl) 2S-[1(R * ),2R * [S * [S * [1( R * ),2R * ]]]]]-(9Cl)CAS Registry Number: 195514-63-7; Molecule Formula: C78H98N4O20 Molecular weight: 1411.65). In certain embodiments, In certain embodiments, the ligand is AP20187. , AP20187 analogs, such as AP1510. In this regard, certain analogs may be suitable for FKBP12, and certain analogs may be suitable for the mutant (V36) version of FKBP12. In one embodiment, one ligand binding region is included in the chimeric protein. In some embodiments, more than one ligand binding domain may be included. For example, the ligand binding domain In the case of FKBP12, when two of these regions are included, one is, for example, It could be a wobble version.
[0133] Other contemplated dimerization systems include the coumermycin / DNA gyrase B system. The dimerization induced by coumermycin is mediated by modified Raf Activates proteins and stimulates the MAP kinase cascade. Farrar et al., 199 See point 6.
[0134] AP1903 API is manufactured by Alphora Research Inc. AP1903 Drug Product for Injection is , produced by AAI Pharma Services Corp. 2 of the non-ionic solubilizer Solutol HS 15 (250 mg / mL, BASF) It is formulated as a 5 mg / mL solution of AP1903 in a 5% solution. The formulation is a clear solution. When refrigerated, the formulation is reversible upon prolonged storage. When the solution is warmed back to room temperature, the phase transition reverses. One serving is 8 mL in a 10 mL glass vial (total per vial) Approximately 40mg of AP1903 for Injection).
[0135] For use, AP1903 is warmed to room temperature and diluted prior to administration. For subjects >100 mL, AP1903 was administered at 40 ml g dose, 50 mL / hour using DEHP-free saline bags and solution sets. Administered via IV infusion at a rate of 0.5 mg / kg over 2 hours. Subjects weighing less than 50 kg should receive 0.5 mg / kg. Receive 4mg / kg AP1903.
[0136] All study drugs were maintained at a temperature between 2°C and 8°C, protected from excessive light and heat, and are kept in a locked area with restricted access.
[0137] The need to administer AP1903 and apoptosis of modified TCR-expressing T cells In determining the need to activate caspase-9 to induce Using a non-DEHP, non-ethylene oxide sterile infusion set, V injection to deliver a single fixed dose of AP1903 for Injection( 0.4 mg / kg) may be administered. The dose of AP1903 will be individualized for every patient. The calculated dose is calculated at the time of injection and is not recalculated unless the body weight changes by ≥ 10%. Pre-diluted to 100 mL in 0.9% saline.
[0138] In a previous Phase I study of AP1903, 24 healthy volunteers were randomly assigned to receive V Injected dose levels of 0.01, 0.05, 0.1, 0.5 and 1.0 mg / kg In the control group, the rats were treated with a single dose of AP1903 for injection. 1903 plasma levels were directly proportional to dose, with mean Cmax values ranging from 0.01 to 1.0 mg / kg. The range of doses was approximately 10 to 1275 ng / mL. After the period, blood concentrations showed a rapid distribution phase, with plasma levels increasing at 0.5, 2, and 1 post-dose. At 0 hours, the concentrations decreased to approximately 18, 7, and 1% of the maximum concentrations, respectively. or Injection has been shown to be safe and well tolerated at all dose levels. It was shown that the drug showed a favorable pharmacokinetic profile. Iuliucci JD et al., J Clin Pharmacol.41:870-9,2001.
[0139] The fixed dose of AP1903 for injection used is e.g. The dose can be 0.4 mg / kg infused intravenously over 2 hours. The amount of AP1903 required in vitro for null transduction is approximately 10-100 nM (MW: 1412 Da). This is 14-140 μg / L or approximately 0.014 ~0.14mg / kg (1.4-140μg / kg). Dosage depends on use. In certain instances, the concentration may vary within the range of 0.1 to 10 nM, or 50 to 15 0nM, 10~200nM, 75~125nM, 100~500nM, 100~600nM M, 100-700nM, 100-800nM, or 100-900nM. Doses up to 1 mg / kg were tolerated in the Phase I study of AP1903 described above. good.
[0140] membrane targeting The membrane targeting sequence provides for transport of the chimeric protein to the cell surface membrane, where the same sequence Alternatively, the chimeric protein may encode a sequence that binds the chimeric protein to a cell surface membrane. The combined molecule contains certain regions that facilitate membrane association, and such regions are By incorporating the protein molecule, it can provide a membrane targeting molecule. For example, Some proteins contain sequences to be acylated at the N-terminus or C-terminus, and these acyl moieties Such sequences are recognized by acyltransferases, which facilitate membrane association. A particular acylation motif is often associated with a single The acyl portion of the carboxylate (followed by several positively charged carboxylates) improves the association with the anionic lipid head groups. The residues that were modified (e.g., human c-Src:MGSNKSKPKDAS It can be modified by (often followed by -QRRR), while others are For example, protein tyrosine kinases can be modified with a number of acyl moieties. The N-terminal sequence of Src may contain a single myristoyl moiety. Certain protein kinases (e.g., a subset of Src family members (e.g., Within the N-terminal region of the G protein alpha subunits Such dual acylation regions are located in the first 18 amino acids of such proteins. It is often located within the amino acid sequence Met-Gly-Cys-X. corresponds to aa-Cys, where Met is cleaved and Gly is N-acylated, One of the Ys residues is S-acylated. Gly can be myristoylated. Most often, Cys can be palmitoylated. The sequence motif Cys-Ala-Ala-Xa a (the so-called "CAAX box"), which is an acylation region that corresponds to the G protein gamma saccharomyces cerevisiae. may be modified by a C15 or C10 isoprenyl moiety from the C-terminus of the subunit, proteins (e.g., at the World Wide Web address ebi.ac.uk / inter pro / DisplayIproEntry?ac=IPR001230) is also used. These and other acylation motifs include, for example, Gauthier-C ampbell et al., Molecular Biology of the Cell 1 5:2205-2217(2004);Glabati et al., Biochem.J.303 :697-700 (1994) and Zlakine et al., J. Cell Science 110:673-679 (1997), and Chief can be incorporated into the chimeric molecule to induce membrane localization. In the present invention, a natural sequence derived from a protein containing an acylation motif is added to a chimeric protein. For example, in some embodiments, Lck, Fyn, or Yes or the N-terminal portion of a G protein alpha subunit (e.g., The first 25 N-terminal amino acids or fewer of the amino acids (e.g., optional mutations) of The amino acid sequence of the native nucleotide sequence of the present invention is From about 5 to about 19 amino acids) can be incorporated into the N-terminus of the chimeric protein. In an embodiment of the present invention, a G protein gamma subunit comprising a CAAX box motif sequence is A C-terminal sequence of about 25 amino acids or less derived from the native sequence (e.g., the native sequence, with optional mutations) about 5 to about 20 amino acids, about 10 to about 18 amino acids, or about 15 to about 18 amino acids of It can be linked to the C-terminus of the chimeric protein.
[0141] In some embodiments, the acyl moiety has a log p value of +1 to +6. , occasionally having log p values of +3 to +4.5. The log p value is a measure of hydrophobicity. and is often derived from octanol / water partitioning studies, where the more hydrophobic Molecules with this property partition more frequently into octanol and have higher log p values. Log p values have been published for some lipophilic molecules and The gp value can be calculated using known partitioning processes (e.g., Chemical Reviews, Vol. 71, Issue 6, page 599, entry 449 3 shows lauric acid, which has a log p value of 4.2.) Any acyl moiety can be linked to the peptide compositions discussed above, using known methods and those discussed hereinafter. The acyl moiety can sometimes be tested for antibacterial activity using methods such as, for example, C 1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, C3-C6 silyl Chloalkyl, C1-C4 haloalkyl, C4-C12 cycloalkylalkyl (cyc alkylalkyl), aryl, substituted aryl or aryl(C1-C4)alkyl The optional acyl-containing moiety is sometimes a fatty acid, an example of a fatty acid moiety is propyl. C3, butyl (C4), pentyl (C5), hexyl (C6), heptyl (C7) , Octyl (C8), Nonyl (C9), Decyl (C10), Undecyl (C11), Lauryl (C12), C12, Myristyl (C14), Palmityl (C16), Stearyl (C18) , arachidyl (C20), behenyl (C22) and lignoceryl moieties (C24). , each moiety may contain 0, 1, 2, 3, 4, 5, 6, 7 or 8 unsaturations (i.e., double bonds The acyl moiety can sometimes comprise a lipid molecule (e.g., a phosphatidyl lipid (e.g., Phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine , phosphatidylcholine), sphingolipids (e.g., sphingomyelin omyelin), sphingosine, ceramide, gangliosides, cerebrosides) and are modified versions thereof. In certain embodiments, 1, 2, 3, 4 or has five or more acyl moieties linked to the membrane-associated domain. It may be associated with one of the other domains of the chimeric protein. Any membrane targeting sequence, which may be unassociated, may be used. In certain embodiments, such sequences include myristoylation targeting sequences, palmitoylation targeting sequences, and the like. prenylation sequences (i.e., farnesylation, geranyl-geranylation, CAAX box), protein-protein interaction motifs, or receptor-derived transmembrane sequences (signature sequences). Examples include, but are not limited to, those that utilize null peptides. , ten Klooster JP et al., Biology of the Cell (20 07)99,1-12,Vincent,S.et al.,Nature Biotechnol Examples include those discussed in Ogy 21:936-40, 1098 (2003). can be done.
[0142] There are additional protein domains that can enhance protein retention in various membranes For example, the approximately 120 amino acid pleckstrin homology (PH) domain is typically expressed in cells. It is found in over 200 human proteins involved in intracellular signal transduction. The main one is the interaction of various phosphatidylinositol (PI) lipids in membranes (e.g., PI(3, 4,5)-P3, PI(3,4)-P2, and PI(4,5)-P2) Recruiting proteins to various membrane or intracellular compartments The phosphorylation state of PI lipids may play a key role in the regulation of PI-3 The interaction of the PH domain with the membrane is regulated by kinases or PTEN. The interaction is not as stable as that with silyl lipids.
[0143] regulatory area 1. Promoter The particular promoter used to control the expression of a polynucleotide sequence of interest. The vector is capable of directing expression of the polynucleotide in the targeted cell. Therefore, when human cells are targeted, the polynucleotide The nucleotide sequence coding region may be, for example, a promoter capable of being expressed in a human cell. Generally speaking, the promoter may be located adjacent to and under the control of the promoter. Such a promoter may include a human promoter or a viral promoter.
[0144] In various embodiments, the human cytomegalovirus (CMV) immediate early gene promoter SV40 early promoter, Rous sarcoma virus long terminal repeat, β-actin The rat insulin promoter and glyceraldehyde-3-phosphate dehydrogenase were can be used to obtain high level expression of a coding sequence of interest, provided that the expression level is adequate for a given purpose. If sufficient, other methods well known in the art may be used to achieve expression of the desired coding sequence. Viral promoters or mammalian cell promoters or bacterial phage promoters The use of promoters with well-known properties is also contemplated. The level and pattern of expression of a protein of interest after transfection or transformation The sequence can be optimized.
[0145] Selection of promoters that are regulated in response to specific physiological or synthetic signals Selection may allow for inducible expression of a gene product. For example, expression of one transgene, or When multicistronic vectors are used, expression of multiple transgenes is If the target gene is toxic to the cell in which it is produced, one or more of the transgenes It is desirable to prevent or reduce expression of the gene. Examples of genes are proapoptotic genes and cytokine genes. Creating viral vectors with virulent promoter systems where the transgene product is toxic (adding a more inducible promoter).
[0146] The ecdysone system (Invitrogen, Carlsbad, CA) is This system is a novel system for the controlled expression of genes of interest in mammalian cells. The system is designed to allow controlled expression of the transgene at basal levels. from a tightly regulated expression mechanism that allows for over 200-fold inducibility rather than expression of The system is based on the heterodimeric ecdysone receptor of Drosophila. When ecdysone or an analogue such as muristerone A binds to the receptor, The receptor activates the promoter, turning on the expression of the downstream transgene, resulting in high levels of This system produces mRNA transcripts for the heterodimeric receptor. Both monomers are constitutively expressed from one vector, whereas the expression of the gene of interest is The ecdysone-responsive promoter driving expression is present on a separate plasmid. This type of system is engineered into a gene transfer vector of interest. It may be useful to then transfect the production cell line with the plasmid containing the gene of interest. By cotransfection of the plasmid containing the receptor monomer, This allows the construction of gene transfer vectors without expressing potentially toxic transgenes. At the appropriate time, expression of the transgene may be regulated by ecdysone or muristerone A. Thus, it can be activated.
[0147] Another potentially useful inducible system was originally described by Gossen and Bujard. It was developed by Gossen and Bujard, Proc. Natl. Aca d.Sci.USA,89:5547-5551,1992;Gossen et al., Sci. nce, 268:1766-1769, 1995), Tet-Off TM or Tet- On TM The system is a Clontech, Palo Alto, CA. The drug also contains tetracycline or a tetracycline derivative (e.g., doxycycline). ) can regulate high levels of gene expression in response to Tet-On TM Sis In the presence of doxycycline, gene expression is turned on in the Tet -Off TM In the system, gene expression is turned on in the absence of doxycycline. These systems consist of two regulatory genes derived from the tetracycline resistance operon of E. coli. The tetracycline repressor binds to the tetracycline operon. The gene of interest is inserted into the plasmid p53. behind a promoter containing a tetracycline-responsive element present in the smid The second plasmid is cloned into a plasmid that is co-activated by tetracycline. It contains a control element called a transactivator that is controlled by the The Tet-Off TM In the system, the VP16 domain from herpes simplex virus was The repressor is composed of the wild-type tetracycline repressor and the doxycycline repressor. In the absence of clin, transcription is constitutively on. Tet-On TM In the system The tetracycline repressor is not wild type, but in the presence of doxycycline When constructing gene therapy vectors, tetracycline or doxorubicin is used to activate transcription. Producer cells can be grown in the presence of cycycline, suppressing expression of potentially toxic transgenes. Tet-Off TM The system may be used, but the vector When introduced into the host, gene expression can be turned on constitutively.
[0148] In some situations, it may be desirable to control the expression of a transgene in a gene therapy vector. For example, various viral promoters with different activity strengths can be used to express the desired Depending on the expression level, the CMV immediate early promoter is used. The CMV promoter is often used to provide efficient transcriptional activation. elly, JJ et al., 1997.Annu.Rev.Immunol.15:617- 48. When low expression levels of the transgene are desired, Modified versions of the CMV promoter that are not potent have also been used. When expression of a transgene is desired, a retrovirus such as a long terminal repeat (LTR) from MLV or MMTV can be used. Other viral promoters are often used depending on the desired effect. Examples of promoters include SV40, RSV LTR, HIV-1 and HIV-2 LTR. TR, adenovirus promoter (e.g., from the E1A, E2A, or MLP regions) ), AAV LTR, HSV-TK and avian sarcoma virus.
[0149] Similarly, tissue-specific promoters may reduce potential toxicity or expression in untargeted tissues. or to induce transcription in specific tissues or cells so as to reduce undesirable effects. These promoters are used to express the ribozyme-dependent nucleotide sequence of the ribozyme. These promoters are much stronger than those used for expression of the ribozyme, such as the CMV promoter. Although these promoters may result in lower expression than the promoters described above, they also have more limited expression and immunogenicity. (Bojak, A. et al., 2002. Vaccine 20:1975-79; Cazeaux., N. et al., 2002. Vaccine 20:3322-31). For example, tissue-specific promoters (e.g., PSA-associated promoters) or prostate-specific gland promoters. The human kallikrein or muscle creatine kinase genes may be used as appropriate.
[0150] Examples of tissue-specific or differentiation-specific promoters include the following: These include, but are not limited to: B29 / CD79b (B cells); CD14 (monocytic cells) ;CD43 (white blood cells and platelets);CD45 (hematopoietic cells);CD68 (macrophages );desmin (muscle);elastase-1 (pancreatic acinar cells);endoglin (endothelial cells); Fibronectin (differentiating cells, healing tissue); and Flt-1 (endothelial cells); G FAP (astrocyte).
[0151] For certain indications, gene therapy vectors may be used to inhibit transcription at specific times after administration. It is desirable to activate the IL-1 receptor, which can be controlled by hormones or cytokines. The present invention is carried out using a promoter such as the following. and inflammatory protein-responsive promoters, such as K kininogen and T kininogen. Gen (Kageyama et al. (1987) J. Biol. Chem., 262, 2345- 2351), c-fos, TNF-α, C-reactive protein (Arcone et al. (1988 )Nucl.Acids Res.,16(8),3195-3207)Haptoglobulin (Oliviero et al. (1987) EMBO J., 6, 1905-1912), serum Amyloid A2, C / EBPα, IL-1, IL-6 (Poli and Cortes e,(1989)Proc.Nat'l Acad.Sci.USA,86,8202- 8206), complement C3 (Wilson et al. (1990) Mol. Cell. Biol., 6 181-6191), IL-8, α-1 acid glycoprotein (Prowse and Ba umann, (1988) Mol Cell Biol, 8, 42-51), α-1 anti-toxin Lipsin, lipoprotein lipase (Zechner et al., Mol. Cell. Biol. , 2394-2401, 1988), angiotensinogen (Ron et al. (1991) M ol. Cell. Biol., 2887-2895), fibrinogen, c-jun (Ho Induced by rubol ester, TNF-α, UV irradiation, retinoic acid and hydrogen peroxide collagenase (inducible by phorbol esters and retinoic acid), Metallothionein (heavy metal and glucocorticoid inducible), stromelysin (holvo ester, inducible by interleukin-1 and EGF), α-2 macroglucose globulin and alpha-1 antichymotrypsin. Other promoters include For example, SV40, MMTV, human immunodeficiency virus (MV), Moloney virus, ALV, Epstein-Barr virus, Rous sarcoma virus, human actin, myosin, hemoglobin Examples include vin and creatine.
[0152] Any of the above promoters may be used alone or in combination with another promoter depending on the desired effect. It is envisioned that promoters and other control elements may be useful in various applications. These promoters are selected to be functional in the desired cells or tissues. The list of promoters should not be construed as exhaustive or limiting; may be used with the promoters and methods disclosed herein.
[0153] 2. Enhancer Enhancers regulate transcription from promoters located at distant sites on the same DNA molecule. An early example is a genetic element that flanks a coding sequence and Immunoglobulin and T-cell receptor-related, present within several introns Enhancers include many viral promoters (e.g., CMV, SV40, and and retroviral LTRs) are closely associated with enhancer activity and are Enhancers are organized much like promoters. That is, enhancers are composed of many individual elements, each of which may contain one or more The basic distinction between enhancers and promoters is that they Enhancer regions are generally located at some distance, often without regard to orientation, stimulates transcription; this does not necessarily apply to the promoter region or its component elements. On the other hand, promoters direct the initiation of RNA synthesis at specific sites and in specific orientations. Whereas a transcription factor has one or more elements that direct the initiation of a transcriptional pathway, an enhancer has these specific Promoters and enhancers are often overlapping and in close proximity, and therefore often They often appear to have a very similar modular organization. A subset of enhancers contains Not only can they increase transcriptional activity, but also, when integrated into the genome, they can enhance the function of adjacent sequences. May help isolate transcriptional elements (along with insulator elements) from arrays , including the locus control region (LCR).
[0154] Any promoter / enhancer combination (Eukaryotic Promo The Epigenetic Data Base (EPDB) is a database of genes that are used to drive gene expression. Although many can be used to restrict expression to specific tissue types or subsets of tissues ( For example, Kutzler, MA, and Weiner, DB, 2008. (reviewed in Nature Reviews Genetics 9:776-88). Examples include enzymes derived from human actin, myosin, hemoglobin, and muscle creatine kinase. These include enhancers, and sequences from the viruses CMV, RSV and EBV. The present invention is not limited to the above. An appropriate enhancer may be selected for a particular application. A suitable bacterial polymerase may be provided as part of a delivery complex or as an additional genetic expression construct. When provided with a gene, eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters. do.
[0155] 3. Polyadenylation Signal If a cDNA insert is used, ensure proper polyadenylation of the gene transcript. It is usually desirable to include a polyadenylation signal to facilitate transcription. The nature of the molecule is not believed to be critical to the successful practice of the method, and any such Such sequences (e.g., human or bovine growth hormone and the polyadenylation sequence of SV40) A non-limiting example is the nucleotide sequence of ... , pCEP3 plasmid (Invitrogen, Carlsbad, California) The SV40 polyadenylation signal present in ia) is also present in the expression These elements are intended to be elements of a cassette. This helps to minimize read-through from the cassette to other sequences. A termination signal sequence or a poly(A) signal sequence may be, for example, located at the 3' end of an mRNA. It may be located approximately 11 to 30 nucleotides downstream from the conserved sequence (AAUAAA) in ontgomery, DL et al. 1993. DNA Cell Biol. 12:77 7-83;Kutzler, MA, and Weiner, DB, 2008.N ature Rev. Gen. 9:776-88).
[0156] 4. Initiation signals and internal ribosome binding sites Specific initiation signals may also be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, such as the initiation codon, may need to be provided. The insert is placed in frame with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be natural or synthetic. The efficiency of can be increased by the inclusion of appropriate transcription enhancer elements.
[0157] In certain embodiments, the use of an internal ribosome entry site (IRES) element These techniques are used to generate multigene or polycistronic messages. IRES elements regulate the ribosome scanning model of 5' methylated cap-dependent translation. It is possible for the Pellet molecule to bypass the ribosome and initiate translation at an internal site (see Pellet ier and Sonenberg,Nature,334:320-325,198 8) I from two members of the picornavirus family (poliovirus and encephalomyocarditis virus) The RES element has been discussed (Pelletier and Sonenber g, 1988), and IRES from mammalian messages have also been discussed (Mac ejak and Sarnow, Nature, 353:90-94, 1991). I The RES element can be linked to a heterologous open reading frame. Multiple open reading frames separated by ES can be transcribed together, Creates polycistronic messages. Thanks to the IRES element, each open The multiple reading frames are accessible to ribosomes for efficient translation. A gene uses a single promoter / enhancer to transcribe a single message can be efficiently expressed using the same vector (U.S. Pat. Nos. 5,925,565 and 5,935,826). 19, each of which is incorporated herein by reference.
[0158] Array Optimization Protein production can also be increased by optimizing codons in the transgene. Species-specific codon alterations can be used to increase protein production. By optimizing the codons, optimized RNA can be generated, thereby Efficient translation can be achieved by optimizing the codons that are incorporated into the RNA. elements that introduce secondary structure that causes instability, e.g., inhibit ribosome binding mRNA secondary structures that may inhibit the nuclear export of mRNA, or cryptic ptic sequences can be removed (Kutzler, MA, and Weiner, DB, 2008. Nature Rev. Gen. 9:776-8 8;Yan.,J.et al.,2007.Mol.Ther.15:411-21;Cheun g,YK et al., 2004.Vaccine 23:629-38;Narum.,D. L. et al. 2001.69:7250-55; Yadava, A., and Ockenh ouse,CF,2003.Infect.Immun.71:4962-69;S Mith., JM et al., 2004. AIDS Res. Hum. Retrovirus. es 20:1335-47;Zhou, W. et al., 2002.Vet.Microbio l.88:127-51;Wu, X. et al., 2004.Biochem.Biophys. Res.Commun.313:89-96; Zhang, W. et al., 2006. Bioc hem.Biophys.Res.Commun.349:69-78;Deml,L. A. et al. 2001. J. Virol. 75:1099-11001;Schneider ,RM et al.,1997.J.Virol.71:4892-4903;Wang,S. D. et al. 2006. Vaccine 24:4531-40;zur Megede,J 2000. J. Virol. 74:2628-2635). For example, FKBP12 or other multimerization domain polypeptides, caspase-9 polypeptides, and TCR polypeptides. The peptide-encoding polynucleotide sequence may be optimized by codon changes.
[0159] Leader sequence Leader sequences are used to enhance mRNA stability and provide more efficient translation. Leader sequences are usually involved in targeting mRNA to the endoplasmic reticulum. Examples include the HIV-1 envelope glycoprotein (EnG), which delays its own cleavage. v), and the IgE gene leader sequence (Kutzl er, MA, and Weiner, DB, 2008. Nature Rev. Gen.9:776-88;Li, V. et al., 2000. Virology 272:41 7-28;Xu, ZL et al. 2001.Gene 272:149-56;Malin , A.S. et al., 2000. Microbes Infect. 2:1677-85; Ku tzler, MA et al. 2005.J.Immunol.175:112-125;Y Ang., J.S. et al., 2002. Emerg. Infect. Dis. 8:1379- 84;Kumar., S. et al., 2006.DNA Cell Biol.25:383- 92;Wang, S. et al., 2006. Vaccine 24:4531-40). IgE Leaders can be used to enhance insertion into the endoplasmic reticulum (Tepler, I. et al. (1988) 9) J. Biol. Chem. 264:5912).
[0160] Expression of the transgene can be optimized by choosing an appropriate method to optimize expression. These methods can be optimized and / or controlled, for example, in the promotion This includes optimizing the target, delivery method, and gene sequence (see, e.g., Laddy, D.J. et al., 2008.PLoS.ONE 3 e2517;Kutzler,MA,an d Weiner,DB,2008.Nature Rev.Gen.9:776- (as presented in 88).
[0161] nucleic acid As used herein, "nucleic acid" generally refers to DNA, RNA or Refers to a derivative or analog molecule (one, two or more chains) of Nucleic acid bases include, for example, DNA (e.g., adenine "A", guanine "G", thymine " "T" or cytosine "C") or RNA (e.g., A, G, uracil "U" or C) The term "nucleic acid" includes the naturally occurring purine or pyrimidine bases found in The terms "oligonucleotide" and "polynucleotide" encompass each of the terms "nucleotide" and "polynucleotide." The nucleic acid is included as a subgenus of "anionic acid." , 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 3 4, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 , 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 7 4, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87 , 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 , 101, 102, 103, 104, 105, 106, 107, 108, 109, 110 , 120, 130, 140, 150, 160, 170, 180, 190, 200, 210 , 220, 230, 240, 250, 260, 270, 280, 290, 300, 310 , 320, 330, 340, 350, 360, 370, 380, 390, 400, 410 , 420, 430, 440, 441, 450, 460, 470, 480, 490, 500 , 510, 520, 530, 540, 550, 560, 570, 580, 590, 600 , 610, 620, 630, 640, 650, 660, 670, 680, 690, 700 , 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 , 810, 820, 830, 840, 850, 860, 870, 880, 890, 900 , 910, 920, 930, 940, 950, 960, 970, 980, 990 or It may be 1000 nucleotides in length, or any derivable range therein.
[0162] The nucleic acids provided herein have regions that are identical or complementary to another nucleic acid. The complementary or identical region may be at least five consecutive residues. is contemplated, the region being at least, at most, or about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 2 4, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 , 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 6 4, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77 , 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 1 30, 140, 150, 160, 170, 180, 190, 200, 210, 220, 2 30, 240, 250, 260, 270, 280, 290, 300, 310, 320, 3 30, 340, 350, 360, 370, 380, 390, 400, 410, 420, 4 30, 440, 441, 450, 460, 470, 480, 490, 500, 510, 5 20, 530, 540, 550, 560, 570, 580, 590, 600, 610, 6 20, 630, 640, 650, 660, 670, 680, 690, 700, 710, 7 20, 730, 740, 750, 760, 770, 780, 790, 800, 810, 8 20, 830, 840, 850, 860, 870, 880, 890, 900, 910, 9 20, 930, 940, 950, 960, 970, 980, 990 or 1000 consecutive It is specifically contemplated that the nucleotide is a nucleotide that is
[0163] As used herein, "hybridization" and "hybridize" Or "capable of hybridizing" refers to a double- or triple-stranded molecule, or It is understood to mean forming molecules that have partial double- or triple-stranded character. As used herein, the term "anneal" is synonymous with "hybridize." The terms "hybridization," "hybridize," or "hybridize The term "stringent conditions" or "high stringency" refers to "stringency" and the term "low stringency" or "low stringency conditions" (multiple possible)" is included.
[0164] As used herein, "stringent conditions" or "high stringency conditions" refers to "Linkency" refers to the relationship between or among one or more nucleic acid strands that contain complementary sequence(s). Allows hybridization within one or more nucleic acid strands, but does not allow random sequence hybridization. Stringent conditions are conditions that prevent cleavage between a nucleic acid and a target strand. Tolerates little, if any, mismatch. Such conditions are well known and It is often used for applications requiring high selectivity. Non-limiting applications include: , isolation of a nucleic acid (e.g., a gene or a nucleic acid segment thereof) or identification of at least one characteristic and detection of abnormal mRNA transcripts or nucleic acid segments thereof.
[0165] Stringent conditions are from about 0.02M to about 0. This may include low salt and / or high temperature conditions, such as those provided by 5M NaCl. The temperature and ionic strength of the desired stringency depend on the length, target nucleic acid(s) of the particular nucleic acid(s). The length and nucleobase content of the target sequence(s), the charge composition of the nucleic acid(s), and Formamide, tetramethylammonium chloride or other in the hybridization mixture It will be understood that the amount of solvent present will be determined in part by the presence or concentration of the solvent(s).
[0166] These ranges, compositions and conditions for hybridization are merely non-limiting. It is mentioned by way of example only and is not intended to be limiting as to the desired Stringency is determined by the use of one or more positive or negative controls. It is understood that the specifications are often determined empirically by comparing with the specifications of the expected use. Accordingly, various hybridization techniques may be used to achieve various degrees of nucleic acid selectivity for the target sequence. In a non-limiting example, stringent conditions may be used. Identification or isolation of target nucleic acids of interest that do not hybridize to nucleic acids at low temperatures and / or can be achieved by hybridization under high ionic strength. The low stringency conditions are called "low stringency" or "low stringency conditions" and A non-limiting example of the efficiency is about 0.1 in the temperature range of about 20° C. to about 50° C. Examples of hybridization methods include hybridization performed at 5M to about 0.9M NaCl. High stringency conditions can be further modified to suit a particular application.
[0167] "Function-conservative variants" are variants that alter the overall three-dimensional structure and function of a protein or enzyme. Proteins or enzymes in which a given amino acid residue has been altered without altering the other amino acid residues, including: Certain amino acids can be classified according to similar properties, including polar or nonpolar nature, size, shape, and charge. These include, but are not limited to, those having the amino acid sequence of the general public. Conservative amino acid substitutions for many of the non-genetically encoded amino acids are well known in the art. Conservative substitutions for other non-encoded amino acids are possible. This can be determined based on its physical properties compared to the properties of the acid.
[0168] Amino acids other than those shown to be conserved are not The protein sequence or sequence between any two proteins that may differ and therefore have similar functions. The percentage of amino acid sequence similarity may vary and is determined according to an alignment scheme. For example, at least 70%, at least 80%, at least 90%, and For example, the degree of sequence similarity may be at least 95%. refers to the degree to which nucleotide or protein sequences are related. The degree of similarity may be based on the percentage of sequence identity and / or conservation. "Sequence identity" in this context refers to the degree to which two nucleotide or amino acid sequences are invariant. "Sequence alignment" refers to the alignment of sequences that maximize identity for the purpose of assessing the degree of similarity. A process to align two or more sequences to achieve a certain level of For aligning sequences and assessing similarity / identity Many methods (e.g., Cluster Similarity based on MEGALIGN algorithm) Methods such as BLASTN, BLASTP and FASTA, as well as the r method, are well known in the art. When using any of these programs, the settings used are the highest This is a setting that results in high sequence similarity.
[0169] Nucleic acid modification Any of the modifications discussed below can be applied to the nucleic acid. Examples of modifications include RNA or modifications to the DNA backbone, sugars or bases, and various combinations thereof. Any suitable number of backbone bonds, sugars and / or bases in a nucleic acid may be modified. (e.g., independently, about 5%, 10%, 15%, 20%, 25%, 30%, 35% , 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% , 90%, 95%, up to 100%). Unmodified nucleosides are β-D-ribo The base adenine, cytosine, guanine, thymine or u is attached to the 1' carbon of the furanose. It is one of the Rasil.
[0170] Modified bases are nucleotides other than adenine, guanine, cytosine and uracil at the 1' position. Non-limiting examples of modified bases include inosine, purine, pyridine- 4-one, pyridin-2-one, phenyl, pseudouracil, 2,4,6-trimethoxy Dibenzoyl, 3-methyluracil, dihydrouridine, naphthyl, aminophenyl, 5- Alkylcytidine (e.g., 5-methylcytidine), 5-alkyluridine (e.g., lysine bothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidin uridine or 6-alkylpyrimidine (e.g., 6-methyluridine), propyne, etc. Other non-limiting examples of modified bases include nitropyrrolyl (e.g., 3-nitro pyrrolyl), nitroindolyl (e.g., 4-, 5-, 6-nitroindolyl), hypoxy Santhinyl, isoinosinyl, 2-aza-inosinyl, 7-deaza-inosinyl, nitro Imidazolyl, nitropyrazolyl, nitrobenzimidazolyl, nitroindazolyl, 4-Fluoro-6-methylbenzyl, 4-fluoro-6-methylbenzyl, 4-fluoro-6-methylbenzyl benzimidazole, 4-methylbenzimidazole, 3-methylisocarbostyrilyl, 5-Methylisocarbostyrilyl, 3-Methyl-7-propynylisocarbostyrilyl, 7-Azaindolyl, 6-methyl-7-azaindolyl, imidizopyridinyl, 9-methyl Imidizopyridinyl, pyrrolopyridinyl, isocarbostyrilyl, 7-propynyl Socarbostyrilyl, Propynyl-7-azaindolyl, 2,4,5-trimethylphenyl phenyl, 4-methylindolyl, 4,6-dimethylindolyl, phenyl, naphthalenyl (n apthalenyl), anthracenyl, phenanthracenyl, pyrenyl, stilbeny Examples of the alkyl groups include aryl, tetracenyl, and pentacenyl.
[0171] In some embodiments, for example, a nucleic acid may have a phosphate backbone modification. Non-limiting examples of backbone modifications include phosphorothioate, esters, phosphorodithioates, methylphosphonates, phosphotriesters, morpholinos , amidate, carbamate, carboxymethyl, acetamidate, polyamide, sulfur Formates, sulfonamides, sulfamates, formacetals, thioformacetals and / or alkylsilyl modifications. The ribose sugar moiety naturally occurring in sugars can be a hexose sugar, a polycyclic heteroalkyl ring, or a cycloalkyl group. In certain cases, the hexose sugar is replaced with an arrowhead. Sugar, altrose, glucose, mannose, gulose, idose, galactose, tarodose Hexose is D-hexose, glucose or malate. In certain cases, a polycyclic heteroalkyl group can have one cyclic heteroaryl group in the ring. In certain cases, polycyclic heteroalkyl may be a bicyclic ring containing an oxygen atom of The group is bicyclo[2.2.1]heptane, bicyclo[3.2.1]octane or bicyclo B[3.3.1] Nonan.
[0172] Nitropyrrolyl and nitroindolyl nucleobases are universal bases It is a member of a class of known compounds. Universal bases are used in oligonucleotide duplexes. Any of the four naturally occurring bases can be substituted without substantially affecting the melting behavior or activity of the strand. The stabilizing hydrogen bonding interactions associated with naturally occurring nucleobases are In contrast to the use of 3-nitropyrrolyl nucleobases, oligonucleotide duplexes containing staphylococci The nitropyrrolyl nucleobases can be stabilized solely by binding interactions. The absence of binding interactions makes specificity for a particular complementary base unnecessary. Furthermore, 4-, 5-, and 6-nitroindolyls have very low specificity for the four natural bases. It only exhibits isomerism. 1-(2'-O-methyl-β-D-ribofuranosyl)-5-nitro The procedure for preparing endothelin is described in Gaubert, G.; Wengel, J. Tetr. Discussed in Ahedron Letters 2004, 45, 5629. Universal bases include hypoxanthinyl, isoinosinyl, 2-aza-inosinyl, 7-Deaza-inosinyl, nitroimidazolyl, nitropyrazolyl, nitrobenzimida Zolyl, nitroindazolyl, aminoindolyl, pyrrolopyrimidinyl and their structures Synthetic derivatives include:
[0173] Difluorotolyl is an unnatural nucleobase that functions as a universal base. Luorotril is an isostere of the natural nucleobase thymine. However, unlike thymine, Difluorotolyl does not show any significant selectivity for any of the natural bases. Other aromatic compounds that function as universal bases are 4-fluoro-6-methylbenzimidines. In addition, the relatively hydrophobic isocarboxamide, The bostyrilyl derivatives 3-methylisocarbostyrilyl and 5-methylisocarbostyrilyl styrilyl and 3-methyl-7-propynylisocarbostyriyl contain only natural bases The oligonucleotide sequence only slightly destabilizes the oligonucleotide duplex. Other unnatural nucleobases include 7-azaindoline, 6-methyl-7-azaindyl, imidizopyridinyl, 9-methyl-imidizopyridinyl Lysinyl, pyrrolopyridinyl, isocarbostyrilyl, 7-propynylisocarbostyri Propylene-7-azaindyl, 2,4,5-trimethylphenyl, 4-methyl Indolyl, 4,6-dimethylindolyl, phenyl, naphthalenyl, anthracenyl, Phenanthracenyl, pyrenyl, stilbenyl, tetracenyl, pentacenyl and the like Structural derivatives of difluorotolyl, 4-fluoro-6-methylbenzoyl Synthesis of midazole, 4-methylbenzimidazole and other unnatural bases mentioned above For a more detailed discussion, including procedures, see Schweitzer et al., J. Org. Chem. .,59:7238-7242(1994).
[0174] Additionally, chemical substituents, such as crosslinkers, may provide additional stability or irreversibility to reactants. Non-limiting examples of cross-linking agents include 1,1-bis(1,2-diphenylphosphine) and 1,3-diphenylphosphine. (diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide Cinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imides Esters (disuccinimidyl esters, e.g., 3,3'-dithiobis(succinimidyl esters, dipropionate), bifunctional maleimides (e.g., bis-N-maleimide- 1,8-octane) and methyl-3-[(p-azidophenyl)dithio]propioimide Examples of agents include date.
[0175] Nucleotide analogs can also include "locked" nucleic acids. The compositions essentially "tether" or "lock" endogenous nucleic acids into a particular structure. Tethering sequences can be used to prevent dissociation of the nucleic acid complex, In addition, it may be possible to prevent replication, as well as to tag, modify and / or clone endogenous sequences. The locked structure may also allow for the regulation of gene expression (i.e., transcription or replication) or to tag endogenous nucleic acid sequences. They can be used as stable structures that can be used to modify or in other ways. Alternatively, it may be used to isolate, ie, clone, the endogenous sequence.
[0176] Nucleic acid molecules are not necessarily limited to molecules containing only RNA or DNA, but may also be chemically modified. The term "non-nucleotide" or "modified" includes nucleotides and non-nucleotides. The percentage of nucleotides can range from 1% to 100% (e.g., about 5, 10, 15, 20, 25 , 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 or 95%).
[0177] Preparation of nucleic acids In some embodiments, e.g., a control or standard in an assay Nucleic acids are provided for use as therapeutic agents or as a therapeutic agent. Produced by any known method (e.g., chemical synthesis, enzymatic production, or biological production, etc.) The nucleic acid may be recovered or isolated from a biological sample. It may be recombinant, or it may be naturally occurring or endogenous to the cell ( (The genome of a cell can be produced from the DNA.) Biological samples are used to increase the recovery of small nucleic acid molecules. It is contemplated that the method may be performed in such a manner that the guanidinium and The method may include a step of lysing the cells with a solution having a detergent.
[0178] Nucleic acid synthesis can also be carried out according to standard methods. Synthetic nucleic acids (e.g., synthetic oligonucleotides) can be prepared by the following steps: Non-limiting examples of the nucleotides include phosphotriesters, phosphites or phosphatides. By in vitro chemical synthesis using phosphoamidite chemistry and solid-phase methods or by deoxy Nucleic acids made via nucleoside H-phosphonate intermediates. A suitable oligonucleotide synthesis scheme is disclosed elsewhere.
[0179] The nucleic acid may be isolated using known techniques. In certain embodiments, small nucleic acid molecules Methods for isolating clonal and / or RNA molecules can be used. Chromatography is used to separate or isolate nucleic acids from proteins or other nucleic acids. Such methods include electrophoresis using a gel matrix. , filter columns, alcohol precipitation and / or other chromatography. When nucleic acid from cells is used or evaluated, the method generally involves the use of a specific RNA. Before carrying out the process to isolate the A population, the cells were incubated with a chaotropic (e.g., Gua Nitinium isothiocyanate) and / or surfactants (e.g., N-lauroyl sucrose The process includes dissolving the product in water (leucine).
[0180] The methods may involve the use of organic solvents and / or alcohols to isolate the nucleic acids. In some embodiments, the amount of alcohol added to the cell lysate is about 55% to 100%. It reaches an alcohol concentration of 60%. Various alcohols can be used, but ethanol is the most popular. The solid support can be of any structure, including those that have electronegative groups. These include beads, filters and columns which may contain inorganic or polymeric supports. Glass fiber filters or columns are useful for such isolation procedures.
[0181] The nucleic acid isolation process sometimes involves: a) isolating the cells in the sample with a lysis solution containing guanidinium; lysing, wherein a lysate having a concentration of at least about 1 M guanidinium is produced. b) extracting nucleic acid molecules from the lysate using an extraction solution containing phenol. Step c) adding an alcohol solution to the lysate to obtain a lysate / alcohol mixture. forming a mixture, wherein the concentration of alcohol in the mixture is about 35% to about 70% d) applying the lysate / alcohol mixture to a solid support; e) applying the ion exchange solution to a solid support; and f) eluting the nucleic acid molecule from the solid support with a carboxylic acid solution; The sample may be dried and then resuspended in a suitable liquid for subsequent manipulation. and may be resuspended in volume.
[0182] Methods of gene transfer In order to mediate the effects of transgene expression within a cell, the expression construct must be transferred to the cell. Such transfer may be possible using viral gene transfer methods or viral In this section, a discussion of gene transfer methods and compositions is provided. Provided.
[0183] A transformed cell containing an expression vector is a cell that has been transformed by introducing the expression vector into the cell. Organelles, cells, tissues or organisms for use with the present methods. Suitable methods for polynucleotide delivery for transformation include the use of polynucleotides (e.g., D The present invention includes virtually any method by which the nucleic acid molecule (NA) can be introduced into an organelle, cell, tissue or organism.
[0184] A host cell can be, and has been, used as a recipient for vectors. The host cell is adapted to express a desired result, which may be the replication of the vector or the expression vector encoded by the vector. Depending on whether it is expression of part or all of the polynucleotide sequence contained therein, it may be prokaryotic or eukaryotic. Numerous cell lines and cell cultures are available for use as host cells. available for use as repositories for viable cultures and genetic material. The American Type Culture Collec In a specific embodiment, the host cell is T cells, tumor-infiltrating lymphocytes, natural killer cells, or natural killer T cells It is.
[0185] An appropriate host can be determined. Generally, this is based on the vector backbone and the desired result. For example, plasmids or cosmids are used in many prokaryotes for the replication of vectors. The host cell can be used as a host cell for replication and / or expression of the vector. The bacterial cells used include DH5α, JM109 and KC8, as well as several commercial Commercially available bacterial hosts (e.g., SURE® Competent Cell ls and SOLOPACK Gold Cells (STRATAGENE® ), La Jolla, CA). Alternatively, bacteria such as E. coli LE392 The cells can be used as host cells for phage viruses. Eukaryotic cells that may be used include, but are not limited to, yeast, insect and mammalian cells. Examples of mammalian eukaryotic host cells for replication and / or expression of vectors include HeLa, NIH3T3, Jurkat, 293, COS, CHO, Saos and Examples of yeast strains include, but are not limited to, YPH499, PC12. These include, but are not limited to, YPH500 and YPH501.
[0186] Nucleic acid vaccines include, for example, non-viral DNA vectors, "naked" DNA and RNA, As well as viral vectors. Methods for optimizing the expression of genes contained in these vaccines are known and include the following: The methods of are also discussed herein.
[0187] Examples of methods for transferring nucleic acids or viral vectors to transfect or transform cells, e.g., T cells, or Any suitable method can be used to administer the nucleotide sequences or compositions of the present method. Certain examples are provided herein, and further include cations. Polymers, lipid-like molecules and certain commercially available products, such as IN-VIVO-JET P Examples of methods include delivery using EI, etc.
[0188] 1. Ex Vivo Transformation Vascular cells and tissues extracted from an organism are transferred to an ex vivo environment. Various methods are available for transfecting canine endothelial cells in vitro. were genetically modified by retroviral gene transfer in mice and transplanted into dogs (Wi (Lyson et al., Science, 244:1344-1346, 1989). Yucatan miniature pig endothelial cells were transfected with retroviruses in vitro. , and implanted into the artery using a double balloon catheter (Nabel et al., Science ,244(4910):1342-1344,1989). Therefore, cells or tissues are extracted and expressed ex vivo using the polynucleotides presented herein. In certain embodiments, the transplanted cells or The cells or tissue can be placed in an organism. For example, T cells can be obtained from an animal and the cells can be transfected or transformed with an expression vector and then administered to the animal. It can be returned.
[0189] 2. Injection In certain embodiments, the cell or nucleic acid vector or viral vector comprises: One or more injections (i.e., injections by needle), e.g., subcutaneous, intradermal, intramuscular, intravenous Cells are secreted through the blood vessels, the prostate (intraprotatic), the tumor, the abdominal cavity, etc. The delivery may be to an organ, cell, tissue or organism. Methods of injection include, for example, saline solution. Further embodiments include direct microinjection of a composition comprising: The amount of expression vector used depends on the nature of the antigen, etc. and may vary depending on the organelle, cell, tissue or organism used.
[0190] Intradermal, intranodal or intralymphatic injections are the more commonly used methods of DC administration. Intradermal injections are part of a drug delivery system that allows slow absorption into the bloodstream but rapid uptake into the lymphatic system. The presence of a large number of Langerhans dendritic cells in the dermis Intact antigens as well as processed antigens can be transported to draining lymph nodes. To do this properly requires proper site preparation (i.e., proper needle placement). (The hair is clipped to observe the placement of the antigen in the nodal area.) Intranodal injection allows for direct delivery of the antigen to lymphatic tissue. Intralymphatic injection allows for the direct administration of DCs.
[0191] 3. Electroporation In certain embodiments, the polynucleotide is delivered via electroporation. Electroporation is the process by which the target gene is introduced into an organelle, cell, tissue or organism. The method involves exposing a suspension of DNA and DNA to a high voltage discharge. Specific cell wall degrading enzymes (e.g., pectin degrading enzymes) that are capable of degrading the target recipient cells The cells are more susceptible to transformation by electroporation than untreated cells. (U.S. Pat. No. 5,384,253, incorporated herein by reference).
[0192] Transfection of eukaryotic cells using electroporation has been fairly successful. In this manner, mouse pre-B lymphocytes are transfected with human κ immunoglobulin genes. (Potter et al. (1984) Proc. Nat'l Acad. Sci. U SA,81,7161-7165), rat hepatocytes were treated with chloramphenicol acetyltransferase The mutant was transfected with the methyltransferase gene (Tur-Kaspa et al. (1986) M ol. Cell Biol.,6,716-718).
[0193] In vivo electroporation for vaccines The vaccine for vaccines, or eVac, is being implemented in clinical practice via a simple injection method. A DNA vector encoding a tumor antigen is injected intradermally into the patient. The electrodes apply electrical pulses to the intradermal space, localizing them there. The cells that are resident in the body, particularly resident skin dendritic cells, take up the DNA vector and encode it in the tumor. Then, activated by local inflammation, the tumor expresses the tumor antigen. These dendritic cells migrate to lymph nodes, present tumor antigens, and induce tumor antigen-specific T cells. If the nucleic acid can be delivered to the cell by electroporation, The nucleic acid may be administered, for example, but not limited to, following injection of the nucleic acid or any other means of administration: When administered using electroporation, It is administered retically.
[0194] The method of electroporation is described, for example, in Sardesai, NY, and W einer,DB,Current Opinion in Immunother apy 23:421-9(2011) and Ferraro, B. et al., Human V accines 7:120-127 (2011), which are incorporated herein by reference in their entireties. (cited in the following article).
[0195] 4. Calcium phosphate In another embodiment, the polynucleotide is introduced into the cell using calcium phosphate precipitation. Using this technique, human KB cells were transfected with adenovirus 5 DNA. Graham and van der Eb (1973) Virology ,52,456-467). In this manner, mouse L(A9), mouse C12 7. CHO, CV-1, BHK, NIH3T3 and HeLa cells were transfected with neomycin marker. Transfected with the CAR gene (Chen and Okayama, Mol. ll Biol.,7(8):2745-2752,1987), rat hepatocytes were The marker genes were transfected with l.,10:689-695,1990).
[0196] 5.DEAE-Dextran In another embodiment, DEAE-dextran followed by polyethylene glycol is used In this manner, the reporter plasmid is delivered to the cell. Transduced into mouse myeloma and erythroleukemia cells (Gopal, TV, Mol C ell Biol.1985 May;5(5):1188-90).
[0197] 6. Sonication Loading Further embodiments are directed to direct sonic loading. The polynucleotide was introduced into LTK fibroblasts by sonication. Transfected with the phosphokinase gene (Fechheimer et al. (1987) Pr oc. Nat'l Acad. Sci. USA, 84, 8463-8467).
[0198] 7. Liposome-mediated Transfection In further embodiments, the polynucleotide is administered in a lipid complex, such as a liposome. Liposomes are characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes are vesicular structures that are characterized by the presence of multiple lipid membranes separated by an aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. These lipid components undergo self-rearrangement and then form closed structures, which are then absorbed by water and dissolved solvents. The protein is trapped between the lipid bilayer (Ghosh and Bachhawat, (199 1)In:Liver Diseases,Targeted Diagnosis a nd Therapy Using Specific Receptors and Ligands.pp.87-104). Lipofectamine (Gibco B Polynucleotides complexed with ELISA kits (RL) or Superfect (Qiagen) were also It is planned.
[0199] 8. Receptor-Mediated Transfection Still further, the polynucleotide can be delivered to a target cell via a receptor-mediated delivery vehicle. These can be delivered to the target cell via receptor-mediated endocytosis occurring in the target cell. Selective uptake of macromolecules by endothelial cell lysis. Cell type-specific distribution of various receptors. In light of this, this delivery method adds another degree of specificity.
[0200] Certain receptor-mediated gene targeting vehicles bind to cell receptor-specific ligands. and polynucleotide binding agents. Others are used to bind to the polynucleotide to be delivered. The antibody comprises an operably attached cell receptor-specific ligand. It has been used for scepter-mediated gene transfer (Wu and Wu, (1987) JB iol. Chem., 262, 4429-4432; Wagner et al., Proc. Nat. l.Acad.Sci.USA,87(9):3410-3414,1990;Pera les et al., Proc. Natl. Acad. Sci. USA, 91:4086-4090 ,1994; Myers,EPO 0273085), which makes the method feasible. Specific delivery in other mammalian cell types has also been discussed (Wu and d Wu,Adv.Drug Delivery Rev.,12:159-167,1 993; incorporated herein by reference). In certain embodiments, the method comprises: A ligand is selected which corresponds to a receptor that is specifically expressed in the
[0201] In another embodiment, the polynucleotide of the cell-specific polynucleotide targeting vehicle The delivery vehicle components may include liposomes as well as specific binding ligands. The polynucleotide(s) to be delivered is / are contained within the liposome and is / are associated with a specific binding ligand. The liposome is thus functionally integrated into the liposome membrane. The cellular receptor(s) can then be specifically bound to the cellular receptor(s) and deliver their contents to the cell. One such system is that epidermal growth factor (EGF) upregulates the EGF receptor. Synthetic nucleotides used in receptor-mediated delivery of polynucleotides to cells exhibiting It was shown to be functional using the stem.
[0202] In yet a further embodiment, targeted delivery vehicle polynucleotide delivery The vehicle component may be the liposome itself, which may, for example, be capable of cell-specific binding. For example, the galactose-terminated Lactosyl-ceramide, an asialoganglioside, was incorporated into liposomes and delivered to hepatocytes. Increased insulin gene uptake by cells was observed (Nicolau et al., 1987 )Methods Enzymol.,149,157-176). Tissue-specific transformation It is contemplated that recombinant constructs can be specifically delivered to target cells in a similar manner.
[0203] 9. Microprojectile bombardment The particle bombardment method involves delivering a polynucleotide to at least one organelle, cell, tissue or organism. can be used to introduce No. 38,880; U.S. Patent No. 5,610,042; and PCT Application WO94 / 096 99, each of which is incorporated herein by reference). This method involves The coated microprojectiles accelerate to high velocities, where they penetrate the cell membrane and kill the cell. It depends on the ability of the receptor to enter those cells without any interference from the receptor (Klein et al. (1987) Ature, 327, 70-73. There are a wide variety of particle bombardment methods known in the art, Many of them are applicable to the present method.
[0204] In this particle bombardment, one or more particles are coated with at least one polynucleotide. The particles can be accelerated and delivered to cells by a propulsive force. One such device generates an electric current that is then turned on. It relies on a high-voltage discharge to provide the transport force (Yang et al. (1990) Proc. Nat'l Acad. Sci. USA, 87, 9568-9572). The microprojectiles used are Consisting of a physically inert material (e.g., tungsten or gold particles or beads) Exemplary particles include those composed of tungsten, platinum, and in one particular example, gold. In some cases, D on metal particles may be used. NA precipitation is not required for DNA delivery to recipient cells using biolistic bombardment. However, the particles are not coated with DNA, but rather are loaded with DNA. It is contemplated that the DNA-coated particles may be used for DNA delivery via a particle gun. It may increase their level, but it is not necessary.
[0205] 10. Transposon-mediated transfer Transposon-mediated transfer methods are also used, for example, in the piggy / Bac gene transfer system. Sato, M. et al., Biotechnol J. 20 14 Oct 24. doi: 10.1002 / biot.201400283. [Electronic publishing ahead of print].
[0206] Examples of viral vector-mediated transfer methods A cell or cells within the subject express a gene encoded by the nucleotide sequence. The nucleotide sequence or a composition containing the nucleotide sequence may be expressed by the Any viral vector suitable for administration to a cell or subject can be used in the present methods. In certain embodiments, the transgene may be used to mediate gene transfer into a cell. Typically, the virus is simply incorporated into a viral particle that is transformed into a suitable host cell. Exposure to erythrocytes under physiological conditions may allow for viral uptake. The method may be advantageously used with a variety of viral vectors, as discussed below. .
[0207] 1. Adenovirus Adenoviruses are well-known due to their medium size DNA genome, ease of manipulation, high titer and broad spectrum. Due to their wide range of target cells and high infectivity, they are ideal for use as gene transfer vectors. The approximately 36 kb viral genome is involved in viral DNA replication and transcription. A 100-200 base pair (bp) terminus that contains cis-acting elements necessary for packaging The early (E) region of the genome, which contains different transcription units bounded by inverted repeats (ITRs). and the late (L) region, which is divided by the onset of viral DNA replication.
[0208] The E1 region (E1A and E1B) regulates the transcription of the viral genome and several cellular genes. It encodes a protein involved in the regulation of transcription. It regulates the expression of the E2 region (E2A and E2B). These proteins are synthesized by the D Involved in NA replication, late gene expression and host cell detachment (Renan, M. J. (1990) Radiother Oncol., 19, 197-218). The late genes (L1, L2, L3, L4 and L5) which contain most of the capsid protein ) is a single primary transcript driven by the major late promoter (MLP). MLP (located at 16.8 map units) is expressed only after significant processing of the ) is particularly effective at the later stages of infection, and all of the mRNAs contain 5' tripartite leaders that make them available for translation. It has a tlite leader (TL) sequence.
[0209] To optimize adenoviruses for gene therapy, large DNA segments can be inserted into the virus. It is necessary to maximize the carrying capacity so that the specific adenovirus product can be contained. It is also highly desirable to reduce the toxicity and immunological responses associated with these two The goals overlap to some extent, in that removal of adenoviral genes serves both purposes. By implementing this method, therapeutic constructs can be relatively easily manipulated. Both of these goals can be achieved while retaining capacity.
[0210] All cis elements required for viral DNA replication are present in the linear viral genome. It is localized to the inverted terminal repeats (ITRs) (100-200 bp) at either end of the genome. Thus, large DNA replacements are possible. Plasmids containing ITRs can be used to transform non-defective adenoviruses. It can replicate in the presence of viruses (Hay, RT et al., J Mol Biol. 1 984 Jun 5;175(4):493-510). Therefore, these elements Inclusion in an adenoviral vector may enable replication.
[0211] In addition, the packaging signal for viral encapsidation is located at the left end of the viral genome. It is located at 94 to 385 bp (0.5 to 1.1 map units) (Hearing et al., J. 1987) Virol., 67, 2555-2558). This signal is near the left end, Specific sequences outside the sticky end sequences encode proteins required for DNA insertion into the head structure. Protein recognition sites in bacteriophage lambda DNA that mediate binding to the substrate The Ad E1 replacement vector is a 450 bp (0–1 (.25 map unit) fragment can direct packaging in 293 cells. (Levrero et al., Gene, 101:195-202, 1991).
[0212] Previously, certain regions of the adenovirus genome have been integrated into the genome of mammalian cells. These cells were then transformed with β-glucosamine, thereby demonstrating that the encoded genes could be expressed. The cell line is an adenovirus that lacks the adenoviral functions encoded by the cell line. "Assistant" vectors, e.g., wild-type viruses or There have also been reports of complementation of replication-deficient adenovirus vectors by conditionally defective mutants. .
[0213] Replication-deficient adenovirus vectors are complemented in trans by helper viruses. However, due to the presence of a helper virus required to provide replication functions, However, this finding alone does not support the isolation of replication-defective vectors, since either preparation may be contaminated. Therefore, replication and / or packaging of the replication-deficient vector is not possible. An additional element was needed that could add specificity to the adenovirus. This comes from Luz's packaging capabilities.
[0214] The packaging signal for adenovirus is located on the left side of the conventional adenovirus map. It has been shown that the nucleosomes are located at the edge of the nucleosome (Tibbetts et al. (1977) Cell, 12, 2 Subsequent studies have revealed that the E1A region of the genome is deleted. Mutants that express this gene grow poorly even in cell lines that complement early (E1A) functions. It has been shown that the iol.167,809-822). Compensating adenoid When the virus DNA (0-353 bp) is recombined with the right end of the mutant, the virus Further mutational analysis revealed a short A novel repetitive position-dependent element was identified, which is located at either end of the genome. When present, one copy is sufficient for efficient packaging, but the Ad5 DNA fragment This was not found to be the case when the child was moved toward the inside (Hearing et al. , J. (1987) Virol., 67, 2555-2558).
[0215] By using mutant versions of the packaging signal, it is possible to package the vector with varying efficiencies. It is possible to create a caged helper virus. Typically, the mutations are: The helper virus is packaged in a low efficiency manner. When grown in cells, the virus showed a slower rate than the wild-type virus. However, the helper is packaged in a genomic DNA fragment, allowing the helper to propagate. These helper viruses were then transfected into cells along with a virus containing a wild-type packaging signal. When grown in Escherichia coli, the wild-type packaging signal is preferred over the mutant version. Considering the limited amount of packaging factors, wild-type sig Null-containing viruses are preferentially packaged relative to the helper. If large, a near homogeneous stock can be achieved.
[0216] To improve the tropism of the ADV constructs to specific tissues or species, receptor binding domains may be modified. Fiber sequences are often substituted between adenovirus isolates. Coxsackie-adenovirus receptor (CAR) ligand identified in virus 5 The adenovirus 35-derived CD46-binding fiber sequence was substituted for the human Viruses with significantly improved binding affinity to hematopoietic cells can be generated. The "deuterotyped" virus, Ad5f35, has been used in several clinical trials. This served as the basis for the virus isolation. Furthermore, the virus was able to target cells, e.g. T cells, There are various biochemical methods to modify the fiber that allow for retargeting. The method involves the use of bifunctional antibodies (one end that binds the CAR ligand and the other end that binds the target sequence). column) and the use of customized avidin-based chimeric ligands Alternatively, the ligand (e.g. , anti-CD205) via a heterobifunctional linker (e.g., containing PEG) It can attach to rus particles.
[0217] 2. Retroviruses Retroviruses convert their RNA into double-stranded DNA in infected cells by a process of reverse transcription. A group of single-stranded RNA viruses characterized by their ability to convert to NA (Coffin, 990) In: Virology, ed., New York: Raven Press. , pp.1437-1500). The resulting DNA was then transfected into cells as a provirus. It stably integrates into the chromosome and directs the synthesis of viral proteins. The viral gene sequences are retained in the recipient cell and its descendants. The R. rus genome contains three genes, one for the capsid protein, one for the polymerase enzyme and one for the . It contains gag, pol, and env, which code for the envelope components. It is called psi. The sequence found upstream from the gag gene is involved in packaging the genome into virions. Two long terminal repeat (LTR) sequences are located at the 5' end of the viral genome. and at the 3' end. These are strong promoter and enhancer sequences. It also contains the nucleotide sequence required for integration into the host cell genome (Coffin, 1990). Thus, for example, the present technology can be used to transduce polynuclear The invention includes cells in which the polypeptide has been integrated into the genome of the cell.
[0218] To construct a retroviral vector, a nucleic acid encoding a promoter is inserted into the virus. By inserting the virus at the location of a specific viral sequence in the genome, a virus that is replication-deficient can be produced. To produce virions, a plasmid containing the gag, pol and env genes is produced. To construct a packaging cell line that contains the LTR and psi components but does not contain the LTR and psi components (Mann et al. 1983) Cell, 33, 153-159). Retroviral LTR sequences and ps When a recombinant plasmid containing human cDNA with i sequences is introduced into this cell line (e.g. For example, by calcium phosphate precipitation, the psi sequence is A transcript is packaged into viral particles which are then secreted into the culture medium. (Nicolas, JF, and Rubenstein, JLR, (19 88)In:Vectors:a Survey of Molecular Clones ing Vectors and Their Uses,Rodriquez and Denhardt,Eds.).Nicolas and Rubenstein;T emin et al. (1986) In: Gene Transfer, Kucherlapati (ed.), New York: Plenum Press, pp.149-188;M The medium containing the recombinant retrovirus is collected and, if necessary, concentrated. , used for gene transfer. Retroviral vectors can infect a wide variety of cell types. However, many types of retroviruses can be integrated and stably expressed. Effective expression requires the division of host cells (Paskind et al. (1975) Virolog y,67,242-248).
[0219] An approach designed to enable specific targeting of retroviral vectors has demonstrated the ability to synthesize retroviruses by chemically adding galactose residues to the viral envelope. Recently developed based on chemical modification. Hepatocytes via asialoglycoprotein receptors. This modification may be desirable in some cases, as it may allow specific infection of certain cells.
[0220] Different approaches to recombinant retroviral targeting have been designed The approach uses biotinylated antibodies against retroviral envelope proteins and specific Biotinylated antibodies against different cell receptors were used. The biotin moiety was bound by avidin (Roux et al., 1988). 9) Proc. Nat'l Acad. Sci. USA, 86, 9079-9083). Using antibodies against major histocompatibility complex class I and class II antigens, Various human cells bearing these surface antigens were infected with ecotropic viruses in vitro. It has been demonstrated that the chromosome 10 of the chromosome 10 is stained with chromosome 10 (Roux et al., 1989).
[0221] 3. Lentivirus The lentiviral vector used in the present method may be any suitable lentivirus. Lentiviral vectors can be derived from retroviral vectors, including both primate and non-primate groups. Lentiviral vectors are a type of lentiviral vector. Examples of lentiviral vectors include, for example, Coffey et al. n et al. (1997) “Retroviruses” Cold Spring Har bor Laboratory Press Eds: JM Coffin, S M Hughes, HE Varmus pp 758-763) Examples of primate lentiviruses include, but are not limited to, the following: Human immunodeficiency virus (HIV), the causative agent of human autoimmune deficiency syndrome (AIDS), and and simian immunodeficiency virus (SIV). Non-primate lentiviruses include the prototype "Slow viruses" Visna / Maedi virus (VMV), Caprine arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV), and feline immunodeficiency virus ( Lentiviruses include the bovine immunodeficiency virus (FIV) and the bovine immunodeficiency virus (BIV). It can infect both dividing and non-dividing cells (Lewis et al. (1992); Lewis and Emerman (1994)).
[0222] A lentiviral vector, as used herein, is a vector that comprises at least one component part. a vector containing a gene, wherein the vector infects a cell and Biological functions by expressing or replicating genes and being derived from lentiviruses Involved in the structure.
[0223] The basic structure of retroviral and lentiviral genomes consists of a 5' LTR and and 3' LTR (between or within which a packaging sequence is inserted so that the genome can be packaged) the host cell genome and the packaging sequence, A combination of gag, pol and env genes that allows for the integration of coding components Lentiviruses share many common features, such as the insertion site of the HIV It contains additional features such as the rev and RRE sequences that are included in the Efficient transport of viral RNA transcripts from the nucleus to the cytoplasm of infected target cells This makes it possible.
[0224] In the provirus, the viral genes are located at both ends in long terminal repeats (LTRs). The LTRs are flanked by regions that mediate proviral integration and transcription. R also acts as an enhancer-promoter sequence, controlling the expression of viral genes. It can roll.
[0225] The LTR itself can be divided into three elements, designated U3, R and U5. U3 is derived from a sequence unique to the 3' end of the RNA. R is U1 is derived from a sequence repeated at one end of the RNA; U2 is derived from a sequence unique to the 5' end of the RNA. The sizes of the three elements can vary considerably among different viruses.
[0226] In the examples of lentiviral vectors discussed herein, one or more of the replication-essential genes are At least a portion of the more abundant protein coding region has been removed from the virus. This makes the viral vector replication-defective. Part of the viral genome can also be can transduce target non-dividing host cells and / or integrate their genome into the host genome. This may be replaced by an NOI to generate a vector containing an NOI that can be inserted.
[0227] In one embodiment, the retroviral vector is , WO 2007 / 072056, U.S. Pat. No. 9,169,491, U.S. Pat. No. 8,000,000. 84,249, or non-incorporated as discussed in U.S. Pat. No. 7,531,648. In some instances, the lentiviral vector is a self-inactivating vector. a transcription enhancer, or U3 in the 3' LTR, The enhancer and promoter in the region have been deleted (e.g., Yu et al. (1 986) Proc. Natl. Acad. Sci. 83:3194-3198 ; Dougherty and Temin (1987) Proc. Natl. Acad. Sci. 84:1197-1201; Hawley et al. (1987) Proc. Natl. Acad. Sci. 84:2406-2410; Ye e et al. (1987) Proc. Natl. Acad. Sci. 91:9564 -9568).
[0228] Lentiviruses used to generate viral genomes in host / packaging cells Viral plasmid vectors also mediate transcription of the genome in the host / packaging cell. A transcriptional control sequence operably linked to the lentiviral genome to direct These control sequences include the transcribed lentiviral sequences, i.e., 5' U3 They may be the native sequences associated with the regions, or they may be expressed by a heterologous promoter (e.g., It may be another viral promoter, for example the CMV promoter.
[0229] 4. Adeno-associated virus AAV uses a linear single-stranded DNA of about 4700 base pairs. , adjacent to each other in the genome. The two genes are present in the genome and are expressed by several different genes. First, the cap gene produces products designated VP-1, VP-2, and VP-3. Second, the rep gene produces four distinct virion proteins (VPs). One or more of these rep gene products encode the nonstructural proteins (NS) of A Involved in transactivation of AV transcription.
[0230] The three promoters in AAV are classified as map units according to their location in the genome. These are, from left to right, p5, p19, and p40. This gives rise to six transcripts, two initiated at each of the three promoters, one each pair of One of the splices is spliced. The splice site derived from map units 42 to 46 is located in each transposon. The four nonstructural proteins are derived from the longer transcript. All three virion proteins arise from the smallest transcript.
[0231] AAV is not associated with any pathological conditions in humans. For replication, AAV requires the use of herpes simplex viruses I and II, cytomegalovirus, " from viruses such as pseudorabies virus and, of course, adenoviruses. The best characterized of these helpers is the Adenoid Many of the "early" functions of this virus are believed to aid in AAV replication. It was shown that low-level expression of AAV rep protein suppresses AAV structural expression. It is believed that helper virus infection reverses this blockade.
[0232] The terminal repeat sequences of AAV vectors are selected from the group consisting of p20, p30, p40, p53, p60, p70, p80, p90, p100, p110, p120, p130, p240, p150, p250, p160, p260, p170, p270, p180, p280, p190, p290, p290, p350, p180, p290, p19 ... 1 by restriction endonuclease digestion of a plasmid such as (Samulski et al., J. Virol., 61:3096-3101 (1987)) or based on the published sequence of AAV Other methods, including but not limited to chemical or enzymatic synthesis of the <10-terminal repeat sequences. It can be obtained, for example, by functional, i.e. stable, site-specific synthesis. The minimal sequence or portion of the AAV ITR required to allow insertion is It is also possible to determine the terminal sequence that directs stable site-specific integration. It is also important to determine what minor modifications of the sequence can be tolerated while still maintaining the repeatability of the sequence. can.
[0233] AAV-based vectors are safe and effective vectors for in vitro gene delivery. These vectors have been developed and have been shown to be effective vehicles for the expression of The potential applications in gene therapy, both in vivo and in preclinical stages, are widespread. It has been tested in the clinical and post-clinical stages (Carter and Flotte, 2013). 995)Ann.NYAcad.Sci.,770;79-90;Chatteij ee et al. (1995)Ann.NYAcad.Sci.,770,79-90;Fer Rari et al. (1996) J. Virol., 70, 3227-3234; Fisher et al. (1996) J. Virol., 70, 520-532; Flotte et al., Proc.N at'l Acad.Sci.USA,90,10613-10617,(1993); Goodman et al. (1994), Blood, 84, 1492-1500; Kaplit t et al. (1994) Nat'l Genet., 8, 148-153; Kaplitt, M .G. et al., Ann Thorac Surg. 1996 Dec;62(6):1669 -76;Kessler et al. (1996) Proc.Nat'l Acad.Sci.US A, 93, 14082-14087; Koeberl et al. (1997) Proc. Nat' l Acad.Sci.USA,94,1426-1431;Mizukami et al.(19 96)Virology,217,124-130).
[0234] Efficient AAV-mediated gene transfer and expression in the lung is a promising treatment for cystic fibrosis. This has led to clinical trials for placement (Carter and Flotte, 1995; Lotte et al., Proc. Nat'l Acad. Sci. USA, 90, 10613- 10617, (1993)). Similarly, AAV-mediated delivery of the dystrophin gene to skeletal muscle Treatment of muscular dystrophy by gene delivery of tyrosine hydroxylase to the brain treatment of Parkinson's disease by hepatic factor IX gene delivery; treatment of hemophilia B by hepatic factor IX gene delivery; And potentially the prospect of treating myocardial infarction with vascular endothelial growth factor genes in the heart is AAV-mediated transgene expression in these organs has recently been shown to be highly efficient. Therefore, it seems to be promising (Fisher et al. (1996) J. Virol., 70, 5 20-532;Flotte et al., 1993;Kaplitt et al., 1994;1996;K oeberl et al., 1997; McCown et al. (1996) Brain Res., 713 ,99-107;Ping et al.(1996)Microcirculation,3,22 5-228; Xiao et al. (1996) J. Virol., 70, 8098-8108).
[0235] 5. Other viral vectors Other viral vectors may also be used as expression constructs in the methods and compositions of the invention. Vaccinia virus (Ridgeway, (1988) In:Vectors:A survey of molecular cloning vectors and their uses,pp.467-492;Baichwal and Sugd en,(1986)In,Gene Transfer,pp.117-148;Cou Parr et al., Gene, 68:1-10, 1988) Canarypox virus and Hepatitis C virus Vectors derived from viruses such as pesviruses are used. These viruses have a variety of The present invention provides several features for use in gene transfer into various mammalian cells.
[0236] Once the construct is delivered into the cell, the nucleic acid encoding the transgene is expressed in various parts. In one embodiment, the nucleic acid encoding the transgene is located at a site The chromosome is stably integrated into the genome of the cell. This integration occurs via homologous recombination. gnate) position and orientation (gene replacement) or in a random, non-specific position In yet a further embodiment, the nucleic acid is integrated into a separate segment of DNA (gene augmentation). Such nucleic acid segments are stably maintained in the cell as episomal segments. An "episome" is a molecule that is maintained and replicated independently of or in sync with the host cell cycle. How the expression construct is delivered to the cell and Where the nucleic acid resides within the cell depends on the type of expression construct used.
[0237] Methods for Engineering T Cells and Evaluation of Engineered T Cells Examples of methods for engineering T cells and evaluation of modified T cells are provided herein. can be.
[0238] (Retroviral transduction) 2. Transfection of 293T Cells with Retroviral Chimeric Polypeptide Constructs for Transient Generation of Retroviruses together with plasmids encoding gag-pol and the RD 114 envelope. GeneJuice transfection reagent (Novagen, Madison, The virus was transfected using the WI. The cells were harvested after 2 hours, flash frozen, and stored at -80°C until use. For transient production, 293T cells were transfected with the above construct and plasmid pLP1 (gag / p ol), pLP2(rev) and pLP / VSVG(VSVG env) together with Ge Transfect using neJuice. The virus was then transfected into After 48-72 hours, the cells were harvested, flash frozen, and stored at -80°C until use. For retrovirus generation, multiple rounds of incubation with transient VSV-G pseudotyped retrovirus supernatants were performed. Transduction generates stable FLYRD18-derived retroviral producer lines. FLYRD18 cells with the highest gene expression were single-cell sorted and the highest virus expression was detected. Expanding titer-producing clones to generate virus for lymphocyte transduction Transgene expression, function and retroviral titers of this clone were confirmed over 8 weeks. The cells were maintained in continuous culture for 10 min. The mice were incubated at 37°C for 1 hour or at 4°C overnight with 7 μg / ml Retronec Coating with tin (TakaraBio, Otsu, Shiga, Japan) The wells were washed with phosphate-buffered saline (PBS) and then incubated at 37° C. for 3 h. Retroviruses were retrovirally isolated by incubating the plate with 1.5 ml of supernatant for 0 min. The T cell blasts were then cultured in 100 U / ml IL-2. 5 × 10 per well in supplemented viral supernatant 5 Plate the cells. Transduction is carried out over a period of time. After transduction, cells are harvested and analyzed by flow cytometry. Phenotypic analysis was performed for expression of CD19 or GFP by ELISA. After transduction, cells were Collect and phenotype for CD19 or GFP expression by flow cytometry Do the following.
[0239] Cytotoxicity of Transduced T Cells Cytotoxic activity of each transduced T cell line was assessed using standard 4-h incubations as previously presented. The 51Cr release assay was performed using the above retroviral or lentivirus-mediated T cell proliferation assay. The virus was transduced and then used to induce autophagy in cells stimulated with phytohemagglutinin (PHA). Domestic lymphocytes (PHA blasts), LNCaP, PC3 or DU145 and A549 cancer cells A549-PSMA expressing cell line and transgenic A549 expressing human PSMA (A549-PSMA A) Compare with Cr51-labeled target cells containing complete medium or 1% Tritium. Targets incubated in X-100 (Sigma, St Louis, MO) The cells are used to determine spontaneous and maximum 51Cr release, respectively. The average percentage of specific lysis of the wells was calculated as 100 × (experimental release - spontaneous release). The release rate was calculated as / (maximum release - spontaneous release). In addition to the chromium release assay, co-culture experiments were also performed. Here, we performed experiments using the cell lines LNCaP, PC3, DU145, A549 and A549 -PSMA was transduced to express fluorescent mOrange and used as target cells Tumor cells expressing mOrange were cultured in complete medium with IL-2 (50 U / ml ) in the presence of untransduced or modified T cells, Tumor cells and T cells were co-cultured at a ratio of 1:10. After 24 hours, T cells were treated with 100 nM Stimulate with AP1903. After 72 hours, cells were harvested, counted, and analyzed to detect T cells. To determine the percentage of mOrange tumor cells, CD3 was labeled using flow cytometry. Analyze by (LSRII;BD).
[0240] Phenotypic analysis and activation status of transduced T cells. The cell surface phenotype of the transduced T cells was examined using the following monoclonal antibodies: Bell: CD3, CD4, CD8, CD19, CD25, CD27, CD28, CD44, CD45RA, CD45RO, CD62L, CD80, CD83, CD86, CD95, CD127, CD134, CD137, HLA-ABC and HLA-DR. 100nM Phenotypic analysis is performed with and without AP1903. Appropriate isotype match Controls were used in each experiment and were analyzed using an LSRII flow cytometer (BD). Analyze the cells using anti-F(ab')2 (Jackson ImmunoResearch Chimera polypeptides were obtained using the ELISA kit (Laboratories, West Grove, PA). The expression of the peptide is evaluated.
[0241] Analysis of cytokine production from transduced T cells in T cell culture supernatants before and after (24 hours) stimulation with 100 nM AP1903 Interferon-γ (IFN-γ), IL-2, IL-4, IL-5, IL-10 and and tumor necrosis factor-α (TNFα) concentrations were measured using human Th1 / Th2 cytokine cytometers. Measured using a Libads Array (BD Pharmingen). Cytokine production was assessed by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions. ;R&D Systems, Minneapolis, MN).
[0242] (Expansion of transduced T cells) The proliferative effects of AP1903-induced activation were examined after exposure to AP1903. By measuring cell growth of transduced and non-transduced T cells T cells were incubated with 10 μM carboxyfluorescein for 10 min at 37°C. Label with diacetate, succinimidyl ester (CFSE). Incubation Afterwards, the cells are washed in PBS and then resuspended in Cellgenix DC medium. Then, 1×10 6 CFSE-labeled modified or untransduced T cells Cells were cultured in Cellgenix DC medium alone or with 100 nM AP 1903. Five days later, cells were harvested and stained with CD3-PerCP.Cy5.5 and C Label with D19-PE and analyze by flow cytometry for CFSE dilution.
[0243] Does soluble immunoglobulin affect the proliferation and expansion of transduced T lymphocytes? To evaluate, human IL-16 cells were obtained from healthy donors without the addition of any exogenous cytokines. Serial dilutions of plasma or purified human immunoglobulins (Jackson Immuno Cells were cultured at 1 × 10 with serial dilutions of 5 Plate cells / well: 7 After 2 hours, the cells were treated with 1 μCi (0.037 MBq) methyl-3[H]thymidine ( Amersham Pharmacia Biotech, Piscataway, NJ ) and cultured for an additional 15 hours. The cells are then harvested onto filters. The cells were then dried and the counts per minute were recorded using a β-scintillation counter (TriC arb 2500 TR;Packard BioScience,Meridien, These experiments were performed in triplicate. In other experiments, control and and engineered T lymphocytes were cultured in medium alone or in plasma or purified immunoglobulins. Serial dilutions of 100% PBS were added every other day and cultured in medium. Trypan blue exclusion was then performed. Count cells every 2 days using a 3x counting kit.
[0244] Ex vivo T cell activation and administration to human subjects Additional chimeric polypeptides (e.g., the chimeric polypeptides discussed herein) may be used for human therapy. The polypeptide may or may not include a polynucleotide encoding a polypeptide (such as ribosome-specific endothelial cell line, ... or a polypeptide encoding a polypeptide of the present invention). Modified T cells (e.g., PRAME-specific recombinant TCR modified T cells) that may be absent A method using is presented in this example.
[0245] material and method Large-scale production of genetically modified T cells T cells are generated from healthy volunteers using standard methods. Peripheral blood mononuclear cells (PBMCs) from patients with cancer were transfected with soluble αCD3 and αCD28 (M iltenyi Biotec, Auburn, CA) were used for propagation and transduction. PBMCs were activated with 100 U / ml IL-2 (Cellgenix). 1 × 10 6 Resuspend at 0.2 cells / ml Stimulate with 0.5 μg / ml αCD3 and 0.5 μg / ml αCD28 soluble antibodies. The cells are cultured at 37°C and 5% CO for 4 days. On the fourth day, cells are cultured with 1 ml of IL-2 Add 1 liter of fresh medium. On day 7, cells were harvested and cultured in Cellgeni Resuspend in x DC medium.
[0246] (plasmids and retroviruses) The compositions and methods of this example comprise a PRAME-specific recombinant T The SFG plasmid may be modified to contain a lentiviral vector encoding CR. The inducible chimeric polypeptide linked to a truncated human CD19 via a cleavable 2A-like sequence The derived chimeric polypeptide consists of the peptide Ser-Gly-Gly-Gly- The F36V mutation was connected to a human chimeric polypeptide via a Ser-Gly linker. Human FK506 binding protein (FKBP12; GenBank AH002 The F36V mutation was generated by the synthetic homodimerizer, AP Increases the binding affinity of FKBP12 to 20187 or AP1903. The sequence, "T2A," is a 20 amino acid peptide derived from the Thosea asigna insect virus. The peptide encodes a cleavage site between glycine and the terminal proline residue that mediates >99% cleavage. The chimeric polypeptide is provided with 19 additional amino acids at the C-terminus thereof and the It brings an additional proline residue to the N-terminus. CD19 has a cytoplasmic domain that is It was shortened from 10 to 19 amino acids and contains all conserved sites that are potential sites for phosphorylation. The complete truncation at amino acid 333 (TDPTRRF) removes all tyrosine residues. long CD19 (GenBank NM001770).
[0247] Stable PG producing gibbon ape leukemia virus (Gal-V) pseudotyped retrovirus Thirteen clones were isolated from the Phoenix Eco cell line (ATCC product #SD3 444; ATCC, Manassas, VA) was transiently transfected with the SFG plasmid. This produces an Eco pseudotyped retrovirus. The PG13 packaging cell line (ATCC) was transduced three times with Eco pseudotyped retroviruses. By introducing multiple SFG plasmid proviral integrants per cell, Generate a producer line containing the highest titer by single cell cloning. The resulting PG13 clone is expanded and used for vector generation.
[0248] Retroviral transduction The culture medium for T cell activation and proliferation contained 100 U / ml IL-2 (Cell Serum-free Cellgenix DC medium (Cellgenix) supplemented with T cells were incubated with soluble IgG for 7 days prior to transduction with retroviral vectors. Activation was performed with anti-CD3 and anti-CD28 (Miltenyi Biotec). If necessary, immunomagnetic selection of ΔCD19 was performed 4 days after transduction; the positive fraction was further Grow for 2 days and store frozen.
[0249] Scale-up production of genetically engineered, allodepleted cells ) Scaling up the transduction process for clinical application involves the use of 10 ml of anti-CD3 0. Fibronectin 7 at 5μg / ml and anti-CD28 at 0.2μg / ml or 10μg / ml T7 non-tissue culture treated cells were coated overnight at 4°C with 1 μg / ml 5 flasks (Nunc, Rochester, NY). Corona-treated fluorinated ethylene propylene bags (2PF-0072AC,A American Fluoroseal Corporation,Gaithersb PBMCs were then immunized with anti-CD3 and anti-CD28 coated fragments. 1 × 10 6 Cells / ml to seed For retroviral transduction, RetroNectin-coated flasks or The bag is loaded once with 10 ml of retrovirus-containing supernatant for 2-3 hours. The cells were cultured in a 3:1 ratio of fresh medium containing retroviral vectors and 100 U / ml IL-1 1 × 10 in T cell culture medium supplemented with 1×10 6 Seed 1000 cells / ml. Harvest cells the next morning. and cultured in tissue culture-treated T75 or T175 flasks with 100 U / ml IL- Approximately 5 × 10 5 cells / ml~8×10 5 Seeding density of cells / ml Increase by degrees.
[0250] (CD19 immunomagnetic selection) In this example, the modified cells express the CD19 marker protein; The cells may be selected using markers other than CD19 or by other methods. It will be understood that immunomagnetic selection against CD19 was performed, in one example, 4 days after transduction. The cells can be incubated with paramagnetic microarrays conjugated to a monoclonal mouse anti-human CD19 antibody. The small-sized IgG was labeled with Clobeads (Miltenyi Biotech, Auburn, CA). On MS or LS columns for mock experiments and on CliniMacs for large-scale experiments The CD19-selected cells were further selected in a CD4+ autoselection device. These cells are then expanded for an additional 4 days and cryopreserved on day 8 after transduction. are called "cells."
[0251] Immunophenotyping and pentamer analysis Flow cytometry analysis (FACSCalibur and CellQuest software) Becton Dickinson) using the following antibodies: CD3; CD4, CD8, CD19, CD25, CD27, CD28, CD45RA, CD45R O, CD56 and CD62L. CD19-PE (clone 4G7; Becton Di ckinson) was found to give optimal staining and was used for all subsequent analyses. Non-transduced controls were used as CD19 negative controls. Used to set the gate.
[0252] statistical analysis A paired two-tailed Student's t-test was used to determine the statistical significance of differences between samples. All data are expressed as the mean ± 1 standard deviation.
[0253] Methods for Treating Disease The methods also include methods of treating or preventing disease, where the method comprises administering, for example, by injection. Administration of cells may be beneficial.
[0254] Cells, e.g., T cells, tumor-infiltrating lymphocytes, natural killer cells, natural killer T cells, or precursor cells, for example, hematopoietic stem cells, mesenchymal stromal cells, stem cells, Pluripotent stem cells and embryonic stem cells, etc., can be used for cell therapy. The cells may be derived from a donor or may be cells obtained from the patient. For example, they can be used to replace the function of diseased cells, for example in regeneration. These cells are characterized in that biological agents are expressed in specific microenvironments, e.g., in diseased bone marrow or metastatic The heterologous gene may be delivered to a metastatic deposit or the like. Mesenchymal stromal cells can also be modified to express a gene that exerts, for example, immunosuppressive activity. It has also been used to provide immunity to cancer and in the treatment of graft-versus-host disease and autoimmune disorders. The cells provided herein can be used to enhance the activity of therapeutic cells after cell therapy. Safety switches can be valuable in situations where power needs to be increased or reduced. For example, T cells expressing a T cell receptor (e.g., a PRAME-targeted TCR) can be used. When cells are delivered to patients, adverse events, such as off-target toxicities, may occur. Upon termination of ligand administration, the therapeutic T cells revert to a non-activated state and become non-toxic. Alternatively, for example, the therapeutic cells may be tumor cells or This can serve to reduce the size of the tumor and may no longer be needed. Then, administration of the ligand may cease and the therapeutic cells are no longer activated. If tumor cells return or tumor size increases after treatment with T The ligand is then reactivated to further activate CR-expressing T cells and re-treat the patient. It can be administered multiple times.
[0255] "Therapeutic cells" refers to cells used for cell therapy, i.e., to treat a condition or disease. By this is meant cells that are administered to a subject for treatment or prevention.
[0256] The term "unit dose" as it relates to an inoculum refers to a unit administration to a mammal. Each unit is a separate unit suitable for use as a single unit dosage. is a predetermined amount calculated to produce the desired immunostimulatory effect, together with any required diluent. The specification for the unit dose of the inoculum is based on the unique It is defined by and dependent on the characteristics and the particular immunological effect to be achieved.
[0257] Effective amounts of pharmaceutical compositions such as the multimeric ligands presented herein are 60%, 70%, %, 80%, 85%, 90%, 95% or more than 97% or 80%, 70%, 60%, such that less than 50%, 40%, 30%, 20% or 10% of the therapeutic cells are killed; This selected result induces apoptosis in T cells expressing caspase-9. The term may be synonymous with "amount sufficient to achieve the intended effect." In the case of modified T cells, an effective amount is defined as the amount of T cells that induces the desired therapeutic response (e.g., the amount of T cells that induces the desired therapeutic response). There was a decrease in tumor size, a decrease in the levels of tumor cells, or leukemia cells compared to the time point before the treatment. The amount may also be an amount that achieves a reduction in the levels of the antibody.
[0258] The effective amount for any particular application will depend on the disease or condition being treated, the Depending on the nature of the disease or condition, such as the particular composition being administered, the size of the subject, and / or the severity of the disease or condition, Effective amounts of any particular composition provided herein may vary depending on a variety of factors, and may be determined without undue experimentation. It need not be construed as limiting the present invention and can be determined empirically.
[0259] The terms "contacted" and "exposed" when applied to a cell, tissue, or organism. , a pharmaceutical composition and / or another agent, such as a chemotherapeutic or radiotherapeutic agent. or the like is delivered to a target cell, tissue or organism, or It is used herein to describe the process of placing a cell in close proximity to an organism. In order to achieve cell killing or stasis, a pharmaceutical composition and / or additional agents (e.g., The total number of molecules that are effective in killing a cell or cells or preventing cell division. The amount of the compound delivered to one or more cells.
[0260] Administration of the pharmaceutical composition may occur at intervals ranging from minutes to weeks, rather than at the same time as the other agent(s). may be performed prior to, may be performed simultaneously with other agent(s) and / or other actions. The pharmaceutical composition and the other agent(s) may be administered separately. In embodiments applied to cells, tissues or organisms, the pharmaceutical compositions and agents (including (several) still exert a beneficially combined effect on the cell, tissue, or organism. It is usually guaranteed that the validity period will not expire between the times of delivery, so that For example, in such cases, two, three, four or more formats may be used. and administering the pharmaceutical composition to the cell, tissue, or organism substantially simultaneously (i.e., within about one minute or less). In other embodiments, one or more agents may be contacted with an expression vector. before and / or after administration of the compound, substantially simultaneously, within about one minute to about 24 hours after administration of the compound. for about 7 days, for about 1 to about 8 weeks or longer, and any guidance therein. Still further, the pharmaceutical compositions presented herein may be administered in combination with one or more of the above-mentioned compositions. A variety of combination regimens with the above agents may be used.
[0261] Optimized and personalized therapeutic treatment The dosage and administration schedule of the modified cells will depend on the level of the disease or condition being treated. For example, the size of any remaining solid tumors may be determined. The patient may then be administered a therapeutically effective amount of the antibody or a targeted cell, e.g., a tumor cell or a leukemia cell remaining in the patient. The level of cells, etc. can be determined.
[0262] For example, if a patient has clinically relevant levels of tumor cells or after initial treatment The determination that a patient has a solid tumor is an indication that modified T cells may need to be administered. In another example, after treatment with the modified cells, a patient is provided with a reduced The determination of having a low level of tumor cells or reduced tumor size is indicative of the altered outcome of additional doses. Similarly, after treatment with the modified cells, the patient may be instructed that the modified cells are not needed. continues to show symptoms of a disease or condition or suffers from a recurrence of symptoms The decision may be made based on clinical findings that at least one additional dose of modified cells may need to be administered. The bedside physician may be instructed.
[0263] The term "dosage" refers to the amount of a drug administered and the frequency of administration (e.g., the timing of subsequent doses). The term "dosage level" refers to the dosage level in relation to the weight of the subject. It refers to the amount of modified cells administered.
[0264] In certain embodiments, the cells are from an animal, e.g., a human, a non-human primate, a bovine The subject is a cell in a human, horse, pig, sheep, goat, dog, cat or rodent. , e.g., animals, e.g., mammals, e.g., humans, non-human primates, cows, horses, pigs, The subject may be, for example, a human, e.g., a sheep, goat, dog, cat or rodent. For example, patients suffering from an infectious disease and / or who are immunocompromised or over-protected. The subject may be suffering from a proliferative disease.
[0265] Thus, for example, in certain embodiments, the methods include The tumor size and / or tumor cell count in the subject is compared to the tumor size and / or tumor cell count after administration of the acid. To determine whether there is an increase in tumor size and / or an increase in tumor cell count, and to determine whether there is an increase in tumor size. In the event that the presence of enlargement and / or an increase in the number of tumor cells is determined, and administering a further dose of the modified cell or nucleic acid to the subject. may also be compared to the level of leukemic cells after administration of the modified cells or nucleic acid, e.g. Determining whether or not there is an increase in leukemic cells in the subject, and determining whether or not there is an increase in leukemic cells in the subject. In the event that the presence of hemogenic cell proliferation is determined, administering the modified cellular In these embodiments, the method includes administering a further dose of the cell or nucleic acid. For example, the patient may be initially injected with therapeutic cells or nucleic acids according to the methods provided herein. After the initial treatment, for example, the size of the tumor, the number of tumor cells, or the number of leukemic cells is reduced. The number may be decreased compared to before the first treatment. The patient is then tested again or the patient continues to be monitored for disease symptoms. For example, the size of the tumor, the number of tumor cells, or the number of leukemia cells may be determined based on the initial treatment. If it is determined that the amount of the modified cell or nucleus is increased compared to the amount immediately after the modification, The acid may be administered for further doses. This monitoring and treatment should be done while keeping in mind that the therapeutic cells remain in the patient. The schedule may continue.
[0266] In other embodiments, the modified cells or nucleic acids (as defined above) are The nucleic acid is a nucleic acid that expresses an inducible caspase-9 polypeptide, and is then administered to the modified cells or In the event that it is necessary to reduce the number of cells modified in vivo, multimeric ligands may be used. In these embodiments, the method includes administering to the patient a therapeutically effective amount of determining the presence or absence of a condition (e.g., graft-versus-host disease, or off-target toxicity); and administering a dose of said multimeric ligand. or monitoring the condition and in the event said symptoms or condition persists, This may further include administering an additional dose of the multimeric ligand. This monitoring and treatment schedule continues for as long as the CR-expressing therapeutic cells remain in the patient. The schedule may continue.
[0267] A subsequent dose of a drug, e.g., a subsequent dose of a modified cell or nucleic acid, and / or or instructions to adjust or maintain subsequent drug dosages, etc., may be provided in any convenient format. The instructions may be provided in some embodiments in tabular form (e.g., on a physical medium or For example, the size of tumor cells or the number of tumor cells in a sample may be provided in a format that is easy to understand. The number or level of tumor cells may be provided in a table, and the clinician may be provided with a list of stages of disease or The clinician can then compare the symptoms to a table or a prescription for the next drug dose from the table. In certain embodiments, the instructions may include: After these symptoms are provided to a computer (e.g., placed in memory on the computer), Afterwards, the information may be presented (e.g., displayed) by a computer. For example, may be provided to a computer (e.g., entered into computer memory by a user). or via a remote device in a computer network. The computer software may then adjust subsequent drug doses. and / or generate instructions for administering or maintaining subsequent drug doses. The drug dose amount can be provided.
[0268] Once the subsequent doses have been determined based on the indication, the clinician should or instructions to adjust the dose to another person or entity. n) may be provided. As used herein, the term "clinician" refers to a decision maker. In certain embodiments, the clinician is a medical professional. In one embodiment, the computer or displayed computer program output based on instructions displayed by the computer or subsequent drug dosages. Decision makers may directly administer subsequent doses. (e.g., subsequent doses may be injected into the subject) or may be administered remotely (e.g., , pump parameters can be changed remotely by a decision maker).
[0269] The methods as provided herein include administering an effective amount of activated cells, nucleic acids or the like to the subject. These include, but are not limited to, delivery of expression constructs encoding activated cells, nucleic acids Or, an "effective amount" of an expression construct generally refers to an amount that detectably and repeatedly produces the stated desired result. A sufficient amount to repeatedly achieve, for example, an amelioration or reduction of a disease or its symptoms Elimination of disease is defined as an amount sufficient to eliminate, minimize, or limit the severity of a disease. Other, more precise definitions may apply, including eradication, eradication, or cure. In this study, biomarkers were used to assess efficacy of treatment and to control toxicity. It is possible to monitor tumor size, tumor antigen expression, or other disease symptoms. There may be.
[0270] In a further embodiment, the expression construct and / or expression vector activates the cell. The term "activating cells" or "activating cells" can be used as a composition or substance that "activates cells." Such compositions that "enhance" or "potentiate" include those that stimulate one or more activities associated with a cell. For example, a composition, such as an expression construct or vector, of the present method can be used to express a gene in a cell. It can stimulate upregulation of costimulatory molecules on the nucleus of NF-κB in cells. or toll-like receptors, or cytokines or It may activate other activities including chemokines.
[0271] The expression constructs, expression vectors and / or transduced cells may, for example, have weaker antibodies. Increasing the immunogenicity of a given antigen (e.g., a highly purified or recombinant antigen), enhancing the immune response, Reducing the amount of antigen required for response and decreasing the frequency of immunizations required to provide protective immunity and reducing the number of subjects with a reduced or weakened immune response (e.g., neonates, Improving vaccine efficacy in elderly and immunocompromised individuals, and mucosal By enhancing immunity in target tissues such as the immune system, the effectiveness of vaccines may be increased. or may contribute to the efficacy of the vaccine, or may have a specific cytokine profile. Induction can promote cell-mediated or humoral immunity.
[0272] In certain embodiments, the cells are also contacted with an antigen. Contacting the antigen in vivo Sometimes, the cells are contacted with the antigen in vivo. In some embodiments, the cells are present in a subject and an immune response is generated against an antigen. Sometimes, the immune response is a cytotoxic T lymphocyte (CTL) immune response. Sometimes, the immune response is directed against a tumor antigen. In certain embodiments, The cells are activated without the addition of an adjuvant.
[0273] In certain embodiments, the cells are transduced with the nucleic acid ex vivo and In another embodiment, the cells are administered to the subject by intravenous administration. In some embodiments, the cells are administered ex vivo using The cell is transduced with the nucleic acid and administered to the subject by subcutaneous administration. The cells are transduced with the nucleic acid ex vivo. Sometimes, the cells are transduced in vivo. Transduced with said nucleic acid.
[0274] In certain embodiments, the cells are transduced with the nucleic acid ex vivo, The cells are administered to the subject by intradermal administration, and sometimes the cells are administered ex vivo to the subject. The antigen is transduced with an acid and administered to the subject by subcutaneous administration. The antigen is a tumor antigen. The migration of cells to the draining lymph nodes can induce a CTL immune response. The antigen may be any antigen, e.g., a peptide or polypeptide, that induces an immune response in a host. The tumor antigen can be a tumor-associated antigen associated with a neoplastic tumor cell.
[0275] In some embodiments, an immunocompromised individual or subject has a reduced immune response. Such individuals may be subjects who have undergone chemotherapy or other treatments that weaken the immune system. Subjects receiving any other medical treatment, transplant recipients, and subjects currently taking immunosuppressants subjects, aging individuals, or individuals with reduced CD4 T helper cells and / or The present method may include any individual in which the immune system is impaired. It is contemplated that the present invention may be utilized to increase the amount and / or activity of CD4 T helper cells. can be.
[0276] antigen When assaying T cell activation in vitro or ex vivo, the target antigen can be a variety of It may be obtained or isolated from a source. Target antigen, as used herein, refers to , an antigen or an immunological epitope on an antigen, which is a target of immune recognition in a mammal. and the ultimate elimination or control of a disease-causing agent or disease state. The immune recognition is crucial in the role of the immune system. In the case of intracellular pathogens and cancer, immune recognition can be, for example, a T-lymphocyte response. The target antigen herein may include, for example, PRAME. The T cell receptor may be Can bind to the epitope, i.e., a polypeptide derived from PRAME, or In the context of peptide-MHC complexes, for example, MHC complexes with HLA class I molecules It is capable of binding to peptide molecules that are presented as part of a complex. The HC molecule binds to the TCR and the CD4 / CD8 coreceptors on T lymphocytes; The MHC molecule also contains a polypeptide fragment, or epitope, that interacts with the TCR. Generally, MHC class I molecules interact with the CD8 receptor and present class I antigens. II molecule interacts with the CD4 receptor. Thus, in the present application, e.g., TC When the CDR3 region of R or TCR specifically binds to PRAME or a target antigen, "Specifically binds to PRAME" means that the CDR3 region binds to the TCR alone and does not bind to the TCR as part of the TCR. as part of a recombinant TCR comprising a heterologous polypeptide sequence or as part of a heterologous polypeptide sequence As a part, PRAME, an epitope or a polypeptide derived from PRAME, As part of a peptide-MHC complex (e.g., HLA class I complex) (or For example, as part of a peptide-MHC complex containing an HLA class I A2.01 molecule) It is understood that the AME-derived epitope or polypeptide can be specifically bound to the AME-derived epitope or polypeptide. The CDR3 regions of the α and β polypeptides together comprise peptide-MH. It recognizes and binds to the C complex, and other TCR regions or other polypeptides bind to it. It is understood that the PRAME may contribute to the The TCR CDR3 region specifically binds to the PRAME peptide-MHC complex. and wherein, for example, the MHC is an HLA class I molecule, e.g., H It is an LA class I A2.01 molecule.
[0277] The target antigen may be, for example, a pathogenic microorganism, such as HIV (Korber et al., eds. HIV Molecular Immunology Database,Los Alamos National Laboratory,Los Alamos,N.Mex.19 77), influenza, herpes simplex, human papillomavirus (U.S. Patent No. 5,71 No. 9,054), Hepatitis B (U.S. Patent No. 5,780,036), Hepatitis C (U.S. Patent No. No. 5,709,995), viruses including EBV and cytomegalovirus (CMV) The target antigen may be derived from or isolated from a pathogen, such as Chlamydia trachomatis. a (U.S. Patent No. 5,869,608), Mycobacteria, Legionella, Meningococcus (M eningiococcus), Group A Streptococcus, Salmonella, Listeria, Hemoph virulence influenzae (U.S. Patent No. 5,955,596) It may be prepared or isolated therefrom.
[0278] Target antigens include, for example, Aspergillus, Invasive Candida (U.S. Patent No. 5,645,999 2) Nocardia, Histoplasmosis, Cryptosporidium The agent may be derived from or isolated from pathogenic yeasts, including yeasts such as Bacillus subtilis and Bacillus anguillis.
[0279] Target antigens include, for example, Pneumocystis carinii, Trypanosoma, Leishmania (U.S. Patent No. 5,965,242), Plasmodium (U.S. Patent No. 5,5 No. 89,343) and Toxoplasma gondii. can be derived from or isolated from pathogenic protozoa and pathogenic parasites, It is possible.
[0280] Target antigens include antigens associated with a preneoplastic or hyperplastic state. may also be associated with or cause cancer. In certain embodiments, In this case, the target antigen is PRAME. Such target antigens include, for example, tumor-specific antigens, Tumor-associated antigens (TAAs) or tissue-specific antigens, their epitopes and their Such target antigens include carcinoembryonic antigen (CEA) and and epitopes thereof, e.g., CAP-1, CAP-1-6D, etc. (GenBank Accession No. session number M29540), MART-1 (Kawakarni et al., J. Exp. Me d.180:347-352,1994), MAGE-1 (U.S. Pat. No. 5,750,39 No. 5), MAGE-3, GAGE (U.S. Patent No. 5,648,226), GP-100 ( Kawakami et al., Proc. Nat'l Acad. Sci. USA 91:645 8-6462, 1992), MUC-1, MUC-2, point-mutated ras oncogene, positive Normal and point-mutated p53 oncogenes (Hollstein et al., Nucleic Acid ids Res.22:3551-3555,1994), PSMA (Israeli et al. , Cancer Res. 53:227-230, 1993), tyrosinase (Kwon et al., PNAS 84:7473-7477, 1987) TRP-1 (gp75) (Coh En et al., Nucleic Acid Res. 18:2807-2808, 1990; US Patent No. 5,840,839), NY-ESO-1 (Chen et al., PNAS 94:1 914-1918, 1997), TRP-2 (Jackson et al., EMBOJ, 11:5 27-535,1992), TAG72, KSA, CA-125, PSA, HER-2 / neu / c-erb / B2 (US Patent No. 5,550,214), BRC-I, BRC- II, bcr-abl, pax3-fkhr, ews-fli-1, TAA and tissue specific These include modified allogeneic antigens, splice variants of TAAs, and epitope agonists. Other TAAs can be prepared by methods known in the art, for example, U.S. Pat. The method disclosed in US Pat. No. 4,514,506, which was used to identify and isolate Clonin The target antigen may be one or more growth factors and their respective splice variants. It may also include Ant.
[0281] An antigen may be expressed more frequently in cancer cells than in non-cancerous cells. The modified cells may be expressed by expression of a prostate specific membrane antigen, e.g., prostate specific membrane antigen (PSMA) or can result from contact with a fragment thereof.
[0282] Prostate antigen (PA001) is a recombinant protein consisting of the extracellular portion of the PSMA antigen. PSMA is a cytoplasmic marker of approximately 100-fold increase in cellular cellular markers with neuropeptidase and folate hydrolase activity. 100 kDa (84 kDa before glycosylation, approximately 180 kDa as a dimer) Although a type II membrane protein, the exact function of PSMA is currently unknown. arter RE et al., Proc Natl Acad Sci USA.93:749- 53, 1996; Israeli RS et al., Cancer Res. 53:227-30 ,1993;Pinto JT et al., Clin Cancer Res.2:1445-5 1,1996.
[0283] The cells may be, for example, unfractionated tumor lysates, peptides eluted from MHC, tumor-derived Heat shock proteins (HSPs), tumor associated antigens (TAAs (peptides or proteins) )) into immature DCs or by pulsing bulk tumor mRNA, i.e., TAA. Transfecting DCs with mRNA encoding the g,J.,Immunol Rev 199,251-63(2004);Gilboa ,E,Nat Rev Cancer 4,401-11(2004)) Tumor antigens, e.g., PSA, e.g., PSMA polypeptides, can be isolated by a variety of methods, including the steps of: may be contacted.
[0284] In the case of organisms that contain a DNA genome, the target antigen or its immunological epitope of interest is encoded by The gene encoding the gene is isolated from its genomic DNA. In the case of organisms with an RNA genome, The desired gene can be isolated from a cDNA copy of the genome. When a map is available, a DNA fragment containing the gene of interest can be extracted by routine methods. The desired gene is excised by restriction endonuclease digestion using the If the genes have been identified, they may be readily obtained from available clones. Alternatively, if the DNA sequence of the gene is known, the gene can be It may be synthesized by any conventional technique for synthesizing nucleic acids.
[0285] A gene encoding an antigen of interest can be prepared, for example, by cloning the gene into a bacterial host. For this purpose, various prokaryotic cloning vectors can be used. Examples of plasmids that can be used are pBR322, pUC and pEMBL.
[0286] A gene encoding at least one target antigen or an immunological epitope thereof is Inserted into a plasmid vector designed for viral recombination in a conventional manner. Generally, the cloned gene is amplified by restriction enzyme digestion. can be excised from a prokaryotic cloning vector. In most cases, the excised fragment is The fragment contains the entire coding region of the gene. The DNA fragment may be, for example, a DNA vector used for recombination with a virus. The ends of the fragment are modified as necessary to make them compatible with the insertion sites of the target. After the vector is purified, it is subjected to restriction endonuclease cleavage sites (cloning). The endothelial cell is inserted into the endothelial cell wall (the endothelial cell wall).
[0287] The antigen (e.g., the PRAME epitope polypeptide) of a cell, e.g., a dendritic cell. Antigen loading with a cell, such as a dendritic cell or a precursor cell, can be used, for example. By contacting the cells with the antigen, e.g., incubating the cells with the antigen Loading can be achieved, for example, by injecting DNA (naked or in a plasmid vector) or RNA; or expressing an antigen recombinant bacteria or viruses (e.g., vaccinia, chickenpox, adenovirus or This can also be achieved by incubating the cells with lentiviral vectors. Prior to loading, the antigen is shared with an immunological partner (e.g., a carrier molecule) that helps the T cell. Alternatively, the dendritic cells may be incubated separately or in the presence of the polypeptide. In the presence of the antibody, the cells can be pulsed with an unconjugated immunological partner. Antigens derived from MHC molecules can be obtained by acid elution or other methods (Zitvo See Gel L et al., J Exp Med 1996.183:87-97. These cells may be stimulated with either antigen before, after, or after the cells are loaded with antigen. At the same time, a nucleotide sequence encoding the chimeric protein is transduced according to the method. In certain embodiments, the antigen loading can be This is done after transduction or transfection.
[0288] In a further embodiment, the transduced cells are transfected with tumor cell mRNA. The transduced or transfected cells are administered to an animal to induce cell injury. It induces antitumor antigen immune responses of cytotoxic T lymphocytes and natural killer cells, and these cells is regulated by dimeric FK506 and dimeric FK506 analogs. The cellular mRNA can be, for example, mRNA from a prostate tumor cell.
[0289] In some embodiments, the transduced cells are pulsed with a tumor cell lysate. The pulsed, transduced cells can be administered to an animal to induce cellular proliferation. It induces antitumor antigen immune responses of cytotoxic T lymphocytes and natural killer cells, Cells are regulated with dimeric FK506 and dimeric FK506 analogs. The tumor cell lysate can be, for example, a prostate tumor cell lysate.
[0290] Immune cell and cytotoxic T lymphocyte responses T lymphocytes are activated by contact with cells containing the expression vectors discussed herein. The cells may be challenged with an antigen or transfected. The cells may be electrofused, pulsed, or electrofused.
[0291] T cells express a unique antigen-binding receptor (T cell receptor) on their membrane and The receptor associates with major histocompatibility complex (MHC) molecules on the surface of other cells. the status of major histocompatibility complex (MHC) molecules on the surface of other cells There are several subpopulations of T cells, e.g., helper Helper T cells and cytotoxic T cells are the first First, they are distinguished by their display of the membrane-bound glycoproteins CD4 and CD8, respectively. Helper T cells act as a complement to B cells, cytotoxic T cells, macrophages, and other members of the immune system. They secrete a variety of lymphokines that are crucial for cell activation. Naive CD8 T cells that recognize the -MHC complex proliferate and produce cytotoxic CD8 T lymphocytes. CTLs differentiate into effector cells called cytoplasmic lymphocytes (CTLs), which mediate cytolysis. By producing antigens, cells in the body that display antigens (e.g. viruses) The inflammatory process is called inflammatory bowel disease (AIDS) and is associated with the elimination of inflammatory bowel disease (AIDS-infected cells and tumor cells).
[0292] Transduced or transfected with the nucleic acid, vector, or composition herein. The modified cells can be, for example, T helper cells, T cytotoxic cells, CD8+ T cells, C D4+ T cells, NK T cells, and NK cells. The modified cells are typically a population of modified cells.
[0293] The activity of CTLs can be assessed, for example, by the methods discussed herein. CTLs can be assessed in freshly isolated peripheral blood mononuclear cells (PBMCs) or in cultured cells. Phytohaemaglutinin (PHA) was established from BMC. ) and expanded with IL-2 (Ber Nard et al., AIDS, 12(16):2125-2139, 1998), or DCs isolated from immunized subjects and infected with antigen-containing adenoviral vectors were used for 6 days. Standard 4-hour 51Cr release microtoxicity by T cells restimulated over a period of time One type of assay uses cloned T cells. The cloned T cells were shown to be highly potent in redirected cytotoxicity assays. Ability to mediate both perforin- and Fas ligand-dependent killing (Simpson et al., Gastroenterology, 115(4):8 49-855, 1998). Cloned cytotoxic T lymphocytes have Fas-dependent killing and pathogenicity. Recently, using a novel fluorescence amplification system, An in vitro dehydrogenase release assay has been developed (Page, B. et al., Anti cancer Res.1998 Jul-Aug;18(4A):2313-6). child The approach is sensitive, rapid, reproducible, and supports the mixed lymphocyte reaction (MLR) ) can be beneficially used for large-scale This is taken into consideration as it can be more easily automated for cytotoxicity testing. Another fluorometric assay developed to detect cytotoxicity uses full-body The fluorophore is the non-toxic molecule AlamarBlue (Nociari et al., J. Immunol. munol.Methods, 213(2):157-167, 1998). Alama rBlue is a mitochondrial product that reduces the fluorescence of AlamarBlue. The fluorescence is quenched ( (i.e., low quantum yield). This assay has been reported to be extremely sensitive and specific. It is a standard 51 The number of effector cells was significantly lower than in the Cr release assay. Not necessary.
[0294] Other immune cells that can be induced by this method include natural killer (NK) cells. NK cells lack antigen-specific receptors and are part of the innate immune system, the lymphoid system. Typically, infected cells react with foreign particles that are normally bound to cell surface MHC. However, the virus-infected cells are destroyed by the T cells that are alerted to this. They signal infection by expressing viral proteins that are recognized by antibodies. These cells can be killed by NK cells. If it has lost expression of MHC I molecules, it may be susceptible to NK.
[0295] Formulations and routes of administration to patients When clinical applications are contemplated, the pharmaceutical compositions (expression constructs, expression vectors, fusion proteins, etc. Transduced, transduced cells, activated T cells, transduced T cells, and loaded T cells It may be necessary to prepare the cell in a form appropriate for the intended use. Generally, this is Essentially free of pyrogens and other impurities that may be harmful to humans or animals. This may involve preparing a composition that is
[0296] Multimeric ligands, such as AP1903, are administered at a dose of, for example, about 0.01 to 1 mg / kg of subject. Subject body weight, approximately 0.05-0.5 mg / kg subject body weight, 0.1-2 mg / kg subject body weight , about 0.05-1.0 mg / kg body weight of the subject, about 0.1-5 mg / kg body weight of the subject, about 0 .2-4 mg / kg subject body weight, about 0.3-3 mg / kg subject body weight, about 0.3-2 mg / kg body weight of the subject or about 0.3 to 1 mg / kg body weight of the subject, for example, about 0.1, 0.2 ,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1.0,1.5,2,2 0.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9 or 10 mg / kg subject body weight In some embodiments, the ligand can be delivered at a dose of 0.4 per dose. The ligand is provided in a concentration of, for example, 10 mg / kg, e.g., 5 mg / mL. Approximately 0.25ml to approximately 10ml per bottle, for example, approximately 0.25, 0.5, 1, 1.5, 2 , 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 , 9, 9.5 or 10 ml, e.g., a vial or other container containing about 2 ml of may be provided.
[0297] Suitable for stabilizing the delivery vector and for enabling uptake by target cells It may generally be desirable to use salts and buffers that are suitable for the incubation of recombinant cells. The aqueous composition may also be used when administered to a patient. Alternatively, the vector may be contained in an effective amount for a cell, dissolved or dispersed in an aqueous medium. Such compositions are also referred to as inocula. "When administered to animals or humans, it is possible to cause adverse reactions, allergies, These molecular entities and compositions do not produce any adverse reactions or other untoward reactions. A pharma- ceutically acceptable carrier refers to any and all solvents, dispersion media, coatings, and the like. Pharmaceutically active agents include, but are not limited to, antibacterial and antifungal agents, isotonic and absorption delaying agents. The use of such media and agents for substances is known. Unless the agent or substance is incompatible with the vector or cell, the therapeutic composition Supplementary active ingredients can also be incorporated into the compositions. .
[0298] The active compositions may include conventional pharmaceutical agents. The administration of these compositions results in the target tissue becoming This may be via any convenient route, so long as it is available via that route. Administration can be by oral, nasal, buccal, rectal, vaginal or topical route. Alternatively, administration can be by orthotopic, intradermal, Administration may be by subcutaneous, intramuscular, intraperitoneal or intravenous injection. Typically, they may be administered in a pharma- ceutically acceptable composition as discussed herein.
[0299] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions, and and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and fluid to the extent that easy syringability exists. It is stable under the conditions of manufacture and storage and survives the contamination of microorganisms such as bacteria and fungi. The carrier is, for example, water, ethanol, polyol (e.g., glycerol, glycerol, propylene glycol and liquid polyethylene glycol), The appropriate mixture may be a solvent or dispersion medium including vegetable oil. For example, the use of a coating such as lecithin, or in the case of dispersions, maintaining the required particle size. This can be maintained by maintaining the soil and by using surfactants. Prevention of this can be achieved by the use of various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenoxyethanol, and the like. In certain instances, isotonic acid may be provided by ethanol, sorbic acid, thimerosal, etc. Injectable compositions may contain agents such as sugars or sodium chloride. Absorption can be delayed by the use of agents that delay absorption, such as aluminum monostearate and gelatin. This can be achieved by using in the composition
[0300] For oral administration, the compositions may be incorporated with excipients and may be used in non-ingestible mouthwashes and The active ingredient can be dissolved in a sodium borate solution (dentifrice) in the required amount. A mouthwash can be prepared by incorporating the active ingredient in a suitable solvent, such as bell's solution. The active ingredient is incorporated into a germicidal cleaning solution that contains sodium borate, glycerin and potassium bicarbonate. The active ingredient may be incorporated into dentifrices, including, for example, gels, pastes, powders and slurries. The active ingredient may also be dispersed in, for example, water, binders, abrasives, flavorings, foaming agents and wetting agents. A therapeutically effective amount may be added to a paste dentifrice which may contain a lubricant.
[0301] The compositions may be formulated in a neutral or salt form. Pharmaceutically acceptable salts include, but are not limited to, For example, inorganic acids such as hydrochloric acid or phosphoric acid, or acetic acid, oxalic acid, tartaric acid, malic acid, Acid addition salts formed with organic acids such as butylated and butylated acids (with free amino groups in proteins) The salts formed with the free carboxyl groups are inorganic salts. Groups such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide or ferric hydroxide, and isopropylamine, trimethylamine, histidine It can also be obtained from organic bases such as procaine, etc.
[0302] Once formulated, the solution is compatible with the dosage formulation. The therapeutically effective amount of the compound may be administered in a manner consistent with the methods described herein, and in an amount that is therapeutically effective. A therapeutically effective amount of modified cells expressing the PRAME TCR discussed herein can be administered, for example, in vivo. in subjects or in mouse or other animal models as discussed herein. The amount or concentration of PRAME-expressing cells in a subject as measured by the assay. Thus, a therapeutically effective amount can be an amount that reduces the percentage or The amount can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%; a therapeutically effective amount can also be an amount sufficient to reduce, e.g., a stable i.e., the number or concentration of PRAME-expressing cells may be sufficient to result in disease. These formulations are available in a variety of dosage forms (e.g., injectable solutions, drug release For parenteral administration, e.g., in an aqueous solution, the liquid The preparations may be suitably buffered, if necessary, and the liquid diluent initially must be diluted with sufficient saline or glucose. These particular aqueous solutions can be administered intravenously, intramuscularly, subcutaneously and intraperitoneally. It is particularly suitable for intracavitary administration. In this context, a sterile aqueous medium may be used. For example, One dose can be dissolved in 1 ml of isotonic NaCl solution and can be used for subcutaneous injection in 1000 ml. It may be added or injected at the proposed injection site (see, for example, "Reming on's Pharmaceutical Sciences”15th Editorial (See, for example, pp. 1035-1038 and 1570-1580.) Some variation in dosage will necessarily occur depending on the condition of the subject. However, the person responsible for administration can determine the appropriate dose for the individual subject. For administration to humans, the preparation must meet the standards of the FDA Office of Biologics. Meet the sterility, pyrogenicity, and general safety and purity standards as required by the do.
[0303] The dosing schedule can be determined as appropriate for the patient, e.g., PRAME TCR-modified cells must be administered at week 0 and subsequently produce a efficacious therapeutic outcome In such cases, or for example, after that, for a total of, say, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 14 weeks, 16 weeks, 18 weeks, 20 weeks, 22 weeks, 24 weeks, 26 weeks, 28 weeks, 30 weeks, 40 weeks, 50 weeks, 60 weeks, 70 weeks, 80 weeks 2, 4, 6, 8, 10, 12, 14, 10, 20, 30, 40, 50, 60, 80, 100 weeks The dosing schedule includes additional cell administration at intervals of 6, 18, and 20 days. obtain.
[0304] If necessary, the method can be used to obtain more cells to be used in the treatment. may further include further leukapheresis.
[0305] The modified cells of the present application may be, for example, 0.25×10 6 (±20%) cells / kg, 0. 5×10 5 (±20%) cells / kg, 0.75×10 5 (±20%) cells / kg, 1×1 0 5 (±20%) cells / kg, 0.3×10 6 (±20%) cells / kg, 0.625×1 06 (±20%) cells / kg, 1.25×10 6 (±20%) cells / kg, 2.5×10 6 (±20%) cells / kg, 5×10 6 (±20%) cells / kg, 7.5×10 6 (±2 0%) cells / kg, 1×10 7 (±20%) cells / kg, 2.5×10 7 (±20%) thin cells / kg, 5×10 7 (±20%) cells / kg, 7.5×10 7 (±20%) cells / kg , or 1 × 10 8 (±20%) cells / kg of subject body weight per injection The dose may be delivered in one or multiple doses.
[0306] If activation or induction of the caspase-9 switch is required, AP1903 or Administration of other chemical inducers can be determined as appropriate for the patient, e.g., initially This dose is required to be administered in week 0 of the initiation of CID treatment and subsequently to obtain effective treatment results. If necessary, or for example, for a total of, for example, 2 weeks, 4 weeks, 6 weeks, 8 weeks, weeks, 10 weeks, 12 weeks, 14 weeks, 16 weeks, 18 weeks, 20 weeks, 22 weeks, 24 weeks weeks, 26 weeks, 28 weeks, or 30 weeks, 40 weeks, 50 weeks, 60 weeks, 70 weeks 2, 4, 6, 8, 10, 12, 14, 20, 22, 24, 26, 8, 10, 12, 28, 30, 32, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, Additional doses of the chemical inducer are administered at intervals of 14, 16, 18, and 20 days. It may include a drug schedule.
[0307] Methods for Treating Disease The present invention also relates to a method for treating or preventing a disease caused by a hyperproliferative disease. Includes.
[0308] Treatment using pharmaceutical compositions (transduced T cells, expression vectors, expression constructs, etc.) Preneoplastic or hyperplastic conditions which may be treated or prevented include colon polyposis. Preneoplastic or hyperplastic conditions such as psoriasis, Crohn's disease, ulcerative colitis, breast lesions, etc. These include, but are not limited to:
[0309] Cancers, including solid tumors, that can be treated using the pharmaceutical compositions include primary or metastatic Metastatic melanoma, adenocarcinoma, squamous cell carcinoma, adenosquamous cell carcinoma, thymoma, uveal melanoma, lymphoma , sarcoma, lung cancer, liver cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia, uterine cancer , breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, colon cancer, multiple myeloma, neuroblastoma, N These include, but are not limited to, PC, bladder cancer, and cervical cancer.
[0310] The T cell activation system and other therapeutic cell activation systems presented herein Other hyperproliferative diseases, including solid tumors, that may be treated using the present invention include rheumatoid arthritis, inflammation, and the like. Intestinal disease, osteoarthritis, leiomyoma, adenoma, lipoma, hemangioma, fibroma, vascular obstruction , restenosis, atherosclerosis, preneoplastic lesions (e.g., adenomatous hyperplasia and prostatic intraepithelial neoplasia, intraepithelial carcinoma, oral hairy leukoplakia, or psoriasis, Not limited.
[0311] In the treatment method, a pharmaceutical composition (expression construct, expression vector, fusion protein, trait Transduced cells, and activated T cells, transduced T cells and loaded T cells The administration of the composition may be for "prophylactic" or "therapeutic" purposes. When provided, it is provided prior to any symptoms. The prophylactic administration of the pharmaceutical composition is then The pharmaceutical composition is useful for preventing or ameliorating any infection or disease of the When provided therapeutically, it is provided at or after the onset of symptoms of infection or disease. Thus, the compositions provided herein can be used to treat disease-causing agents or It may be provided prior to anticipated exposure to the condition or after the onset of infection or disease. In accordance with the present invention, the nucleic acids and cells discussed herein can be used to treat solid tumors (e.g., cancers found in or for the prophylactic treatment of solid tumors, such as, but not limited to, prostate cancer. Methods for prophylactically preventing tumors in a subject are provided herein. or reducing the size thereof, said methods comprising the steps of any of the methods discussed herein. and administering to the subject a nucleic acid or cell that induces a tumor in the subject, whereby the nucleic acid or cell induces a tumor in the subject. The method includes administering in an amount effective to prevent or reduce the size of the tumor.
[0312] Solid tumors of any tissue or organ origin can be treated using the present methods, for example. Solid tumors of the present invention include those that express PSA, e.g., PSMA, in the vasculature. Any tumor that may be involved, such as, for example, lung, bone, liver, prostate or brain, and also, for example, breast, Ovaries, intestines, testes, colon, pancreas, kidneys, bladder, neuroendocrine system, soft tissue, bone masses Other solid tumors that can be treated include lymphatic masses and solid tumors located in the lymphatic system. Malignant tumors include, for example, glioblastoma and malignant myeloma.
[0313] The term "unit dose" as it relates to an inoculum refers to a unitary administration to a mammal. Each unit refers to physically separate units suitable for use in combination with any required diluents. , containing a predetermined amount of the pharmaceutical composition calculated to produce the desired immunogenic effect. The specification for the unit dose of is based on the unique features and It is defined by the particular immunological effect to be achieved and depends on its characteristics.
[0314] An effective amount of a pharmaceutical composition is an amount that achieves the selected result of enhancing the immune response. For example, an effective amount for treating an immune system disorder may be determined by measuring the amount of the immune system that is affected. This activates the immune system and generates an antigen-specific immune response upon exposure to an antigen. The term may be synonymous with "a sufficient amount."
[0315] The effective amount for any particular application will depend on the disease or condition being treated, the Depending on the nature of the disease or condition, such as the particular composition being administered, the size of the subject, and / or the severity of the disease or condition, Effective amounts of any particular composition provided herein may vary depending on a variety of factors, and may be determined without undue experimentation. Thus, for example, in one embodiment, the above formula The transduced T cells or other cells can be administered, for example, in an amount effective to induce an immune response, or For example, the compound is effective in reducing tumor size or reducing the amount of tumor vasculature. The subject is administered an amount sufficient to
[0316] A. Gene-Based Therapies In certain embodiments, the cells include a recombinant TCR polypeptide (e.g., For example, an expression construct capable of providing a PRAME-specific recombinant TCR polypeptide is provided. A discussion of the expression vectors and genetic elements used therein is provided in this section. In certain instances, the expression vector is a viral vector (e.g., For example, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, In another example, the vector can be It may be a lysosome-encapsulated expression vector.
[0317] Gene delivery can be performed in both in vivo and ex vivo situations. In the case of a vector, generally a viral vector stock can be prepared. An example of viral vector-mediated gene delivery in vivo is presented in this application. For in vivo delivery, depending on the type of virus and the titer achievable, e.g., about 1 2, 3, 4, 5, 6, 7, 8 or 9 x 10 4 , 1, 2, 3, 4, 5, 6, 7, 8If 9×10 5 , 1, 2, 3, 4, 5, 6, 7, 8 or 9 x 10 6 , 1, 2, 3, 4 , 5, 6, 7, 8 or 9 x 10 7 , 1, 2, 3, 4, 5, 6, 7, 8 or 9×1 0 8 , 1, 2, 3, 4, 5, 6, 7, 8 or 9 x 10 9 , 1, 2, 3, 4, 5, 6, 7, 8 or 9 x 10 10 , 1, 2, 3, 4, 5, 6, 7, 8 or 9 x 10 11 Ma or 1, 2, 3, 4, 5, 6, 7, 8 or 9 x 10 12 infectious particles delivered to the patient Similar figures can be obtained by comparing the relative uptake efficiencies of liposomal preparations. This may be extrapolated to other non-viral formulations. Formulations of multimeric ligands, such as AP1903, can be formulated, for example, in Approximately 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 , 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9 or 10 mg / The dose may be delivered in kg of subject body weight.
[0318] B. Cell-Based Therapies Another contemplated treatment is the administration of engineered T cells, such as, for example, transduced T cells. The T cells may be engineered in vitro. Formulation as a composition is discussed herein.
[0319] In cell-based therapies, engineered cells can be engineered to, for example, contain a retroviral vector encoding a target antigen nucleic acid. Can be transduced with viral or lentiviral vectors; target antigen nucleic acid (e.g., mRNA or DNA) or protein; Can be pulsed with cell lysates, proteins or nucleic acids; or electrically fused with cells The cells, proteins, cell lysates or nucleic acids may be derived from cells, such as tumor cells. or other pathogenic microorganisms, such as viruses, bacteria, protozoa, and the like.
[0320] C. Combination Therapy To enhance the effectiveness of the expression vectors presented herein, these compositions and It may be desirable to combine the method with an agent effective in treating the disease. do.
[0321] In certain embodiments, anti-cancer drugs may be used in combination with the present methods. A "cancer" agent may, for example, be an agent that is capable of killing one or more cancer cells, Inducing apoptosis, slowing the growth rate of one or more cancer cells, and preventing metastasis Reducing the incidence or number of tumors, reducing the size of tumors, or inhibiting tumor growth reducing the blood supply to a tumor or one or more cancer cells; Promoting an immune response against cancer cells or tumors, which may prevent cancer progression by inhibiting or preventing the progression of cancer or by extending the lifespan of subjects with cancer. Anticancer drugs include, for example, chemotherapeutic agents (chemotherapeutic agents). chemotherapy), radiotherapy (radiotherapy), surgical procedures (surgery), immunotherapy (immunotherapy), Genetic therapeutic agents (gene therapy), hormone therapy, other biological agents (biotherapy) and / or or alternative therapies.
[0322] In a further embodiment, antibiotics are used to treat and / or prevent infections. The antibiotics may be used in combination with the pharmaceutical composition. Aminoglycosides (e.g., gentamicin), amoxicillin, amphotericin B, ampicillin, antimonials, atovaquone, stiboglu Sodium cone, azithromycin, capreomycin, cefotaxime, cefoxitin tin, ceftriaxone, chloramphenicol, clarithromycin, clindamycin , clofazimine, cycloserine, dapsone, doxycycline, ethambutol, Ethionamide, fluconazole, fluoroquinolones, isoniazid, itraconazole , kanamycin, ketoconazole, minocycline, ofloxacin), para-aminox Licylic acid, pentamidine, polymyxins, defensins, promycin Lothionamide, pyrazinamide, pyrimethamine, sulfadiazine, quinolones (e.g., Ciprofloxacin), rifabutin, rifampin, sparfloxacin, strepto mycin, sulfonamides, tetracyclines, thiacetazone, trimethoprim (t Rimethaprim) - Sulfamethoxazole, Viomycin or a combination thereof These include, but are not limited to, combinations of
[0323] More generally, such agents are used to kill cancer cells and / or microorganisms. or an expression vector effective for inhibiting the proliferation of cancer cells and / or microorganisms. The process may also include providing a total amount of the cell(s) with the drug(s) and The method may include contacting the cells, tissues, and / or tissues simultaneously or within a period of time with the pharmaceutical composition, Alternatively, the desired therapeutic benefit may be achieved by separate administration of the pharmaceutical composition and the agent to an organism. This may be achieved by combining a single composition or a pharmacological agent that contains both the pharmaceutical composition and one or more agents. by contacting a biological preparation with a cell, tissue, or organism, or by two or more separate Compositions or formulations (wherein one composition comprises a pharmaceutical composition and the other comprises one or more drugs) This can be achieved by contacting the cells with a
[0324] The terms "contacted" and "exposed" when applied to a cell, tissue, or organism. , a pharmaceutical composition and / or another agent, such as a chemotherapeutic or radiotherapeutic agent. are used herein to describe the process by which the The process by which the target cell, tissue or organism is used or placed in close proximity to the target cell, tissue or organism is described. As used herein to describe the use of pharmacological agents to achieve cell killing or stasis. The composition and / or additional agent(s) are effective in killing the cell(s). The therapeutic agent is delivered to one or more cells in a total amount effective to inhibit or prevent the division of the cells.
[0325] Administration of the pharmaceutical composition may occur at intervals ranging from minutes to weeks, rather than at the same time as the other agent(s). may be performed prior to, may be performed simultaneously with other agent(s) and / or other actions. The pharmaceutical composition and the other agent(s) may be administered separately. In embodiments applied to cells, tissues or organisms, the pharmaceutical compositions and agents (including (several) still exert a beneficially combined effect on the cell, tissue, or organism. It is usually guaranteed that the validity period will not expire between the times of delivery, so that For example, in such cases, two, three, four or more formats may be used. and administering the pharmaceutical composition to the cell, tissue, or organism substantially simultaneously (i.e., within about one minute or less). In other embodiments, one or more agents may be contacted with the expression vector. Substantially simultaneously, within about 1 minute to about 2 minutes before and / or after administration of the drug. 4 hours, about 7 days, about 1 to about 8 weeks or longer, and any Furthermore, the pharmaceutical compositions presented herein may be administered in a range that can be derived. A variety of combination regimens with one or more agents may be used.
[0326] In some embodiments, the chemotherapeutic agent may be a lymphodepleting chemotherapeutic agent. In another embodiment, the chemotherapeutic agent is Taxotere (docetaxel) or another taxane. The chemotherapeutic agent may be, for example, cabazitaxel. can be administered before, during or after treatment with the cells and inducers. , the chemotherapy agent may be administered approximately one year prior to administration of the first dose of activated nucleic acid, 11, 10, 9, 8, 7, 6, 5 or 4 months ago, or 18, 17, 16, 15, 14, 13, 12, May be administered 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 weeks or 1 week prior Alternatively, for example, the chemotherapeutic agent may be administered about one week after the first dose of cells or inducer is administered. After, or 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 1 After 6, 17 or 18 weeks or after 4, 5, 6, 7, 8, 9, 10 or 11 months , or one year later.
[0327] The administration of the chemotherapeutic agent may include administration of two or more chemotherapeutic agents. For example, cisplatin may be administered in addition to taxotere or other taxanes, such as cabazitaxel. do.
[0328] The methods as provided herein can include, without limitation, the preparation of activated cells, nucleic acids, or An "effective amount" of a pharmaceutical composition generally includes delivery of an effective amount of an expression construct encoding the , detectably and repeatedly to achieve the desired results described, e.g., the above diseases. or to ameliorate, reduce, minimize, or limit the severity of its symptoms. Other, more precise definitions may be used, including elimination, eradication, or cure of the disease. In some embodiments, to assess the effectiveness of a treatment, Although there are indications for monitoring biomarkers to control efficacy and toxicity, good.
[0329] The effective amount of modified cells can be determined by the physician in consideration of the individual patient. Factors to be considered include, for example, the extent of the disease or condition, tumor size, and the extent of the infection. The dosage and frequency of administration may be determined by a physician or other By the clinician, by monitoring the patient for symptoms of the disease or condition; and response to previous doses, e.g., tumor size, or tumor antigen levels. In certain instances, the amount of the modified Cells are 10 4 ~10 9 10 modified cells / kg body weight 5 ~10 6 pieces, 10 9 ~ 10 11 Pieces or 10 10 ~10 11 The dose was 100 modified cells / kg body weight. can be given.
[0330] D. PRAME TCR-expressing T cells in patients with relapsed or refractory myeloid neoplasms Dose escalation study to evaluate the safety and feasiblity of cells T cells expressing PRAME TCR containing chimeric caspase-9-encoding nucleic acid (Cell A ) is administered to a subject having a condition or disease associated with expression of the PRAME antigen, e.g., to the bone marrow. The iCaspase-9 safety switch (iCasp9) may be administered to subjects with a chronic neoplasm. is included in the Cell A design and is a predictor of treatment with PRAME TCR expressing T cells. Methods are provided to control levels or to stop treatment.
[0331] A Phase I, open-label, non-randomized feasibility, safety, and dose-finding study. centre During the Phase I MTD stage, subjects will receive one dose of Cell A on Day 0. The design was a 3+3 dose escalation / de-escalation trial. tion) scheme, 3-6 patients per cohort will be treated in Cell A. The study consists of five cohorts of subjects in Cell A. Phase Ib expansion stage (e During the expansion stage, subjects received a maximum tolerated dose of Cell A on Day 0. Uncontrolled toxicity is mediated by dimerizers that activate the CaspaCIDe suicide switch This induces the use of the dimerizer drug, rimizucide, and therefore Cell A PRA Eliminate ME-reactive T cells.
[0332] Medication Design 1 / 3 experience DLT at starting dose (cohort 3); another 3 subjects will be enrolled and treated in cohort 3. The first 3 patients will be followed for 3 weeks after each patient. Follow-up will be conducted and any further patients will be enrolled thereafter. All subsequent cohorts will be Ports may be registered simultaneously.
[0333] If 0 / 3 or 1 / 6 subjects experience DLT in cohort 3 (starting dose) If >= 2 / 6 subjects are enrolled in Cohort 3, then the subsequent subjects will be enrolled in Cohort 4. If a subject experiences a DLT in cohort 2, then the subsequent subject will be enrolled in cohort 2.
[0334] If 0 / 3 or 1 / 6 subjects experience a DLT in cohort 4, then Subsequent subjects will be enrolled in cohort 5. ≥2 / 6 subjects experienced DLT in cohort 4 If only 3 subjects experience the cohort 3, then the MTD is declared and only 3 subjects experience the cohort 3. If treated in Horde 3, then 3 additional subjects will be enrolled to confirm the MTD will be registered.
[0335] If 0 / 3 or 1 / 6 subjects experience DLT in cohort 5, cohort 5 is designated as the MTD, and if only 3 subjects are treated in cohort 5, Three additional subjects will be enrolled to confirm the MTD. ≥ 2 / 6 subjects will be enrolled in the cohort. If a DLT is experienced in cohort 5, cohort 4 will be designated as the MTD, and only 3 subjects will experience If treated in cohort 4, then 3 additional subjects will be The information is registered for this purpose.
[0336] If 0 / 3 or 1 / 6 subjects experience DLT in cohort 2, Cohort 2 is designated the MTD; only 3 subjects were treated in cohort 2. Then, 3 additional subjects will be enrolled to confirm the MTD. If a DLT is experienced in cohort 2; subsequent subjects will be enrolled in cohort 1.
[0337] If 0 / 3 or 1 / 6 subjects experience DLT in cohort 1, Cohort 1 is denoted the MTD. ≥2 / 6 subjects experience DLT in cohort 1 If so, the study will be discontinued and the data will be used by the Clinical Trial Research is evaluated by the team.
[0338] DLT for Cell A treatment is defined as follows: New adverse events occurring within the first 21 days were related to Cell A infusion. ≥ Grade 5 hematologic toxicity was associated with Cell A; Grade 3 or higher non-hematologic toxicities, including hypersensitivity reactions and autoimmune reactions, occurred with Cell A injections. Related to Treatment effects will be calculated relative to baseline using the International Working Group criteria.
[0339] Examples of inclusion criteria for medication studies 1. Acute leukemia: Refractory or relapsed AML other than acute promyelocytic leukemia (APL) Patients with 2. Patients with monosomal or complex karyotypes should undergo induction if residual disease is identified. Patients will be enrolled at the time of biopsy on day 14 after chemotherapy. 3. Patients must express HLA-A2.01 and have myeloid blast ) must express PRAME. 4. Absolute lymphocyte count (ALC) > 300 / mm 3 or CD3+ >150 cells / mm 3 . 5. Patients who have relapsed and are more than 100 days post-stem cell transplant have a systemic immune disorder. Patients are eligible if they do not have active GVHD requiring immunosuppressive therapy. 6. Relapsed or refractory AML or MDS Patients with AML had >5% AML at study entry without alternative causation (e.g., bone marrow regeneration) Must have bone marrow blasts. - Relapsed or refractory AML according to the revised International Working Group criteria for AML - 10-19% blasts and responding to hypomethylation therapy or IPSS INT-1 No IPSS INT-2 or high-grade MDS (RAEB-2), relapse after initial response Int-2 or high-grade MDS with seizures 7.Age > 18 years. 8. Life expectancy of at least 2 months. 9.ECOG performance status: <= 2 10. Hydroxyurea given only if needed to control leukocytosis Except for the above, the previous cytotoxic agent among the previously administered drugs was not administered before the first study drug administration. Have at least 14 days off previous cancer treatment for persistent cancer from previous chemotherapy. Clinically significant toxicity of chemotherapy should not exceed grade 1 at the time of enrollment. If control of rapidly growing disease is required, up to 100% T cell therapy should be administered prior to T cell reinfusion. May be given for 5 days. 11. Meet facility criteria for T cell apheresis collection. 12. Kidney function: 1. All patients had a calculated creatinine crisis according to Cockraft-Gault. The patient must have a flow rate of >40 mL / min. 2. Routine urinalysis should not reveal any clinically significant abnormalities. 13. Appropriate LFTs: Total bilirubin ≤ 3.0 x institutional upper limit of normal (ULN) Bilirubin <1.6 × ULN. 14. ALT / AST and alkaline phosphatase ≤ 5 x ULN 15. Acceptable coagulation conditions: -INR / PT≦1.5×upper limit of normal (ULN) -PTT<1.5×ULN [Table 1B]
[0340] [Table 1C-1] [Table 1C-2]
[0341] Abstract Relapsed or refractory acute myeloid leukemia has no clear path to determining optimal management. Therefore, it is a challenging clinical situation for patient survival. Overall survival in curable AML is consistently poor: SWOG-related findings for patients over 60 years of age For patients under 60 years of age, the overall mortality rate was 3% over 4 years, and for patients under 60 years of age, the overall mortality rate was 7% over 5 years. The survival rate was 4% over 2 years in patients over 60 years of age. A retrospective analysis of 594 patients with AML who had previously received second-line salvage therapy. A study reported a 1-year survival rate of 8% with a median survival of 1.5 months. The Golism trial is aimed at treating MDS patients with progressive disease who are undergoing HSCT or clinical trials with novel agents. “The potential for healing with transplantation is clear” (Sekeres, 2014). To be eligible, patients with myeloid neoplasms must have clinically significant progress in keeping their disease under control. The physical needs are not being met.
[0342] PRAME expresses A at a frequency and at levels much higher than those detected in normal tissues. Any off-tumor / on-target side effects are expressed in ML. e suicide switch and elimination of Cell AT cells. Therefore, TCR immunotherapy is a “no option” option for patients with relapsed or refractory myeloid neoplasms. "This is a potential treatment strategy that should be evaluated in patients with glaucoma.
[0343] In this dose-finding protocol, Patients with thiamine-resistant MDS were recruited via apheresis and were randomized to receive a known class of drugs. Transactivation of PRAME targeting genes in the context of HLA-restricted element HLA A2.01 Retrovirally modified to express a transgenic T cell receptor (TCR) The cells are adoptively transferred, engineered therapeutic T cell lineages. Suitable for providing homeostatic expansion of the product Once the patient is identified as having lymphopenia, re-administration will be performed according to the titration schedule. It can be injected.
[0344] (Primary refractory AML) For patients initially treated with intensive induction chemotherapy (1 or 2 cycles) 20-40% of patients do not achieve remission and are considered to have primary refractory disease (Ches on 2004). Primary refractory disease is characterized by complex or monosomal karyotypes, or secondary Treatment-related AML or AML resulting from antecedent hematologic disorders are not included in the overall risk stratification of AML disease. It is more commonly identified in patients with AML, which can be diagnosed in adults under the age of 60. Approximately 10% of patients with AML have a monosomal karyotype within their leukemic clone. While previously identified as a comorbid condition, this molecular subtype is increasingly being identified with age, with Approximately 20% of patients over the age of 18 express this resistant disease phenotype. With chemotherapy, the remission rate for patients under 60 years of age is approximately 14-50%. In patients over 60 years of age, the remission rate drops to 13-34% (Breems, 2013). 008; Lowenberg, 2009; Medeiros 2010).
[0345] Recurrent AML Outcomes for patients with relapsed AML are similarly disappointing. Among patients with relapsed AML, although risk and biological risk groups vary, Thirty to sixty percent of patients can achieve a second remission with salvage chemotherapy (Mangan, 2011), data from MD Anderson Cancer Center showed that Those patients who proceeded to cell transplant had a median survival of 11.7 months compared with 1.2 months for chemotherapy alone. has a median survival time of 5.6 months (Armistead, 2009). If patients require second-line salvage therapy, the outcome is extremely poor. A follow-up study of 594 patients with AML receiving second-line salvage therapy alongside standard of care A prospective analysis reported a 1-year survival rate of 8% with a median survival of 1.5 months. When analyzing the subgroup of patients (13%) who achieved complete remission (CR), median duration of CR The duration was 7 months. Upon multivariate analysis, a number of poor prognostic features were identified (age, >60, first CR duration <12 months, and second CR duration <6 months ) (Giles, 2005). Importantly, standard treatments are limited to patients who relapse within <12 months. The government has also sought to improve the governance of the country, but this does not appear to have an impact on the government’s profits (Kumar, 2011).
[0346] MDS have been treated with hypomethylating agents and the disease has progressed or is non-responsive Patients with myelodysplastic syndromes (MDS) who have not undergone any There is also no evidence that treatment offers any benefit beyond supportive care. The standard algorithm is to "Clinical trials with new drugs" are recommended (Sekeres, 2014). and overexpression have been identified in MDS by several groups. PRAME expression in BRCA1 has been investigated as a marker for higher risk disease. Worse outcomes have been shown, but this has not been validated in larger patient cohorts (Andrews, 2014).
[0347] Treatment Options in Relapsed or Refractory Myeloid Neoplasms transplant In patients with persistent or recurrent AML, the leukemia is not considered to be chemotherapy sensitive. Alternative management strategies are now required for these patients. Allogeneic hematopoietic stem cell transplantation, assuming they are not frail and can tolerate the rigors of the procedure. If a patient has refractory, relapsed AML and clinically If remission is not achieved and the patient has a suitable HLA-matched donor, good performance, Long-term post-transplant outcomes in patients with a KPS of >90% and no circulating blasts Overall survival is 20-30% (Craddock 2011, Duvall 20 10) Without transplantation, there is no meaningful long-term survival.
[0348] Elderly patients with acute leukemia who are not eligible for allogeneic HSCT generally have poor outcomes. AML is a rare and highly lethal form of AML, and therefore remains quite difficult to treat. 30-40% achieve CR with standard induction, but the median survival in this population is The poorer outcome in this population is closer to 10 months (Oran 2012). , high-risk cytogenetics, higher secondary leukemia rates, increased multidrug resistance large intestine, decreased performance status, significant comorbidities, and post-remission consolidation The ill-defined benefits of remission consolidation and This is attributed to the high procedure-related mortality rate (Oran 2012). Changes in clinical strategies aimed at including older patients and narrowing HSCT eligibility are has expanded (Hegenbart, 2006).
[0349] Cell A: PRAME TCR immunotherapy As a treatment modality, adoptive T cell therapy is effective in managing relapse after allogeneic transplantation. It has been shown to be a useful tool (Collins, 1997; Kolb, 1999). 95; Porter, 2005).
[0350] T cells from unprimed donors adoptively transferred in the absence of immunosuppression The cells may be effective, especially when combined with chemotherapy, to restore clinical remission that may be durable. Ex vivo expanded IgG antibodies restricted to HLA antigens and specific tumor peptides can be used. The T cells were then used to treat patients with WT1 or PR1-like targets in small-center series (in In recent years, chimeric antigen receptors have been shown to have small institutional series (SAR) benefits. Modified T cells (transduced into autologous T cell products by lentiviral vectors) The emergence of novel markers has been extremely useful in targeting known lineage-specific antigens in various disease states. It has been shown to be effective and currently represents the best experience in B-cell malignancies ( Porter, 2011; Grupp, 2013). The most recent of these advances are They can be linked to standard manufacturing and have malignant tumors that express a common antigen. It has been rapidly commercialized because it has become possible to generalize it to a variety of patients. However, the treatment of AML and MDS is elusive because CAR-T cells are effective. However, it appears to be associated with prolonged cytopenias.
[0351] Another peptide antigen of interest is a peptide that targets several tumor types, including AML and MDS. The tumor antigen, Preferentially Expressed Melanoma Antigen (PRAME), is expressed on malignant cells of PRAME is a signaling regulator that may be disrupted and may contribute to leukemogenesis. It plays a role in regulating the regulation of inflammatory bowel disease (pathways known to be important in the regulation of inflammatory bowel disease).
[0352] PRAME is a member of the cancer-testis antigen family and is expressed in embryonic tissues and several It is expressed at high levels in malignant tumors. It was first identified in melanoma tissue. However, it has since been detected in multiple cancers (lymphoid and myeloid malignancies). PRAME has been characterized by multiple groups as a AML cell line. PRAME has been identified above and is considered a leukemia-associated antigen (LAA). T cells that are immunogenic and expanded ex vivo are expressed in the context of HLA restriction elements. In this way, the PRAME peptide can be targeted through the T cell receptor, which may be beneficial for adoptive cell therapy. This suggests that these compounds may be targets that can be used to treat cancer.
[0353] PRAME overexpression has been studied and is associated with a high incidence of AML in newly diagnosed patients. 32% in another study (Goswami, 2014), and 35% in a study by van Baren et al. % (van Baren, 1998) and 55.4% in a study by Qin et al. High expression was observed in a study by Ding et al. ) was associated with t(8;21) and t(15;17) leukemia (40.7%). reported 74.4% and 56.6% expression, as well as bone marrow samples in patients with MDS. Overexpression in the mutant was identified (Qin 2009).
[0354] Targeting HLA-restricted PRAME antigenic determinants is a promising treatment for patients with refractory AML and MDS. As an alternative cellular therapy for patients with leukemia, these patients may also be targeted for adoptive T cell therapy.
[0355] PRAME-targeted TCR immunotherapy Associated with both on-target and off-target reactivity against healthy normal tissues However, there are safety risks associated with TCR immunotherapy. The high affinity TCR is a T cell specific for MART-1 that is being tested in clinical trials. As reported in the literature, some patients have on-target / off-tumor disease requiring treatment. Therefore, expression in cancer and normal tissues is poorly understood. It is important to select a target antigen that is highly conserved in the kidney. Identified by expression in cells, renal function can be assessed by imaging and laboratory tests. Careful monitoring of the
[0356] Genetically modified in the event of uncontrollable off-tumor / on-target T cell toxicity The inclusion of a "safety switch" to remove induced T cells would improve clinical safety. Cell A, TCR-based therapy targeting the PRAME antigen is a promising treatment for AML. It is designed to incorporate CaspaCIDe suicide switch technology for Cell TCR expressed in AT cell products binds to HLA-A2 on the surface of cancer cells The compound recognizes and binds to the PRAME peptide, resulting in apoptosis of tumor cells. .
[0357] The TCRs that have been developed have a natural high affinity, but the affinity has not been further enhanced. Furthermore, activation of the CaspaCIDe safety switch in response to administration of rimizucide was Activation of the caspase-9 cascade and elimination of Cell AT cells in vivo This safety switch allows patients to receive the benefits of adoptive T cell therapy while and reduce the associated health risks.
[0358] T cells expressing the TCR expressed by CELL A are PRAME-positive tumor cells Highly reactive against a panel of lines and against primary AML cells and proximal tubule epithelium Normal cell types except for low reactivity to dendritic cells and moderate reactivity to mature dendritic cells. The TCR α and β chain genes were sequenced and iC Transduce patient T cells with the asp9 suicide gene to generate Cell A TCR T cells. The antibody was inserted into a retroviral vector used to generate a cellular immunotherapy product.
[0359] High-affinity PRAME-specific T cells were isolated from AML patients after allogeneic stem cell transplantation (Amir et al. CCR 2011). These T cells were The PRAME-derived peptide SLLQHLIGL ( These high-affinity PRAME-specific T cell clones were found to recognize the PRAME-specific T cell antigen (SLL). Further analysis of the markers was performed against a panel of PRAME-positive tumor cell lines, as well as against metastatic melanomas. It is highly reactive against leukocytes, sarcomas, and primary AML cells, and is highly reactive against proximal tubule epithelial cells. The reactivity of IgG4-dependent IL-16 to normal cell types was not observed, with the exception of low reactivity to IgG4-dependent IL-16 and moderate reactivity to mature dendritic cells. The PRAME-specific T cell clone HSS showed no reactivity against the PRAME-specific T cell clone HSS. The TCR α and β chain genes of iCasp1 (referred to as AAV54) were sequenced and 9 Transduce T cells with suicide genes for Cell A TCR T cell immunotherapy It was inserted into a retroviral vector that was used to generate the product.
[0360] In vivo preclinical studies Immunocompromised mouse models predict unexpected on-target / off-tumor toxicities and associated toxicities Historically, in vivo mouse models and Cell A models have not been useful for measuring Use with PRAME TCRs has been shown to increase the efficacy of killing by PRAME-directed TCRs, as well as Ca Rimiside activation of the spaCIDe switch results in functional elimination of Cell AT cells Two in vivo studies, both of which show that iCasp9 and Cell A, transduced with a γ-retrovirus encoding the PRAME αβTCR; Using HLA-A2.01-restricted human T cells, immunodeficient NSG (NOD.CgPrkd cscid Il2rgtm1Wjl / SzJ; NSG) mouse model The Cell A construct contains cytogenetic variants designed to minimize mismatches. It contains the same cysteine-modified amino acid sequence as the modified TCR HSS1 (Amir, 201 1).
[0361] Cell A efficacy against PRAME-expressing tumors Normal donor HLA-A2.01-restricted human T cells were activated with pSFG-iC9.2A. PRAME-derived Cell A vector was used to transduce the cells. Transduced (NT) control T cells were cloned using the variable domain segment of the β chain of the Cell A TCR. The expression of Vβ1, a marker of bone marrow function, was analyzed by flow cytometry. Myeloma tumors were 2 × 10 6 U266-EGFP-luciferase (U266-luc) tumor Tumor engraftment was established in 10 NSG mice by tail vein injection of 10 tumor cells / animal. On day 24, five mice were given 1 × 10 7 Non-transduced (NT) T cells or Cell 1 x 10 transduced with A 7 T cells were given via i.v. injection. IVIS imaging was performed on a weekly basis to measure tumor size.
[0362] Cell A was compared to control for post-treatment background after a single iv injection of Cell A. showed tumor elimination to tumor levels in less than 2 weeks, whereas injection of NT T cells significantly reduced tumor growth. We did not control for tumor burden (Figure 21). Using mean radiance as a measure of tumor burden In contrast, the tumors in mice treated with NT T cells were larger than those in mice treated with Cell AT cells. These data suggest that Cell A has approximately 800 times more cells than Cell A via i.v. injection. 1 × 10 7T cell doses were effective in vivo against U266 myeloma tumors Indicates that there is something.
[0363] In vivo Cell A response to rimizuside Sixteen mice were inoculated with 1 × 10 7 Cell AT After 48 hours, eight of the mice were given an iv injection of 5 mg / kg of Rimiduzidin was injected i.p. to measure the activation of iCasp9 and the proliferation of Cell AT cells. apoptosis was assessed in 8 mice; the other 8 mice were left untreated. Flow cytometric analysis of spleens after 4 hours showed that non-transduced human T cells were expressed in 8 mice in each group. 5 animals, whereas rimiduside was not transduced in treated animals. We demonstrated that the majority of human T cells were efficiently eliminated from Cell AT cells. 42 ± 1.1% in treated animals compared with 7.3 ± 0.2% in rimizucide-treated animals. The Vβ1+ in untreated mice (p<0.0001) (Figure 22, top: untreated mice Animals; bottom row: mice treated with rimiduzid. Thus, iCas encoded in Cell A p9 represents a functional safety switch that can be triggered in vivo to eliminate Cell A cells .
[0364] The CaspaCIDe (iCasp9) switch was expressed in Cell A after 51 days in vivo. Remains sensitive in T cells Spleen and bone marrow cells were cultured with either NT T cells or Cell A modified T cells. Treated mice were harvested and counted 51 days after T cell injection (74 days after tumor implantation). CD4 + and CD8 + Vβ1 expression on T cells was analyzed by flow cytometry. Even in animals that showed effective tumor elimination, Cell AT cells were not found to be secreted from the spleen. The C-cells persisted in the liver and bone marrow (Fig. 3). Approximately 600-fold more total CD8+ T cells in the spleens of mice that received ell AT cells , there were approximately 130-fold more Vβ1+CD8+ T cells.
[0365] Spleen and bone marrow cell fractions were collected from Cell A-treated animals as analyzed above. and incubated with or without 10 nM rimizuside to determine the sensitivity of the suicide switch. Rimiduzside inhibited the activation of Vβ1+ T cells isolated from both spleen and bone marrow. The fraction of surviving Cell A cells was significantly decreased (p<0.05). It was confirmed that the cells harbored a functional iCasp9 suicide gene (Figure 24).
[0366] Preclinical study conclusions Following tail vein injection into NSG mice, Cell AT cells were expressed as early as 24 hours later. It can be detected in the spleen and increased in number 48 hours after injection. The cells showed measurable survival and U266 expression when administered iv in NSG mice. The Cell A modified T cells show antitumor efficacy against myeloma cells. 7 T cells At a dose of 100 mg / kg / day, it eliminated U266 myeloma tumors in less than 2 weeks after administration and maintained tumor growth for more than 50 days. iCasp9, encoded in Cell A, was expressed by rimiduside administration. induced by α-aminobutyric acid, which can eliminate Cell A cells by inducing apoptosis. Luciferase bioluminescence (by IVIS) acts in vivo as a safety switch. Despite the absence of detectable tumors by immunohistochemistry (measured by 51 These cells can be harvested from both the spleen and bone marrow within days; remained susceptible to
[0367] These data suggest that Cell A is a marker for tumor cells expressing the PRAME / HLA-A2 antigen. and that the iCasp9 switch was transduced after rimizucide treatment. These results suggest that the antibody may be effective in eliminating resistant T cells.
[0368] Clinical evaluation of the safety and functionality of rimizuside Safety of TCR cell therapy in humans In general, one safety concern with TCR cell therapy is the proliferation of T cells in tumor antigen-expressing normal tissues. The risk of on-target and off-tumor toxicity due to cellular activation. Short-term toxicity may be latent. Currently, acute fluid reactions, anaphylaxis and cardiac arrest, on-target toxicities (e.g. , tumor lysis syndrome and cytokine release syndrome (CRS).
[0369] Rimizuside / AP1903 Dimerizer Drug AP1903 induces clustering of engineered proteins inside cells A new class of lipid-permeable compounds called activator drugs, or dimerizer drugs, acts through the AP1903-induced activation of the caspase-9 suicide gene is a member of the human F Chimeric fusion with drug-binding domain derived from K506 binding protein (FKBP) This is achieved by expressing a chimeric protein (iCasp9). , AP1903, which crosslinks the FKBP domain and initiates iCasp9 signaling This signaling is then transmitted to the genetically modified cells. AP1903 induces apoptosis in 25% Solutol HS 15 (non- It is formulated in 0.1% ionic solubilizer at a concentration of 5 mg / ml.
[0370] Rimizuside in human volunteers A Phase I, placebo-controlled, single-blind, intravenous, single ascending dose study was conducted in healthy adult subjects. In subjects, the effect of rimizucide / (AP1903) (Iuliucci, 2001 The safety, tolerability, and pharmacokinetics of 28 subjects were enrolled in 5 treatment arms. In these groups, five dose levels of AP1903 (i.e., 0.01 mg / kg, 0.05mg / kg, 0.1mg / kg, 0.5mg / kg and 1.0mg / kg) were prepared. Within each group, four subjects received AP1903 and one subject received a placebo. One subject received normal saline. The only exception was the 0.5 mg / kg treatment group. In this study, three subjects were given AP1903 and one subject was given normal serum Within each treatment group, AP1903, placebo, and normal saline were administered. Dose volumes of the lines were equivalent on a weight basis. All treatments were administered over a 2-hour period. The drugs were administered as an intravenous infusion. Clinical assessments were performed pre-administration, 10 minutes after the start of the infusion, and 20 minutes, 40 minutes, 1 hour, 1 hour 20 minutes, 1 hour 40 minutes, 2 hours, 4 hours, 8 hours, 12 Vital signs were measured at 1 h and 24 h, and again on day 7 (supine blood pressure, supine A 12-lead resting ECG was obtained before administration and after the start of the infusion. Continuous cardiac monitoring was performed at 3 and 24 hours, and on day 7. The infusion was started approximately 1 hour after the start of the infusion and continued for up to 3 hours after the start of the infusion. It has been shown to be safe and well tolerated at all dose levels and has a favorable pharmacokinetic profile. The rule was shown.
[0371] Clinical functionality of AP1903 (rimizucid) Ten subjects in the CASPALLO trial were randomly assigned to receive T-cell therapy that contains the caspase-9 suicide switch. Four subjects developed acute GVHD after treatment with AP1903. Following administration, the immune response was rapidly abrogated, with selective elimination of alloreactive T cells via apoptosis. AP1903 inhibited inducible caspase-9 expression 30 min after the end of a 2-h intravenous infusion. AP1903 infusion resulted in the elimination of >90% of active T cells. Adverse events associated with AP1903 infusion were Not reported.
[0372] The DOTTI trial is a follow-up study to the CASPALLO trial. Grade I and II acute GVHD subsequently developed, and dimerizing agents were Four subjects were treated with a single dose of AP1903 (a single-drug treatment). The median survival time (range, 278–674 days) was 14 days, and they There were no immediate or delayed adverse events associated with AP1903.
[0373] Study design It reacts with the PRAME peptide in the context of the restriction element HLA A2.01. Safety of autologous T cells genetically modified with a retroviral construct consisting of the / b T cell receptor A single-arm, dose-escalation / tapering, single US center phase to determine efficacy and safety The use of an escalation / taperation design was demonstrated in patients with relapsed or refractory AML or MDS. The lack of effective treatments for patients with idiopathic pulmonary disease and the need to start with subtherapeutic doses To determine whether there is rapid leukemia progression and any efficacy signals. This study is supported by the recognition that the effects of The study enrolled approximately 36 patients, resulting in 24 This allows patients to be treated and evaluated for efficacy. Patients who are eligible for the study will be enrolled and scheduled to undergo T cell apheresis. Best practice effort is based on the patient's recurrence and It is used to treat refractory leukemia or MDS, but generally, manufactured T cells Lymphocyte depletion prior to activation of study treatment at the time of cell injection It can be incorporated into standard AML or MDS salvage regimens that also achieve the above objectives. Contains rare purine analogs.
[0374] Safety will be monitored throughout the trial. Established knowledge on gene therapy products for advanced therapeutic products using viral constructs Based on the guidelines (FDA) established by the FDA, all patients treated with Cell A are Patients will be monitored for specific toxicities for up to 15 years in total, regardless of whether they responded to treatment. All patients will be monitored for 5 years in this study. This will be followed by annual safety assessments in a separate long-term safety follow-up protocol. The aim is to assess the risk of acute and delayed adverse events associated with cell therapy. , as well as monitoring RCR (replication-competent retrovirus).
[0375] The efficacy of the treatment was evaluated by molecular, cytogenetic and hematological complete and partial responses. Clinical response may be assessed through secondary endpoints of disease control, including evaluation of This measure determines the percentage of patients who proceeded to HSCT who were not otherwise eligible. That is the thing.
[0376] Dosage Design: 1 / 3 experience DLT at starting dose (cohort 3); another 3 subjects will be enrolled and treated in cohort 3. The first 3 patients will be followed for 3 weeks after each patient. Follow-up will be conducted and any further patients will be enrolled thereafter. All subsequent cohorts will be Ports may be registered simultaneously. If 0 / 3 or 1 / 6 subjects experience DLT in cohort 3 (starting dose) If >= 2 / 6 subjects are enrolled in Cohort 3, then the subsequent subjects will be enrolled in Cohort 4. If a subject experiences a DLT in cohort 2, then the subsequent subject will be enrolled in cohort 2. If 0 / 3 or 1 / 6 subjects experience a DLT in cohort 4, then Subsequent subjects will be enrolled in cohort 5. ≥2 / 6 subjects experienced DLT in cohort 4 If cohort 3 experiences If treated in Horde 3, 3 additional subjects will be recruited to confirm the MTD. It will be registered. If 0 / 3 or 1 / 6 subjects experience DLT in cohort 5, cohort 5 may be designated the MTD if only 3 subjects are treated in cohort 5 To confirm the MTD, 3 more subjects will be enrolled. ≥2 / 6 subjects will be enrolled in the cohort. If cohort 5 experiences DLT, cohort 4 may be shown to be MTD, with only 3 patients If subjects are treated in cohort 4, three additional subjects will be enrolled to confirm the MTD. Subjects are enrolled. If 0 / 3 or 1 / 6 subjects experience DLT in cohort 2, cohort 2 may be designated the MTD; if only 3 subjects are treated in cohort 2, Three additional subjects will be enrolled to confirm the MTD. ≥ 2 / 6 subjects will be enrolled in the cohort. If a subject experiences a DLT in Cohort 2; then subsequent subjects will be enrolled in Cohort 1. If 0 / 3 or 1 / 6 subjects experience DLT in cohort 1, If ≥2 / 6 subjects experience a DLT in cohort 1, then the MTD may be indicated. The study will be discontinued and the data will be shared with the clinical research team, including the sponsor and investigator. The evaluation is based on the [Table 2]
[0377] The safety of the medication may be evaluated by a clinical research team, which may The committee is made up of the Chief Investigator, Study Medical Monitor, and researchers. The clinical research team will review the safety data emerging from each cohort and Determine whether dose escalation or de-escalation is contemplated. Alternatively, determine whether the non-tolerated dose level is consistent with the previously tolerated dose level. Dose levels intermediate between the 100% and 150% doses may be investigated, with <2 of 6 subjects receiving the 100% dose. MTD may be indicated when a DLT is experienced at any one time.
[0378] If there are inadequate cells to meet the target dose for a given patient, the subject may be available, but are not considered evaluable for determination of MTD. Good too.
[0379] Frequent comorbidities and concurrent medications in the study population It is difficult to attribute AEs to a specific drug due to the Therefore, any AE that cannot be clearly determined to be unrelated to AT Cells should be considered. may be considered relevant to DLT decisions and may be reviewed by the clinical research team.
[0380] Prior to unmobilized T cell leukapheresis, subjects' blood counts and differential counts (bl ood count and differential may be collected and recorded. Established regulatory guidelines Infection monitoring along the line may be performed. Prior to starting leukapheresis, subjects should CBC and platelets must meet institutional standards. Differential white blood cell count must be performed according to standard The subject may be collected during apheresis using automated continuous-flow centrifugation. The standard apheresis procedure for approximately 3-4 blood volumes can be performed in leukemia patients. The volume to be processed and The duration of leukapheresis may be documented and recorded. 9 Less than 100 mononuclear cells were collected. If necessary, advice from the medical monitor should be sought.
[0381] PRAME-TCR cell (Cell A) manufacturing process Starting material for Cell A product is shipped fresh overnight to a centralized GMP manufacturing facility. or a patient-derived PBMC collection from which mononuclear cells have been previously selected. The patient-derived PBMC collection was collected and cryopreserved. The ficolled collection was stored frozen in multiple aliquots, which were then concentrated. Upon receipt and after confirmation of acceptability of the starting materials, An aliquot is transferred to the production clean room and rapidly thawed. The cells are washed and T cells are Place in culture medium to grow until the target cell number for transduction is reached. The T cells are transduced with the Cell A retroviral construct. The cells are then frozen and stored at room temperature for 30 min. The cells are formulated using storage medium (CryoStor CS10) and cryopreserved. l A products are stored frozen in the vapor phase of liquid nitrogen (LN2) until release testing is completed. The Cell A product is stored in a validated cryo-transport container (cryoshipper). It can be shipped in the vapor phase of LN2. It will take approximately It is expected to take two to four weeks.
[0382] Packaging and Formulation: Cell AT cells in 10~15mL freezing medium (Cryostor, BioLife) and then cryopreserved in the vapor phase of liquid nitrogen. Store in a storage bag and freeze.
[0383] Transport and storage: The cryopreserved Cell A was stored in a validated shipping container (shipping company). The cells can be transported in the vapor phase of LN2 in a container to the clinical site. The receiving cell processing laboratory The product is stored in the gas phase of LN2 until it is time for injection. At that point, the product is The day of shipment, the cells may be thawed at 37°C ± 2°C according to instructions for infusion into the recipient. Depending on the date, the timing of delivery may be longer than one day.
[0384] Chemotherapy and lymphodepletion prior to AT cell infusion Chemotherapy before AT cell infusion Prior to treatment with the engineered T cells, patients were monitored by a clinical physician to determine their disease biology and comorbidities. Based on the evaluation and to provide temporary disease control, With one of them, you will receive bridge chemotherapy and lymphodepleting chemotherapy at the same time. -FLAG-Ida (Fludarabine, Cytarabine, GCSF, Idarubicin) -FLAG (Fludarabine, Cytarabine, GCSF) -Single Agent Cladribine -Single agent cyclophosphamide (as follows).
[0385] Lymphocyte depletion before AT cell infusion If the subject's absolute lymphocyte count is less than 1000 / μl, lymphocyte count should be administered prior to Cell A infusion. If the subject's ALC is greater than 1000 cells / μl, then the patient should be treated with Bendamustine 90mg / m 2 or fludarabine 9 0 mg / m 2 and cyclophosphamide 750mg / M 2 Lymphocyte depletion chemistry in Therapy may be administered no later than 3 days prior to infusion.
[0386] Additional lymphodepleting agents (e.g., fludarabine) may be administered to subsequent subjects at the investigator's discretion. The body may also be considered.
[0387] Cell AT cell injection Cell A cells can be thawed in a 37°C water bath and stored according to the laboratory procedure manual. As instructed, 50 mL Plasmalyte (first 35 mL, then 15 mL) was added. The solution may be diluted with 100 mL of DMSO ("rinsing" the bag) and administered over 15-30 minutes.
[0388] Subjects will be admitted to the hospital overnight for administration of Cell A on Day 0. The duration of hospitalization will be overnight unless an unexpected AE occurs. Pretreated with acetaminophen and diphenhydramine according to in-house standards for obtain.
[0389] Monitoring may be performed according to in-house standards. Before injection and 4 hours after injection. , blood samples may be collected for biomarker monitoring. The rings may be evaluated en bloc. This AE monitoring should be continued for a minimum of 4 hours after injection. , continue.
[0390] Tumor Assessment and Biomarkers Tumor assessment In AML (Cheson, 2003) and MDS (Cheson, 2006) Determine tumor response to treatment based on the revised International Working Group (IWG) response criteria for Serial blood and bone marrow sampling for Bone marrow biopsies may be completed at the following times: -Within 7 days prior to registration Within 7 days prior to T cell infusion - 4th day after T cell injection -28 days (±1 day) after T cell injection - As clinically indicated.
[0391] Biomarkers Serial blood sampling can be collected and selective cytokines and biomarkers can be analyzed. The markers are then frozen and stored for further analysis.
[0392] Rimizuside (AP1903) Dimerizer Drug Packaging, Labeling and Storage Packaging and Formulation: AP1903 for injection, either 10mL or 2mL Package in Type 1 clear glass serum vials. The contents of each vial are , as an injection solution with AP1903 concentration of 5 mg / mL and pH 5.0 to 7.5. AP1903 drug substance dissolved in doxorubicin-free 25% Solutol HS 15 Each vial contains the indicated content of 40 mg or 10 mg. The bottle comes with a Teflon coated serum stopper and flip-off sheet. It is sealed with a cork.
[0393] display: The primary product label for AP1903 for injection (applied directly to the vial) is as follows: The following information may be included: product name, AP1903 for injection; manufacturer's lot number; product strength; 5 mg / mL; volume of solution available in the vial; total AP1903 content in the vial ( 40 mg or 10 mg); states "For IV administration, preservatives not included" and IN D designation: "WARNING: New drug for investigational use only by Federal law." may be displayed according to the requirements of
[0394] storage: AP1903 vials for injection are stored in a limited access, qualified refrigerator for 5 °C ± 3 °C (41 °F ± 5 °F) and may be stored protected from light.
[0395] Preparation for treatment: For use, AP1903 may be diluted prior to administration. 903 was administered over 2 hours using a DEHP-free saline bag and solution set. The target dose was 0.4 mg / kg IV, diluted in normal saline, with a volume that could be adjusted to accommodate the It is administered via injection. Details are contained in the pharmaceutical manual.
[0396] Suicide induction of PRAME-TCR with rimizucide A dose of 0.4 mg / kg of rimiduside (AP1903) may be injected. Antibiotics, H1 and H2 blockers and any other standard institutional precautions / precautions , potential anaphylactic-like infusion reactions (such as Kolliphor, Solutol, is required prior to injection of rimizucide as a precaution against potential side effects (potentially present in the product). The injection of Rimiside shall be done using a non-DEHP saline bag, details of which are given in the Li Blood samples were taken pre-infusion and post-infusion. The samples can be collected for biomarker monitoring at 4 hours. This AE monitoring will continue for a minimum of 4 hours after injection. If no unexpected AEs occur, the maximum expected length of stay is one night.
[0397] On-target-off-tumor In situations where Cell A PRAME-TCR T cells react with non-tumor targets, patients should receive supportive medical care, and...
Claims
1. 1. A nucleic acid molecule comprising a CDR3-encoding polynucleotide, comprising: the CDR3-encoding polynucleotide encodes a CDR3 region of a T cell receptor that specifically binds to a melanoma preferentially expressed antigen (PRAME); the CDR3-encoding polynucleotide comprises a first polynucleotide encoding a first polypeptide comprising a VJ region of a TCRα polypeptide, the first polypeptide comprising a CDR3 region of the TCRα polypeptide, a CDR1 region of the TCRα polypeptide, and a CDR2 region of the TCRα polypeptide; the CDR3-encoding polynucleotide comprises a second polynucleotide encoding a second polypeptide comprising a VDJ region of a TCRβ polypeptide, the second polypeptide comprising a CDR3 region of the TCRβ polypeptide, a CDR1 region of the TCRβ polypeptide, and a CDR2 region of the TCRβ polypeptide; the CDR3 region of the first polypeptide comprises the amino acid sequence of SEQ ID NO:25; and the CDR3 region of the second polypeptide comprises the amino acid sequence of SEQ ID NO:28; said TCR alpha polypeptide and said TCR beta polypeptide together specifically bind to a peptide-MHC complex, said MHC molecule being an MHC class I HLA A2.01 molecule, and said peptide being a PRAME polypeptide comprising the amino acid sequence SLLQHLIGL; The nucleic acid molecule encodes a T cell receptor. Nucleic acid molecule.
2. 2. The nucleic acid molecule of claim 1 , A nucleic acid molecule, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:31, or an amino acid sequence that is 90% or more identical to the sequence of SEQ ID NO:31; and the second polypeptide comprises the amino acid sequence of SEQ ID NO:34, or an amino acid sequence that is 90% or more identical to the sequence of SEQ ID NO:
34.
3. The nucleic acid molecule of claim 1 or 2, wherein the first polypeptide further comprises a constant region of the TCR alpha polypeptide and the second polypeptide further comprises a constant region of the TCR beta polypeptide.
4. The nucleic acid molecule according to any one of claims 1 to 3, wherein the CDR3 region of the T cell receptor binds to PRAME expressed on the cell surface.
5. A nucleic acid molecule according to any one of claims 1 to 4, a) a promoter operably linked to the CDR3-encoding polynucleotide; or b) a first promoter operably linked to the first polynucleotide, and a second promoter operably linked to the second polynucleotide. The nucleic acid molecule further comprising:
6. The nucleic acid molecule of any one of claims 1 to 5, further comprising a polynucleotide encoding a chimeric caspase-9 polypeptide comprising a multimeric ligand binding region and a caspase-9 polypeptide.
7. A vector comprising the nucleic acid molecule of claim 1 or 6.
8. 8. The vector of claim 7, wherein the vector is a plasmid vector or a viral vector, optionally wherein the viral vector is a retroviral vector or a lentiviral vector.
9. A modified cell transfected or transduced with a nucleic acid molecule according to any one of claims 1 to 6 or with a vector according to any one of claims 7 to 8.
10. A pharmaceutical composition comprising the modified cells of claim 9 and a pharma- ceutically acceptable carrier.
11. A pharmaceutical composition comprising the nucleic acid according to any one of claims 1 to 6, or the vector according to claim 7 or 8, and a pharma- ceutically acceptable carrier.
12. 12. A composition comprising a therapeutically effective amount of the pharmaceutical composition of claim 10 or 11 for use in a method for enhancing an immune response in a subject diagnosed with a hyperproliferative disease or condition.
13. The composition for use of claim 12, wherein the subject has been diagnosed with a disease selected from the group consisting of melanoma, leukemia, lung cancer, colon cancer, renal cell carcinoma, breast cancer, non-small cell lung cancer, renal cell carcinoma (RCC), acute lymphoblastic leukemia, acute myeloid leukemia, myeloid neoplasms, cervical cancer, sarcoma, neuroblastoma, Ewing's sarcoma, synovial sarcoma, uveal melanoma, neuroblastoma, and ovarian cancer.
14. 12. A composition comprising a therapeutically effective amount of the pharmaceutical composition of claim 10 or 11 for use in a method for stimulating a cell-mediated immune response to a target cell population or tissue in a subject.
15. 15. The composition for use of claim 14, wherein the target cells are selected from the group consisting of melanoma, non-small cell lung cancer, renal cell carcinoma (RCC), myeloid neoplasms, breast cancer, cervical cancer, colon cancer, sarcoma, neuroblastoma, Ewing's sarcoma, synovial sarcoma, uveal melanoma, acute lymphoblastic leukemia, leukemia, lung cancer, colon cancer, renal cell carcinoma, acute myeloid leukemia, neuroblastoma, and ovarian cancer cells.
16. 12. A composition comprising a therapeutically effective amount of the pharmaceutical composition of claim 10 or 11 for use in a method for providing anti-tumor immunity to a subject.
17. A composition comprising the nucleic acid of claim 1 or 6 for use in a method for expressing a T cell receptor that specifically binds to PRAME in a cell, the method comprising contacting the nucleic acid with a cell under conditions in which the nucleic acid is incorporated into the cell, whereby the cell expresses the T cell receptor from the incorporated nucleic acid.
18. A T cell receptor encoded by a nucleic acid molecule according to any one of claims 1 to 6.
19. 12. A pharma- ceutically effective amount of the pharmaceutical composition of claim 10 or 11 for use in a method for treating a subject having a hyperproliferative disease or condition.
Citation Information
Patent Citations
Targeting the tumor microenvironment using manipulated NKT cells
WO2013040371A2
Methods for inducing partial apoptosis using caspase polypeptides
WO2014197638A2
